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One of the major challenges within the rapidly growing field of regenerative 
medicine is the efficient integration of stem cells after transplantation. To address 
this issue, an artificial cell membrane binding nanobiohybrid was rationally 
designed to provide donor cells with cartilage tissue adhesion properties. The 
protein constituent consists of a peptide sequence from placenta growth factor 2 
(PlGF-2) fused to a supercharged green fluorescent protein (scGFP), giving 
[scGFP_PlGF2]. Significantly, PlGF-2 has an extremely high binding affinity for 
extracellular matrix (ECM) proteins and the supercationic scGFP provides a cell 
membrane anchor region for anionic polymer surfactant conjugation. Accordingly, 
the solvent-exposed sites of the protein were electrostatically conjugated with a 
polymer surfactant, forming [scGFP_PlGF2][S]. This allowed the construct to 
insert into the membrane of human mesenchymal stems cells (hMSCs), whilst the 
PlGF2 domain is displayed to provide the cells with affinity for ECM proteins. 
The addition of the polymer surfactant did not affect the structure and function of 
the fusion protein. Moreover, hMSCs modified with [scGFP_PlGF2][S] did not 
exhibit any signs of cytotoxicity at working concentrations, and there was no 
impact on the cells ability to proliferate or differentiate. Importantly, there was a 
significant increase in cellular adherence to collagen II when comparing modified 
cells to unmodified cells with in vitro models. Moreover, the modified cells adhered 
strongly to bovine ex vivo articular cartilage explants and could be readily 
observed on the cartilage using confocal and electron microscopy. These findings 
suggest that re-engineering hMSC membranes with [scGFP_PlGF2] could be a 
viable approach to improve stem cell therapy outcomes in the regeneration of 
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This chapter outlines the burden of osteoarthritis (OA) and the economic impact of 
musculoskeletal disorders. These topics are followed by the aetiology and 
pathogenesis of OA disease, as well as the innate attempt of the human body to 
repair damaged sites. The advantages and disadvantages of traditional surgeries 
are also discussed. Significantly, surgery fails to induce repair and tends only to 
alleviate pain symptoms. As a result, the area of tissue engineering has emerged 
with regenerative stem cell therapies to overcome these shortfalls. Accordingly, a 
review of literature that covers recent approaches to treat osteoarthritis is 
presented, which includes the re-engineering of the stem cell membrane using 
different materials and approaches. 
1.1 The importance of osteoarthritis 
1.2.1 Definition of osteoarthritis 
The Osteoarthritis research society international (OARSI) has defined 
osteoarthritis (OA) as “a disorder of the movable joints characterised by 
extracellular matrix (ECM) degradation and cell stress originated by micro- or 
macro-injuries that stimulate dysfunctional repair responses, including 
inflammatory pathways of innate immunity”1. 
OA is the most common disease among older individuals, with half the population 
aged 65 years or older diagnosed with chronic articular disorders2. Pain is the main 
symptom of this disability, impeding people from performing basic daily activities3. 
OA can develop in the hip, hands or the knee, with the latter one being the most 




Figure 1.1 Representation of age and gender rates (/1000 person-years) of osteoarthritis 
(OA). Combined population (solid line), women (short dashed line), and men (long dashed 
line). Different types of OA are plotted: knee(black), hip (red), and hand (green). Reproduced 
with permission from Annals of the Rheumatic Diseases5. 
The information from Figure 1.1, from the analysis in Spain, can be extrapolated 
to other countries. The probability of osteoarthritis of occurring in women is higher, 
presumably caused by the change in hormones typically around menopause age5. 
1.1.1 The economic impact of osteoarthritis 
Given the high occurrence of OA disease, it is necessary to standardise the cost 
of OA-related expenses per country including direct and indirect costs6, as these 
can be substantial. Direct costs include hospital fees, medical visits, prescriptions, 
surgery, and care services7. Indirect costs are linked to the value of loss of 
productivity owing to illness (i.e. days off work)7. Depression, anxiety, and suffering 
are considered intangible costs8. 
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For instance, a study conducted by Le Pen in 2003 highlighted that the direct cost 
of OA was approximately 1.6 billion euros per year (£1.1 billion), distributed as 
€820 (£558) million in hospital admissions, €270 (£183) million in physician visits 
and €520 (£354) million spent in medications9. 
Nevertheless, most of the available data can only be obtained from developed 
countries, which does not allow for a global estimation. A review by Puig-Junoy 
and colleagues concluded that the majority of the OA-related studies are 
conducted in the United States of America, which accounted for 56% of the total 
publications up to 2015, this was followed by Canada with 8%, Australia and Spain 
with 5% and France 1%10. 
It has been estimated from the gathered studies so far, that the average amount 
of money spent per patient suffering from an osteoarthritic knee in a year is €4,257 
EUR (£3,108 GBP), ranging from €838 (£612) to €7,675 (£5,603), furthermore, the 
average incremental cost per year is €4,175 (£3,048), ranging from €528 (£385) 
to €11,293 (£8,244) from direct costs10, either in medical visits or medications. The 
highest end of the cost corresponds to patients undergoing surgery, spending 
nearly 30 times more than non-hospitalised individuals9. These rates were 
converted from euros to GBP according to the average exchange rate in 2015 
provided by the European Central Bank11. 
According to the National Health Service (NHS), in the United Kingdom (UK) the 
primary treatment for patients with OA is the prescription of painkillers including 
non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol12, with over 50% 
of the patients taking NSAIDs8. Topical and oral NSAIDs incurred a cost of £19.2 
million, and £25.65 respectively, in 2010. Furthermore, the cost of proton pump 
Chapter 1 
 6 
inhibitors (PPIs) as gastroprotective agents against NSAID, was £11.6 million 
(Figure 1.2). 
 
Figure 1.2 The cost of osteoarthritis in the United Kingdom according to the National Health 
Services. NSAIDs: non-steroidal anti-inflammatory drugs, PPIs: proton pump inhibitors. 
Adapted from8. 
Other costs are derived from arthroscopy and expensive total joint replacements8. 
Additionally, the costs for patients requiring recurrent medical visits due to OA 
symptoms are estimated to as high as £36 million a year13. Moreover, the indirect 
costs of OA is reported to have a major effect on the UK economy, since it has 
been estimated that £3.2 billion are lost in economic production every year8. 
According to Versus Arthritis, the largest research organisation for arthritis in the 
UK, £1.6 billion pounds were spent by research charities in 2016. Unfortunately, 
the research funding for musculoskeletal diseases (including hip, back and knee 
osteoarthritis and rheumatoid arthritis) remains disproportional, as it received only 
2.8% of the funding for research in 2014. This is despite a reported 9% of disability 
adjusted life years (DALYs)14 attributed to OA. DALYs are a measure of the impact 
of diseases, for instance, the years of healthy life lost or early death15 (Figure 1.3). 













Figure 1.3 Research spend, expressed as a percentage of total research funding (grey), 
versus burden of disease (pink). The top health research categories are represented. DALY: 
disability adjusted life year. Adapted from14.  
At present, all commercially available therapies concern the treatment of OA 
symptoms instead of avoiding the progression of the disease. Importantly, it is 
crucial to understand the pathology of osteoarthritis. 
1.2 Hyaline cartilage 
1.2.2 Function and structure of hyaline cartilage 
There are three main types of cartilage in the human body: elastic, fibrocartilage, 
and hyaline cartilage. The first one offers support to structures frequently 
subjected to deformation such as the epiglottis, larynx, and the external ear. 
Fibrocartilage is present in intervertebral discs and tendons. It possesses thick 
collagen fibres, characteristic of dense connective tissue and, like elastic cartilage, 
is rich in glycosaminoglycans16. 
Hyaline cartilage, also called articular cartilage (AC), serves the key role of 
providing mechanical support for developing bones and nose. Additionally, this 












type of tissue provides a lubricated surface for the diarthroidal joints, and helps in 
the distribution of loads17. The knee joint cavity is also lined by a thin connective 
tissue that secretes the lubricating synovial fluid. This tissue layer is called the 
synovium (Figure 1.4). AC is avascular, alymphatic and aneural. It is comprised 
by a dense extracellular matrix (ECM), which is secreted by a highly specialised 
type of cells called chondrocytes18. 
The unique structure of the ECM is what confers to this tissue the important 
function of protecting the joints. Approximately three quarters of the wet weight of 
AC is water19. The water flow transports essential nutrients to the chondrocytes 
and provides lubrication17. From the remaining 25%, most of the dry weight (50–
80%) is concentrated in collagen fibres with a triple helical structure19. 
 
Figure 1.4 Schematic representation of a knee joint. Articular (hyaline) cartilage surrounds 
the bone to distribute the load. Reproduced from Anatomy & Physiology20. 
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Collagen type II constitutes 85–90% of the total extracellular matrix components, 
along with proteoglycans (10–15%)21, and specialised glycosaminoglycan 
hyaluronic acid (HA). 
Proteoglycans are proteins containing glycosaminoglycan (GAG) chains 
covalently attached to a core protein. These anionic chains repel each other by 
electrostatic repulsion due to the negative charge17. Proteoglycans provide the 
ECM the ability to resist compressional forces due to its osmotic properties22. 
GAGs are categorised into keratan sulphate, heparan sulphate, chondroitin 
sulphate, dermatan sulphate, and HA, depending on the repeating disaccharide. 
HA surrounds migrating and proliferating cells and has a large number of anionic 
residues that interact with water, forming a hydrated gel. It also keeps cells 
separated from one another, providing them with freedom to move and 
proliferate23. HA binds to aggrecan, the most abundant proteoglycan which 
contains over 100 GAG polysaccharides in its protein core23 (Figure 1.5). 
 
Figure 1.5 Schematic representation of articular cartilage extracellular matrix. Aggrecan is 
bound to hyaluronic acid in a collagen network. 
The ECM, along with chondrocytes, is arranged into four different zones within the 





Figure 1.6 Schematic representation of articular cartilage zones in the knee joint. The left 
image depicts the orientation of the chondrocytes while the right image represents the 
collagen fibres. Reproduced from Zhang et al.24 
The superficial layer is the most exposed to the synovial fluid, it contains a high 
density of flattened chondrocytes and the collagen fibres are aligned parallel to the 
articular surface. The stability of this area is crucial for the deeper layers of 
cartilage, as it protects them from shear stress17. 
Adjacent to the superficial zone is the transitional or middle zone. In this layer, the 
collagen fibres are wider and are ordered in oblique positions. The chondrocytes 
present a spherical shape and exist at lower densities than the superficial zone17. 
The deep zone contains the largest collagen fibres in diameter, arranged, along 
with chondrocytes, in a perpendicular fashion to articular surface. This layer is 
characterised by having the highest proteoglycan content and the least water 
concentration. Importantly, it resists the greatest amount of compression17. 
Chondrocytes in the deep zone can undergo terminal differentiation and produce 
collagen X25. 
Finally, the calcified cartilage is divided from upper uncalcified zones by the 
tidemark. The calcified zone has the key role to anchor the collagen fibrils onto the 





Figure 1.7 Schematic representation of cartilage regions. The pericellular matrix surrounds 
the chondrocytes, and it is in turn enclosed by the territorial matrix. Interterritorial space is 
the area between chondrocytes. 
The pericellular matrix, or chondron, surrounds the chondrocytes and it is rich in 
proteoglycans and glycoproteins26. Next is the territorial matrix, which contains 
collagen fibrils and protects the cells from the load-bearing stress17. The 
interterritorial region is the largest and contains the collagen fibrils arranged in 
different positions depending on the zone17. 
1.2.3 Damaged cartilage and osteoarthritis 
The severe stress affecting hyaline cartilage due to biomechanical pressure can 
lead to wear and tear27. Injuries in the cartilage can lead to progressive joint 
degeneration due to the poor capacity of endogenous tissue healing. This is owed 
to the absence of progenitor cells, blood vessels, nerves, and the low proliferation 
rate of chondrocytes. Damage in cartilage has been associated with a number of 




1.2.1.1 Osteoarthritis disease 
Chondrocytes are the only cell type that reside in cartilage. They are responsible 
for synthesising a number of compounds such as collagen, proteoglycans, 
glycoproteins and hyaluronan, to form the ECM29. The metabolic activity of these 
cells can be disrupted by the presence of pro-inflammatory cytokines and growth 
factors25. Amongst the collagens secreted by chondrocytes, the expression of 
collagen type X also results in the production and release of proteolytic enzymes. 
These enzymes cause clearance of the ECM and aid in the undesirable formation 
of bone and vascularisation29. 
A frail balance between synthesis and degradation of ECM must be achieved to 
maintain homeostasis25. Injuries in the AC can lead to loss of ECM, which in turn 
can trigger the chondrocytes’ natural function to secrete more ECM components. 
However, the turnover rate of these components is intrinsically unbalanced, i.e., 
proteoglycan renewal rate is approximately 25 years, while the half-life of collagen 
fibres varies from decades to 400 years30. As a consequence, the damage of ECM 
can slowly degrade AC, this is in part, because it is not possible to detect OA in its 
early stages. 
Degradation of the cartilage also occurs because the number of chondrocytes 
decreases with age. As a result, the chondrocytes situated in the superficial layer 
migrate to the deeper layers, resulting in poor hydration and elevated compressive 
stiffness on the matrix joint25. 
1.2.3.1 Osteoarthritis pathogenic mechanisms 
A unique mechanism for the aetiology of osteoarthritis (OA) has not yet been 
found31, although it is thought to be the combination of various changes occurring 
in the cartilage simultaneously. In healthy ECM, the phosphorylation of ALK5 and 
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Smad3 proteins play an important role as receptors for TGF-β, and transduction 
of the TGF-β signal into the cell, respectively32,33. The function of TGF-β1 is to 
actively block the hypertrophic changes of chondrocytes33,34. Furthermore, 
fibroblast growth factor 2 (FGF-2), cooperates with TGF-β2 to inhibit hypertrophy35. 
The active phosphorylation of ALK5 and Smad3 is decreased with age31, thus 
initiating hypertrophy in the remaining cells (Figure 1.8). 
Hypertrophic chondrocytes secrete HtrA136, a potent protease involved in the 
blocking of TGF-β31, causing terminal differentiation in chondrocytes. Additionally, 
hypertrophic chondrocytes, often referred to as activated chondrocytes, gradually 
start to proliferate35, form chondrocyte clusters37, and secrete collagen type X.  
 
Figure 1.8 Schematic representation of chondrocyte hypertrophy. Transforming growth 
factor (TGF-β) phosphorylation by Smad3 and ALK5 is reduced with age, downregulating 
the production of aggrecan and collagen II. This event causes hypertrophic chondrocytes 
as they start the production of HtrA (blocking TGF- β), collagen X, and metalloproteinases 
(MMPs) which cleave collagen II. Hypertrophic chondrocytes proliferate and form 
chondrocyte clusters. 
Activated chondrocytes initiate the synthesis of various proteolytic enzymes, 
including matrix metalloproteinases (MMPs), which cleave the collagen and 
proteoglycan fibres25, disrupting the crosslinked network. Here, MMP13 plays a 
critical role in the cleavage and denaturation of collagen II38, the main component 
of cartilage ECM. MMP13 upregulation increases 40-fold in damaged cartilage 
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compared to non-osteoarthritic cartilage39, hence it is commonly used as a 
biomarker for OA40. 
Although the exact mechanism that drives chondrocytes to secrete HrtA1 and 
MMPs is still unclear41,42, it has been proposed that their expression is a resultant 
of mechanical stress and inflammation43. In the progression state of OA, the 
overexpression of HtrA1 and MMPs is followed by denaturation of the pericellular 
and intracellular matrix. As a consequence, the biomechanical microenvironment 
of the chondrocytes is altered, promoting chondrocyte hypertrophy31. 
Furthermore, signalling cascades coming from inflammatory cytokines, 
interleukins, and tumour necrosis factor, including IL-1β, IL-6, and TNF-α, are 
present during OA development (Figure 1.9). Such inflammatory cytokines are 
secreted by synoviocytes and chondrocytes. They play a key role in cell 
metabolism by upregulating the expression of MMPs and preventing the 
production of MMPs inhibitors44, such as tissue inhibitor of metalloproteinases 1 
(TIMP-1)45. 
 
Figure 1.9 Schematic representation of osteoarthritis pathogenesis. Synoviocytes and 
chondrocytes secrete cytokines, interleukins and tumor necrosis factor (IL-1β, IL-6, and 
TNF-α, respectively), which prevents tissue inhibitor metalloproteinases to counteract the 
degradative metalloproteinases (MMPs). Interleukins cause chondrocytes to dedifferentiate 
into fibroblast cells, secreting collagen I and III.  
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The presence of TNF-α in the cartilage ECM can be recognised by receptors in 
nerve terminals and activate high threshold ion channels, which propagate pain 
signals from surrounding tissues to the central nervous system46. 
Cytokines such as IL-1 can induce dedifferentiation. In this scenario, the 
chondrocyte phenotype is altered to a fibroblast-like cell. Dedifferentiated 
chondrocytes cease the synthesis of collagen II and aggrecans, and instead they 
secrete collagen I and III37. 
After the loss of ECM, healthy chondrocytes actively start the production of 
collagen II and proteoglycans; however, the disparity of production of collagen II 
versus proteolytic enzymes results in the in eventual loss of AC. 
In addition, mechanical and humoral factors stimulate the formation of 
osteophytes37 and fibrosis47. Osteophytes are a bony outgrowth containing 
fibrocartilage on their top surface48. In an attempt to repair and stabilise the joint37, 
stem cells from the bone marrow are recruited to the injured area from the bone 
surface (i.e. periosteum), however, these cells, and hypertrophic chondrocytes25, 
often differentiate into aberrant osteoblast-like cells25, forming osteophytes. 
Nevertheless, studies have found that in larger osteophytes, some hyaline 
cartilage has formed on the surface, and the new ECM fibres seem to have a high 
content of collagen II and TGF-β49. 
In summary, the early stages of OA begin with age and the loss of chondrocyte 
population, followed by a cascade of reactions leading to cell hypertrophy and 
degeneration of the ECM and erosion of the cartilage. These factors induce the 
formation of osteophytes and fibrosis in the cartilage, compromising motility and 
causing pain. Conversely, the mixture of damaged fibrillated cartilage and calcified 
osteophytes marks the end stage of OA31. 
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1.2.3.2 Articular cartilage injuries 
Injuries of the cartilage are divided into matrix disruption, partial thickness, and full 
thickness defects28 (Figure 1.10). Matrix disruption is often caused by a mild 
trauma injury, in this case, the remaining chondrocytes would increase their 
metabolic activity in order to restore the damaged matrix28. 
 
Figure 1.10 Schematic representation of cartilage defects. Partial thickness affects only the 
cartilage while full thickness injury reaches the bone. Adapted from50. 
Partial thickness damage in articular cartilage is often the result of a fissure on the 
superficial zone. In order to repair the damage, neighbouring cells initiate 
proliferation, however, the attempted restoration by the cells concludes before 
healing completion28. 
Full thickness defects develop from acute injuries going deep into the subchondral 
bone, damaging blood vessels, where a spontaneous repair response occurs. 
Blood, growth factors, and progenitor cells are simultaneously released from the 
bone marrow, and migrate to the injured site51. First, a spontaneous blood clot is 
created consisting primarily of a fibrin matrix containing proteins, red and white 
blood cells, and growth factors52. This clot is only capable of adhering to the 
surface of the bone and rarely to cartilage52. However, the clot is only able to fill 




Subsequently, mesenchymal stem cells (MSCs) replace the blood clot with a 
vascularised scar-like tissue54. Following this, endochondral ossification is 
generally started from the sides and floor of the injury towards the joint fissure, 
growing bone and new cartilage at the surface52. This new form of cartilage is 
indeed more similar to fibrocartilage than hyaline cartilage55. Fibrocartilage 
presents a more permeable matrix, but its mechanical competence is inferior to 
hyaline cartilage56 and these two types of tissue do not integrate. Therefore, the 
new formed fibrocartilage begins to degenerate after formation. 
1.2.3.3 Surgical treatments for osteoarthritis 
At the present, several surgical methods have been developed in order to treat 
osteoarthritis, such as arthroscopy, drilling, and osteotomy, to name a few. 
(i) Arthroscopy and lavage 
The lavage of the knee is the irrigation and rinsing of the joint with saline solution 
to remove debris or loose AC fragments52. Despite this approach being merely 
empirical, it has been proved to alleviate pain in OA patients57. It has been 
postulated that, through lavage, some pain-signalling molecules may be 
removed52. However, other studies suggest that pain relief is owed to a placebo 
effect of the surgical intervention58. 
(ii) Pridie drilling 
Pioneered by Kenneth Pridie in 1959, this surgery follows the premise of 
spontaneous repair by drilling therapeutic holes in the subchondral bone59 (Figure 
1.11). Patients have demonstrated that the benefit from this surgery as that pain 
is diminished, however, there is no long-term advantage to it, since the newly-




Figure 1.11 Schematic representation of Pridie drilling. First, the injured site area is 
homogenised, and small holes are drilled into the bone. Then, fibrocartilage is formed due 
to the endogenous immune response. 
An extreme approach to this technique is spongialisation, whereby the whole 
subchondral bone is removed to expose the remaining cartilage to the cancellous 
bone or spongiosa zone. This technique has not gained popularity and the 
approach is still questionable52. 
(iii) Osteotomy 
High tibial osteotomy is one of the most frequent surgeries to relieve pain from 
patients with severe joint deformities due to OA. This consists in the reshaping of 
the bone to distribute load more evenly. Osteotomy is often combined with a micro-
drilling procedure60. 
(iv) Osteochondral transplantation 
This approach, also called mosaicplasty, is achieved by transferring one or more 
cylindrical osteochondral autografts or allografts from a low weight-bearing area of 
the knee to the injured site61 (Figure 1.12). This should be the last resort in surgery. 
In order to successfully complete the procedure, a correct alignment of the inserted 
discs is needed. The results from some studies have shown to be favourable for 
the majority of patients where the new matrix successfully integrated with the 




Figure 1.12 Schematic representation of mosaicplasty. Autografts are harvested from a low 
weight-bearing area of the knee to the injured site. 
However, deterioration of the donor site can result in complications, and cartilage 
grafts often disintegrate as their biomechanical properties are inferior63, since they 
are harvested from a low weight-bearing area in the knee joint.  
(v) Total knee replacement 
This has shown to be a durable approach compared to the previously discussed 
surgeries, lasting for 15 years64. The total knee replacement involves the removal 
of bone from the femur and tibia to insert a prothesis. The metallic femoral and 
tibial components possess a polyethylene disc shape that to resembles a natural 
joint64. 
 
Overall, the strategies discussed above are able to help alleviate pain and improve 
joint motility, however, they do not provide the properties of native and mechanical 
cartilage. For this reason, new approaches are being developed using tissue 
engineering techniques, for example, with hydrogels.  
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1.3 The emergence of regenerative cell therapies 
Autologous chondrocyte implantation (ACI) is the first and most popular cell-based 
therapy for articular cartilage (AC) repair65. This technique was clinically initiated 
by Peterson and Brittberg in 198766,67. Here, a cartilage sample is taken from a 
low-weight bearing part of the cartilage, followed by isolation of the chondrocytes 
and in vitro monolayer expansion, before being injected into the patients defect 
site. In order to lock the chondrocytes in place, a periosteal flap is placed and 
sewed over the injury site67 (Figure 1.13). 
 
Figure 1.13 Schematic representation of autologous chondrocyte injection. First, 
chondrocytes are harvested and isolated from a healthy cartilage biopsy. Then, 
chondrocytes are expanded and injected into the damaged site. Adapted from68. 
The majority of the patients submitted to this treatment had a satisfactory outcome 
in the first years69. Nevertheless, a follow-up from patients after five years revealed 
that the repair was not homogeneous67. 
ACI still encounters limitations, including cost and complications resulting from the 
two surgical procedures: flap graft failure, donor site morbidity, and chondrogenic 
phenotype loss of chondrocytes during in vitro expansion70,71. Dedifferentiated 
chondrocytes are more prone to generate fibrous cartilage than hyaline cartilage. 
A proposed solution has been to administer cells that are able to fabricate any type 
of tissue with the adequate biological signalling72, such as stem cells. Accordingly, 
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the clinical trend in cell therapies has moved from the use of cartilage cells to bone 
marrow derived cells73. 
1.2.4 Stem cells overview 
Stem cells (SCs) are defined as cells having the capacity for self-renewal and the 
ability to differentiate into multiple cell types. SC can be further categorised owed 
to their origin as embryonic, adult, or genetically induced pluripotent stem cells 
(iPSCs). 
Embryonic stem cells (ESCs) are derived from the inner cell mass of pre-
implantation embryos, when the blastocyst is formed five days after fertilisation74. 
ESCs are pluripotent, as they have the capacity to undergo differentiation into all 
somatic cell lines in vitro. They are able to undergo extensive proliferation. 
However, the use of ESCs remains controversial due to the moral value of the 
embryo and the harvesting of oocytes75; which remains restricted in several 
countries76. Furthermore, the transplantation of ESCs has been associated with 
the formation of teratomas77. 
An alternative to ESCs are induced pluripotent stem cells (iPSCs) and adult stem 
cells, which could overcome the ethical issues associated with ESCs. iPSCs were 
generated by Takahashi and Yamanaka in 200678. In order to create them, mature 
cells were reprogrammed in vitro with genes to dedifferentiate them into a 
pluripotent state74. iPSCs are believed to possess the same characteristics of 
embryonic stem cells including pluripotent differentiation, and a number of different 
reprogramming techniques have been established, including integrating systems 




Adult stem cells are rare populations of undifferentiated cells located inside the 
body. They contribute to homeostasis of organs and tissues and are responsible 
for regenerating cells that are lost due to tissue turnover, injury or pathological 
processes80. These cells include haematopoietic stem cells, found in the umbilical 
cord and bone marrow, as well as mesenchymal stem cells, predominantly located 
in the bone marrow. 
Bone marrow (BM) is the major source for adult human mesenchymal stem cells 
(hMSCs). BM derived stem cells can undergo multilineage differentiation into a 
range of cell types, including adipocytes, osteoblasts, and myocytes (Figure 1.14). 
This type of cells is characterised for being plastic-adherent in vitro. Unlike ESCs, 
the pluripotency of hMSCs is limited and can only undergo population doubling 20 
to 40 times before reaching senescence81. 
 
Figure 1.14 Human mesenchymal stem cells (hMSCs). hMSCs are able to either self-
replicate or differentiate into various cell types such as osteoblasts, adipocytes, 
chondrocytes, myocytes, and fibroblasts. Adapted from83. 
In order to comply with clinical standards, the harvested cells should be effectively 
isolated and expanded in vitro while maintaining their multipotency70. Nevertheless, 
a universal protocol for scalable expansion or isolation has not been established 
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for hMSCs82. Besides bone marrow, hMSCs can be isolated from adipose tissue, 
synovium, and muscle. 
1.2.5 Biology of mesenchymal stem cells 
Besides their inherent adherence to plastic, human mesenchymal stem cells 
(hMSCs) are identified by the expression of surface markers such as CD44, CD90, 
CD105, CD106, CD166, and stro-1; and by the lack of hematopoietic markers 
CD14, CD34, and CD45, and endothelial cell markers (CD31)84,85, depending on 
the source86. 
Since stem cells are maintained quiescent in their specialised niches until they are 
recruited, it is imperative that they are protected from immune response87. hMSCS 
are considered to have immunosuppressive properties via cell-cell contact and 
interactions with innate (e.g. neutrophils, dendritic cells, macrophages) and 
adaptive immune cells (T and B lymphocytes)87.  
Studies have suggested that stem cells are also capable of expressing chemokine 
receptors, demonstrating their potential to home and to decrease inflammation88. 
For instance, hMSCs secrete IL-6, which can reduce the respiratory processes of 
neutrophils, in turn inhibiting production of reactive oxygen species89. Additionally, 
MSCs have been shown to supress lymphocyte proliferation90. 
Due to these characteristics: multipotent differentiation, immunosuppression, and 
secretion of pro-inflammatory cytokines91, human MSCs (hMSCs) have been the 
main focus of study in the development stem cell therapies. 
1.2.6 Immune response to mesenchymal stem cells 
Severe tissue damage is followed by inflammation92. The diffusion of 
macrophages and neutrophils is mediated by the release of the components of 
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necrotic cells93. It is the phagocytosis of necrotic cells leads to the secretion of pro-
inflammatory factors including tumour necrosis factor (TNF-α) and free radicals94. 
After tissue damage, hMSCs are recruited in response to pro-inflammatory 
factors95,96. This initiates a complex signalling pathway for the mobilisation of 
hMSCs after injury97. It has been proposed that hMSC homing follows a similar 
pathway that have been described for leukocyte homing. In this process, cell 
migration to the damaged vicinity occurs as a consequence of the release of 
cytokines by the vascular endothelium and platelets. Then, a number of molecules, 
through coordinated expression, are implicated in hMSCs rolling and adhesion. 
This results in deceleration of the cells in the blood flow, followed by endothelial 
transmigration and movement into the extracellular space98,99. 
The mechanism by which stem cells contribute to tissue repair has not yet been 
elucidated. Besides hMSCs ability to differentiate and integrate into existing 
tissue98,100 it has been proposed that hMSCs can impact the injury site 
microenvironment with the release of trophic factors that modulate paracrine 
signals101 or the secretion extracellular vesicles (EVs), which contain active 
signalling molecules102. For instance, mesenchymal stem cell EVs have been used 
to treat AC defects in murine models102,103. 
MSCs have also been isolated from the synovium fluid104, where they contribute 
to cartilage repair in small animals105; however, it has been suggested that due to 
the large size of human joints, it is improbable that these cells can migrate the long 
distances to injury sites106. Furthermore, two sub-populations of senescent MSC-
like progenitor cells were found inhabiting knee articular cartilage in OA patients, 
which could be an indication of attempted cartilage repair leading to replicative 
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exhaustion and loss of proliferation107. This suggests that the MSC senescence 
and loss of replication capability leads to the progression of OA106. 
Due to the rare population of hMSCs in the human body (1 in 10,000 BM cells108) 
it is not surprising that research has endeavoured to enhance the recruitment of 
resident stem cells onto the injury sites. This includes the exploitation of the natural 
mechanisms of cell homing, such as the artificial administration of the growth 
factors TGF-β and platelet derived growth factor from blood plasma, which are 
present when wounds initiate109. Furthermore, the local injection of chemokine 
stromal derived factor (SDF-1α)110 and adhesion molecule E-selectin has 
exhibited an increase in the recruitment BM-MSCs111. The excess of cytokines on 
the damaged site might reduce endogenous stem cell response by saturating the 
cell receptors, which are unable to sense difference in chemokine levels and inhibit 
migration110. Other approaches include the modification of the site with DNA 
peptides before injection112. 
1.2.7 Stem cell therapies 
Considering the ability of stem cells to differentiate, they are a promising tool for 
tissue repair and gene therapies. Stem cell therapy involves the injection of stem 
cells into the damaged site (Figure 1.15). Stem cells can be harvested from the 
same person (autologous) or from a donor (allogenic) before being administered 
to the patient. Stem cell therapies are currently being used to treat a variety of 
diseases, including cancer113, heart disease (strokes)114, osteogenesis 




Figure 1.15 Schematic representation of mesenchymal stem cell transplantation. Cells are 
harvested from the bone marrow, isolated, and expanded in vitro. Stem cells can be treated 
or not before injection into the damaged site. Reproduces from68. 
After in vivo transplantation into the patient, common findings have been inhibition 
of innate inflammatory response, survival of existing cells, and fibrosis decrease118. 
Importantly, bone marrow (BM) derived stem cells have been the most popular 
type of SC for research after a PUBMED research involving the use of stem cell in 
cartilage regeneration, from 2000 to 2019. This is primarily because of their 
availability and regeneration capabilities. For example, Sacchetti et al. 
demonstrated that BM resident hMSCs are the only type of MSCs capable of 
forming a whole ectopic ossicle (very small bone) containing bone and 
hematopoietic cells119. Despite this bone ossicle assay not being translatable to 
the clinic, it demonstrates the ability of BM-derived MSCs to differentiate into two 
complimentary tissues106. Additionally, tissues created using autologous stem 
cells do not induce an immune response74. 
1.2.7.1 Stem cell therapies in osteoarthritis of the knee 
The use of human mesenchymal stem cells (hMSCs) to treat osteoarthritis (OA) 
has increased over the past years, encouraged by successful pre-clinical trials in 
large animals, which demonstrated a decrease in the progress of OA120. 
Furthermore, the administration via local intra-articular cavity injection in the knee 
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has been demonstrated to be the safest and optimum approach121,122 and as such, 
has been used in all clinical trials. 
At the present, there are 7067 clinical trials active or completed involving the use 
of stem cells in regenerative therapies (world-wide search in clinicaltrials.gov), 
however, only 20 of these are focussed on treating knee osteoarthritis. There is 
no published data about the outcomes of these studies at present. 
In 2016 a systematic review of the available data demonstrated that implantation 
of hMSCs could successfully alleviate pain symptoms and improve joint motility in 
the knee by forming new hyaline-like cartilage, compared to the control123,124. A 
meta-analysis in 2017125, designed to summarise previous reviews for hMSCs 
therapies in knee defects, was conducted by Yubo, et al. Only articles with a 
sufficient number of candidates submitted to treatment and with an established 
control were used.  The results are summarised in Table 1.1. 
Table 1.1 Available publications of clinical trials for mesenchymal stem cell injection 
therapies, adapted from125 and 126. CT=clinical trial, ACI= autologous chondrocyte injection, 
HA= hyaluronic acid. 
















III 36(20); 36(18) 44.0; 42.5 25 ACI 1–1.5×107 
2014 
(USA)128 
II 18; 19 46 24 Placebo 5×107 
2014 
(USA)128 
II 18; 19 46 24 Placebo 15×107 
2015 (China)125 III 40(14); 40(13) 55.9; 55.1 12 HA 11.5×107 
2015 (Spain)129 II 15(6); 15(5) 56.6; 57.3 12 HA 4×107 
 
Other clinical trials, where adipose-derived stem cells were injected with or without 
growth factors, or osteotomy, have also proven to be successful125. More recently, 
a phase II trial was carried out whereby freshly harvested cells from bone marrow 
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were isolated and administered by intra-articular injection during the same surgery 
with positive results130. 
Importantly, stem cell therapies hold substantial benefits for patients suffering from 
osteoarthritic knee. Nevertheless, there are still limitations regarding clinical trials 
as, for instance, clinical trials for AC repair have scarcely been conducted in 
different countries73, there are no multinational large samples to analyse stem cell 
therapies for OA, and some negative results remain unpublished125. To overcome 
these issues, a greater patient population is needed for a more robust analysis. 
1.2.8 Challenges in stem cell therapies 
One of the main barriers for the clinical translation of stem cell therapies is the lack 
of cell engraftment. Less than 1% of in vitro expanded stem cells can home to the 
damaged tissue. Poor attachment is, in part, because MSCs lose their in vivo 
homing receptors on the cell surface131. Additionally, MSCs cease to produce in 
vivo markers in artificial in vitro expansion culture and, consequently, markers for 
stem cell identification may be different for newly isolated cells than for in vitro 
expanded cultures86. 
The appropriate interaction between hMSCs and ECM is crucial to permit cell 
viability and engraftment. Failure to accomplish MSC-ECM interactions result in 
anoikis (homelessness) and apoptosis132. Cell adhesion is crucial for cell 
communication, and the maintenance and development of tissue. Adhesion is 
implicated in the differentiation, survival, migration, and cycle of the cell. In vivo, 
cells communicate through extracellular and intracellular stimuli by cell-cell 
adhesion or cell-ECM adhesion (focal adhesion) through integrins132. Integrins are 
a subclass of transmembrane adhesion-receptors, which facilitate cell-to-matrix 
adhesion by forming a bridge between the cell cytoskeleton and ECM133. It has 
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been demonstrated that focal adhesions and cell spreading increase with integrin 
binding and clustering134. In musculoskeletal diseases, the effective cell-ECM 
interactions are impeded by the inflammatory toxic environment on the damaged 
site132 (Figure 1.16). 
 
Figure 1.16 Consequences of adhesion and lack of adhesion of stem cells after injection. 
Peripheral vein injection or local injection are the two methods used for stem cell 
transplantation into large organs such as heart and lungs. Both techniques have 
demonstrated the ability of MSCs to engraft into the damaged site, the latter being 
superior for stem cell retention135. In some cases, peripheral intra-artery 
administration leads to MSCs distribution to other healthy tissues such as the 
lungs and small blood vessels (i.e. microvasculature)136. 
A limited number of cells are retained when they are injected in a saline 
suspension, leading to cell death and clearance. Lan et al., found that less than 5% 
of the administered MSCs were retained in the injured lungs site after seven 
days137. Due to this low engraftment rate, large numbers of cells are needed for a 
beneficial effect after transplantation. On average, 107–108 cells are transplanted, 
as seen in the previous section form the clinical trials. This means that a population 
of 105 cells should undergo at least 17 doublings, which may lead to the cells 
reaching senescence, although, this effect might be reversible81. 
Regardless the type of targeted tissue or disease, the survival and engraftment of 
MSCs in injured or healthy tissue are crucial for successful tissue repair, and low 
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engraftment might limit tissue regeneration and reduce paracrine activity138. 
Optimal delivery and engraftment could result in the need of fewer cells. 
In order to improve adhesion and viability of stem cells in the inflamed aggressive 
environment, a variety of techniques have been employed. For instance, it has 
been suggested that the encapsulation of cells in biomaterials might protect them 
from mechanical stress and at the same time, allow them to access nutrients such 
as oxygen and growth factors, and avoid cell displacement139. 
Another factor to consider in the administration of stem cells is the injection itself. 
The shear force produced by the needle while the injection is carried out might 
have a significant impact in the viability of the cells as it can cause rupture of the 
cell membrane140. Therefore encapsulation of cells in hydrogels before delivery is 
ideal to prevent membrane damage, as these materials can also have growth 
factors and proteins embedded in their fibres to improve the cell environment141. 
Hydrogels have proven their ability to retain cells in the damaged site and are 
discussed below in section 1.4. 
The lack of in vivo stem cell retention after transplantation is hampering 
experimental progress and clinical implementation of stem cell therapies. In light 
of this, new methods to condition the stem cells for transplantation are necessary.  
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1.4 Tissue engineering based approaches for 
osteoarthritis 
The inefficient endogenous repair of damaged ECM has led to the progress of 
tissue engineering, mainly utilizing scaffolding materials. The aim of these novel 
materials is to mimic the cartilage ECM environment by supporting cell viability, 
proliferation, and matrix secretion while substituting the function of the missing 
matrix until new articular cartilage (AC) is formed142. For instance, inserted 
collagen scaffolds act as a mesh to enhance the spontaneous healing response, 
this expands the blood clot created after a deep injury in the AC52. 
In order to recreate the ECM microenvironment, scaffolds must be biodegradable 
without exuding toxic by-products. They must be porous to allow circulation of 
nutrients, integrate with existing tissue, and give mechanical support142. 
Over the past years, many of the materials utilised for scaffolds are hydrogels. 
These scaffolds contain a three-dimensional network, allowing for high water 
retention143. They are made by crosslinking polymer chains through covalent 
bonds or sustained by intermolecular interactions (i.e. electrostatic interactions), 
to provide them with elastic and osmotic properties144. Hydrogels can be 
administered with minimal invasion surgery, are injectable and, because of their 
nature, can fill any shape of defect site145 (Figure 1.17). 
Hydrogel-based scaffolds are being created using natural and synthetic polymers. 
Natural polymers include alginate147, chitosan148, collagen149, and fibrin150, which 
can be degraded by natural enzymes. Polyethylene glycol (PEG) is the most 
studied synthetic polymer due to its biocompatibility151, the same is true for its 
derivatives polyethylene glycol methacrylate (PEGMA), polyethylene glycol 
diacrylate (PEGDA)152, followed by polyvinyl alcohol (PVA)153. A mixture of natural 
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and synthetic polymers is often used to attune the material to  the desired 
properties154. 
 
Figure 1.17 Schematic representation of the preparation of hydrogels for tissue 
regeneration. Image reproduced from146. 
Moreover, hydrogels can be produced with a variety of methods, including 
emulsification155, lyophilisation156, electrospinning157, solvent casting158, 
lithography159, and cutting-edge 3D printing technology160,161. 
Importantly, injectable hydrogels can be employed as carriers for medications162, 
growth factors157, or combinations of these163. More recently, hydrogels have been 
used as a cell delivery vehicle. For instance, Smerglio et al. developed a hydrogel 
scaffold containing chondrocytes where the cells were able to survive for up to 
three weeks164. In another study, Chen et al., seeded chondrocytes in an alginate 
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matrix for delivery to in vivo rabbit osteochondral defect model, with an observed 
improvement in knee wound healing165. 
As mentioned above, another functional characteristic of hydrogels is that they can 
be rationally designed to exhibit a wide portfolio of properties. Scaffolds can be 
decorated with different molecules such as the integrin binding tripeptide Arginine-
Glycine-Aspartic Acid (RGD)166. RGD is the minimal sequence within fibronectin 
type III that can be recognised by cell integrins to induce adhesion23, although, this 
affinity is less than that of native fibronectin. Growth factors, fibronectin167, and 
collagen168 have also been used to enhance cell adhesion or to attract cells to the 
injured site. A few studies have revealed the use of hydrogels as a vehicle to 
deliver genes via non-viral vectors (i.e. transfection), with the release of DNA 
before the scaffold is degraded169. Needham reported polymeric scaffolds loaded 
with transcription factors typical for skeletal development and improved the healing 
of osteochondral defects in rats170. However, a significant restriction of these 
scaffolds is the rapid diffusion of DNA content in vivo, low DNA content, and the 
tendency of DNA for aggregation171. At the present, a number of hydrogel-based 
scaffolds with one or more of the aforementioned properties are commercially 
available172. 
Despite biodegradability being the most attractive property of hydrogel-based 
scaffolds, this characteristic also makes them susceptible to mechanical failure, 
since most hydrogels undergo bulk erosion151. For instance, when hydrogels are 
used for AC regeneration, there is a trade-off between stiffness to bare the loads 
and degradability due to compression. 
Regardless of the technique and materials used to create hydrogel-based 
scaffolds, porosity is an essential characteristic to maintain biocompatibility. Pore 
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density and size are crucial to guarantee that cells are at the optimal distance from 
their nutrient source173, and accordingly so that cells can migrate and penetrate 
the full scaffold depth. Pores should be big enough to surround the cells and retain 
them, but not too small to prevent migration. 
Another concern for in vivo compatibility of hydrogel-scaffolds is the toxic remnant 
chemicals that are used for polymerisation or cross-linking precursors146. 
Unreacted monomers, organic solvents and other materials utilised for the 
manufacture of hydrogels may be present even after extensive washing, causing 
cytotoxic and detrimental effects to the implanted site146. Hydrogel scaffolds may 
also instigate foreign body reaction in sensitive patients, leading to the release of 
oxygen free radicals and degradative enzymes174. 
1.2.9 Stem cell conditioning 
Cell resistance to hostile microenvironments has been the focus of many 
investigations to improve stem cell delivery. It has been proposed that the amount 
of oxygen stem cells were exposed to during in vitro expansion has an effect on 
their proliferation, differentiation capacities, and ability to secrete paracrine soluble 
factors175. After injection, MSCs are subjected to sudden stress in a low oxygen 
environment within the tissue defect. Therefore preconditioning within hypoxic 
conditions (1% oxygen) before transplantation has been practised, providing an 
enhancement in the survival rates and engraftment of hMSCs in a pulmonary 
fibrotic mice model137. Adipose-derived MSCs have been treated with hypoxia and 
SDF-1α, which enhanced their retention after administration176. The use of small 
molecule antioxidants, such as curcumin, to treat BM-MSCs  prevents oxidative-




The combination of various techniques has been studied in an attempt to achieve 
superior tissue engineering. Cai et al. demonstrated that MSCs delivered in a 
hydrogel matrix can increase the number of attached cells in a mouse model140. 
In a similar manner, hydrogel nanofibers containing growth factors and seeded 
muscle stem cells proved to enhance cell engraftment and, therefore, tissue 
repair179. The fibres are also able to degrade in parallel with tissue regeneration179. 
Another approach is to treat the target tissue prior to cell transplantation180. 
Regulatory requirements must be complied with when designing new materials, 
such as toxicity, scalability, and cost-effective commercialisation181. In light of all 
of this, there is a vast window of opportunity to improve stem cell therapies by 
employing stem cell membrane engineering strategies. 
1.2.10 Stem cell membrane reengineering 
The engineering or modification of the cell membrane can be achieved by different 
strategies, such as the addition of antibodies, synthetic or natural molecules, as 
well as genetic modification. The introduction of genetic materials into MSCs can 
be accomplished using viral or non-viral vectors. Viral vector modification enables 
long term stable transgene expression. For instance, transfection using a lenti-
virus enhanced the survival rates of rat MSCs and increased resistance to cell 
apoptosis in a hypoxic environment in rat ischaemia model182. 
In the same manner, genetic modification has enabled MSCs to induce 
overexpression of antiapoptotic signalling183,184 and cell adhesion enhancement183. 
However, the use of these viral vectors is accompanied by high levels of pressure 
in the gene regulation185, as overexpression of a gene could cause detrimental 
secondary effects in the long term. 
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The engineering of cell membranes can also be achieved via surface chemistry. 
Hao Cheng et al., engineered the membranes of human MSCs in a two-step 
reaction. First, the amine groups on the cell membrane proteins were 
functionalised with a maleimide containing group, which was subsequently reacted 
with a cystein-cotaining peptide K, a known E-selectin binding peptide to enhance 
cell adhesion into the injured site186. In the innate wound healing mechanism, P- 
selectin plays a key role in the recruitment of leukocytes to the injured site and in 
healthy tissue remains dormant inside of endothelial cells as granules. After 
endothelial cells are activated during inflammation by histamine or thrombin, P-
selectin is transported to the endothelial cell surface. E-selectin has a similar 
purpose, however, it is secreted by endothelial cells in response to the influence 
of cytokines such as TNF-a187. Inspired by this naturally occurring process, Sarkar 
et. al. modified the cell membrane surface of MSCs with cell adhesion molecules. 
Sialyl Lewix X (SLEx), the active site of P-selectin glycoprotein ligand in leukocytes, 
was covalently attached on the surface of the cell membrane with a biotin-
streptavidin bridge. These cells showed superior rolling capacity and attachment 
compared to unmodified cells188. Two years later, the same group used 
biotinylated unilamellar vesicles that integrated into the cell membrane of MSCs. 
Subsequently, SLEx was immobilised on the cell surface with a streptavidin linker. 
The inserted biotinylated lipids were internalised after 8 hours189. 
Another approach has exploited the hydrophobic nature of the cell membrane to 
enhance the adhesion properties of the cells. DNA origami technology was used 
to assemble modified-cell arrays onto chemically functionalised surfaces with 
complimentary DNA sequences190. Akbari et al., used hydrophobic anchors to 
attach DNA self-assembled origami nano-structures to primary cells. Cholesterol 
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conjugated oligonucleotides were used for amphiphilic insertion into the 
membrane, which subsequently bound ssDNA with an incorporated self-
assembled nano-platform that served as a tuneable “breadboard” for specific cell-
cell binding191.  
Artificial membrane-binding proteins have been used to reduce necrosis in MSC-
seeded scaffolds by creating a myoglobin-polymer surfactant complex. This 
complex was created by electrostatic conjugation of the anionic polymer surfactant 
to solvent-exposed positively charges on chemically cationized myoglobin. 
Significantly, when introduced to the cell, the polymer surfactant corona 
surrounding the protein reconfigured to spontaneously insert into the plasma 
membrane, effectively anchoring the construct to the cell at extremely high 
loadings. Pre-treating MSCs with these complexes imparted an oxygen reservoir, 
which under hypoxia, released oxygen when levels were significantly low. The 
synthesis of polymer-protein complexes or conjugates has been utilised not only 
to modify stem cell surfaces, but also to give proteins enhanced solubility 
characteristics192. 
As an alternative to chemically induced cationization during the synthesis of these 
electrostatic conjugates, the use of genetically modified proteins that exhibit a high 
level of positive charge, such as supercharged GFP193 (scGFP) could be 
employed. Indeed, this is core to this thesis and will be discussed below.   
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1.5 The green fluorescent protein 
The green fluorescent protein (GFP) is an inherent protein found in the jellyfish 
Aequorea victoria, and was cloned by Douglas Prasher in 1992194. The GFP gene 
has been used as a marker for gene expression195, as a mutagenesis biosensor196, 
as a probe to detect localisation into cell compartments, and as a non-invasive 
marker for living cells. Wild type GFP is a 21 kDa protein, consisted of 238 residues, 
which defines its primary structure197. GFP has a β-barrel structure, formed by β-
turns, 11 β-sheets and five α-helices, which constitute the secondary 
structure198,199, held by the hydrogen bonds between amino acids (Figure 1.18). 
A segment folded into an α-helix creates a spiral, holding the backbone in a 
straight position where the residues point outwards. The β-strands are short, 
almost completely extended polypeptide segments. Packed β-strands form a β-
sheet. The U-shaped β-turns produce the reverse direction of the protein chain 
(anti-parallel β-sheets), and also helps proteins fold into compact structures23. 
GFP tertiary structure is stable due to the hydrophobic non-covalent interactions. 
 
Figure 1.18 Schematic representation of the green fluorescent protein (GFP). GFP is 
comprised by a β-barrel structure and α-helices. Adapter from200. 
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Correct folding of the GFP structure is necessary to observe the fluorescent 
properties of the fluorophore, as the resulting tertiary structure provides shielding, 
which prevents quenching in the aqueous environment. The native protein has a 
quaternary structure, it forms a dimer, although this has been knocked out of 
laboratory grade GFP. 
The GFP fluorophore is an α-helix with the covalently bound 4-(p-
hydroxybenzylidene) imidazolidine-5-one or HBI. It has been suggested that the 
formation of the chromophore is due to a nucleophilic attack of the amino group in 
glycine 67 (Gly67) on the carbonyl group of serine 65 (Ser65), leading to the 
creation of imidazoline-5-one, which is subsequently dehydrated201. This results in 
the chromophore maturation, which is the formation of a cyclic group with the 
amino group in tyrosine 66 (Tyr66)201. 
Multiple variants of wild-type green fluorescent protein (GFP) have been 
synthesised in order to improve protein folding or to change the emission and 
excitation spectra, the latter resulting in yellow, blue, or cyan fluorescent 
proteins202. Superfolder GFP (sfGFP) was created to enhance folding 
robustness203. This protein was based in the previously modified enhanced GFP 
(eGFP) and Cycle3 GFP, containing 12 mutations in total with respect to the wild-
GFP204. sfGFP remains well folded regardless the stability of the fused protein 
partner203. 
Recently, sfGFP was radically reengineered such that 29 of the solvent-exposed 
amino acids were altered to the positively charged amino acids lysine and arginine 
This novel protein, called supercharged GFP (scGFP), has a theoretical net 
charge of +36 (Figure 1.19). 
The native protein has a quaternary structure, it forms a dimer, although this 




Figure 1.19 Surface representation of supercharged green fluorescent proteins variants. 
Blue: positive charge, red: negative charge. Reproduced from193. 
This scGFP is resistant to aggregation and remains soluble when heated to 100°C. 
Furthermore, scGFP has the ability to interact with mammalian cells in an 
electrostatic fashion with the negatively charged proteoglycans on the cell 
membrane surface205 with low toxicity upon internalisation206. Significantly, this 
new highly cationic globular fluorescent protein presents an exciting new 
opportunity to extend on the work of Armstrong et al.207 to develop a completely 
new class of cell membrane binding proteins. Accordingly, the synthesis of novel 
scGFP-polymer surfactant hybrid constructs is a central to this thesis. 
1.6 Adhesion to the extracellular matrix 
Martino et al. screened the most predominant proteins in the extracellular matrix 
(ECM): fibronectin, vitronectin, tenascin C, osteopontin, fibrinogen and collagen I; 
against 25 growth factors from three different families208. After an enzyme-linked 
immunosorbent assay (ELISA), it was found that placenta growth factor 2 (PlGF2) 
exhibited high affinity for the six ECM proteins. In contrast, placenta growth factor 
1 (PlGF1) did not display significant affinity towards any of the screened proteins. 
The only difference between PlGF1 and PlGF2 is a 21-aminoacid peptide in PlGF2 
with the sequence RRPKGRGKRRREKQRPTDCHL in between amino acids 123 
and 144, subsequently named PlGF2_123−144. 
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Accordingly, the peptide was genetically fused to growth factors platelet derived 
growth factor (PDGF-BB), to produce PDGF-BB/PlGF2_123−144, and to vascular 
endothelial growth factor (VEGF-A165), producing VEGF-A165/PlGF2_123−144. 
These were then administered into a mouse skin would model. The engineered 
growth factors displayed strong binding and retention in endogenous ECM, which 
was attributed to the insertion of the peptide. Moreover, the addition of the 
PlGF2_123−144 domain did not interfere with the growth factors biological activity 
In addition, a significant difference in the number of cells recruited to the damaged 
site was detected when wounds were treated with the modified growth factors 
compared to the wild type due to their persistence on the ECM. 
In light of these findings, it was reasoned that the supercharged GFP could be 
recombinantly expressed fused with the peptide PlGF2_123−144. The new 




1.7 Project design and aims 
In light of the discussion of the literature above, it is becoming clear that one of the 
major challenges in regenerative therapies involving stem cells injection, is the 
efficiency of prompt and firm adhesion for subsequent engraftment of the 
transplanted cells onto the target site. Accordingly, this project is focused on the 
modification of human mesenchymal stem cells (hMSCs) surface membrane using 
protein-polymer surfactant nanobiohybrids, in order to increase the cell adhesion 
number. This can be accomplished by the expression of rational design and the 
synthesis of a fusion protein formed by supercharged green fluorescent protein 
(scGFP) and a placenta growth factor 2 domain (PlGF2_123–144), the expressed 
protein was named [scGFP_PlGF2]. The positively charged scGFP moiety is 
electrostatically bound to the anionic oxidised IGEPAL co-890 polymer surfactant, 
while the PlGF2 domain is free to interact and associate with the ECM surface, 
creating [scGFP_PlGF2][S]. The hydrophobic tail of the polymer surfactant serves 
as an anchor to associate with the cell membrane (Figure 1.20). This 
nanobiohybrid can be used to reengineer the surface of hMSCs to instil enhanced 
ECM binding properties to regulate cell adhesion to natural scaffold might provide 




Figure 1.20 Schematic representation of nanobiohybrid interaction. The supercharged GFP 
barrel is electrostatically conjugated with the surfactant (yellow), which anchors onto the 





1.8 Thesis structure 
This thesis consists of one materials and methods chapter, followed by three 
chapters of results, and a general conclusions chapter. All techniques used to 
perform the research are described in Chapter 2: Materials and methods. In the 
first chapter of results, Chapter 3, the synthesis and characterisation of the 
electrostatically formed nanobiohybrid construct is detailed, including structural 
and biophysical analyses. Chapter 4 describes the interaction of the novel 
nanobiohybrids [scGFP_PlGF2], and [scGFP_PlGF2][S] with human 
mesenchymal stem cells (hMSCs), utilising microscopy, as wells as in vitro 
cytotoxicity, proliferation, and differentiation assays. The final data chapter 
(Chapter 5) explores the ability of the modified hMSCs to interact with proteins 
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All chemicals were purchased from Sigma, UK, and used without further treatment 
unless stated otherwise. Deionised water (dH2O) was obtained with a resistivity of 
18.2 MΩ·cm using a Millipore Milli-Q Reference Water purification system with a 
Quantum TX polishing cartridge. 
2.1 Designing the plasmid 
2.1.1 Plasmid construction 
A multi histidine tag (His6-tag) was placed on the N terminal of the supercharged 
green fluorescent protein (scGFP), and the sequence for peptide PlGF2_123–144 
was placed on the C terminal. 
The plasmid with sequence N-His6-scGFP-PlGF2_123–144-C was designed for 
pOPIN F vector1, which is enhanced for multi-histidine tag purification under 
control of the lac-operon. This vector was also designed for ampicillin resistance. 
This will be referred as scgfp-plgf2_123-144 (Appendix A). 
2.1.2 Gene amplification 
Polymerase chain reaction (PCR) was used to amplify the gene sequence. In 200 
μL PCR Eppendorf, the following mix was added: 1 μL template scgfp-plgf2_123–
144, 1 μL of reverse primer, 1 μL of forward primer, 1 μL polymerase LabTAQ 
(LabTech, UK) and 10 μL of buffer 5x (LabTech, UK), plus 36 μL of DNase free 
water to make a final volume of 50 μL. 
This was submitted for PCR in a thermocycler (Thermo Fisher Scientific, UK) with 
the following settings: 95°C for 5 minutes, 95°C 30 seconds for denaturation at the 
beginning of each cycle, 62°C 30 seconds, 72°C 3 minutes, 90°C to 2°C 30 times, 




Table 2.1 Settings on thermocycler for gene amplification on PCR. 
Step Temperature Time Process 
1 95°C 5 minutes Initialisation 
2 95°C 30 seconds Denaturation 
3 62°C 30 seconds Annealing 
4 72°C 3 minutes Replication 
5  30 times Step 2 to 4 
6 72°C 10 minutes  
7 4°C ∞  
 
A 1.5% w/v gel was made by mixing 0.75 g of agarose DNA grade in 50 mL of 
TAE buffer (Tris base, acetic acid and EDTA). The mixture was boiled in a 
microwave at 800 W (Tesco, UK) and 10 μL of SYBR safe stain (Invitrogen, UK) 
was added to the mixture after cooling down to 40°C. The gel blend was placed 
into a cast and allowed to set for approximately 30 minutes. 
The solid gel was placed in an electrophoresis tank, and enough TAE buffer was 
used to cover the gel. An aliquot of 16 μL of PCR sample was mixed with 4 μL of 
5× DNA loading buffer (Qiagen, UK), and the 20 μL were carefully placed into the 
wells of the gel in duplicate. Hyper ladder (New England BioLabs, UK) was placed 
in the edges of the gel as a reference for molecular weight. A power source of high 
voltage was used to apply 100 V to the electrophoresis system for 40 minutes. The 
band was identified by screening in UV light, and the fluorescent band was 
carefully cut with a razor. For extraction, a QIAquick gel extraction kit was used as 
indicated by the manufacturer. Briefly, the gel was dissolved with buffer provided 
QG, the solution was placed in a column to bind DNA and washed several times 




2.1.3 pOPIN F linearization 
The pOPIN F vector was acquired from the Oxford Protein Production Facility 
(Addgene plasmid # 26042). For linearization, 100 μL of the vector (80 mg×mL-1) 
were added in a 500 μL reaction tube together with 20 μL of 1´ cut smart buffer, 2 
μL restriction enzyme Hind III, 2 μL of Kpn I (New England BioLabs, UK) and 76 
μL of nuclease-free water. The mixture was left to react overnight at 37°C. The 
sample mixture was then treated with a NucleoSpin Gel and PCR clean-up kit 
following the instruction of the manufacturer (Gmbg & Co. KG, Germany) to 
remove enzyme excess. 
2.1.4 Plasmid ligation 
The In-Fusion cloning method2 was used to insert genes into the linearized 
plasmid. 2 μL of infusion 5×-In-Fusion mix (Clontech, USA), 4 μL of purified DNA 
insert scgfp-plgf2_123-144, 2 μL of double despaired pOPIN F, and 2 μL of dH2O 
were placed in a 200 μL reaction tube before equilibration on ice for 20 minutes. 
This tube was then placed in a water bath for 15 minutes at 50°C, and then 
returned into the ice bath. 
2.1.5 Transformation in competent Cells 
Transformation in Competent Stellar Cells (Clontech, UK) was performed 
according to the manufacturer’s instructions. In summary, 2 μL of In-Fusion 
mixture were added to 30 μL of Stellar Competent Cells, and gently mixed. The 
mixture was then submitted to heat shock transformation for 45 seconds at 42°C 
and then placed in an ice bath for equilibration. Subsequently, 1 mL of Super 
Optimal broth with Catabolite repression (SOC) medium was added before the cell 
suspension was incubated for one hour at 37°C. The cell suspension was then 
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centrifuged at 13000 rpm for 10 minutes; the supernatant was discarded, and the 
cell pellet was resuspended in 50 μL of SOC medium. 
2.1.5.1 Lysogenic Broth (LB) agar plates 
LB agar plates were made by autoclaving a mixture of 2.5 grams of LB (Fisher 
scientific, UK) and 1.25 grams of Agar No1 bacteriological (Thermo Fisher 
Scientific, UK). Approximately 25 mL of LB-agar, mixed with carbenicillin (5 μg·mL-
1) were placed in a 9 cm petri dish under sterile conditions, and left to solidify at 
room temperature for 30 minutes. 
2.1.5.2 Blue-white screen 
The blue-white screening is a method that allows the detection of successfully 
transformed bacteria. It relies on the ability of the bacteria to metabolise X-
galactose (X-gal) and generate a white metabolite. 
Under sterile conditions, 40 μL of isopropyl β-D-1-thiogalactopyranoside (IPTG) 
from a 1 M stock in dH2O, as well as 40 μL of X-gal (4 mg·mL-1 in dimethyl sulfoxide 
DMSO) were added to one LB agar plate containing carbenicillin, and 
homogeneously distributed with a cell spreader. The transformed cell suspension 
was carefully dripped on the surface of the agar plate and dispersed with a cell 
spreader. The plate was placed in an incubator at 37°C overnight.  
A single white colony was carefully taken from the LB agar plate and placed in 10 
mL of starter culture (Lysogenic broth with added carbenicillin 5 μg·mL-1), and left 
in rotating motion incubator at 200 rpm over night at 37°C.  
For plasmid DNA purification, a QIAgen Spin Miniprep kit was used according to 
the manufacturer’s instructions, whereby the cells were first lysed in the presence 
of an alkaline buffer, then neutralised in the presence of a high salt buffer to ensure 
binding onto the silica membrane column. The column was washed to remove cell 
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debris and contaminants before the DNA was eluted in a low salt buffer by 
centrifugation3. 
2.2 Expression of scGFP_PlGF2 
2.2.1 Transformation on BL21 cells 
An aliquot of 2 μL of purified plasmid scgfp-plgf2_123–144 was added to a 1.5 mL 
Eppendorf tube containing 50 μL of Competent BL21 Escherichia coli (E. coli) cells 
(New England BioLabs, UK) and equilibrated on ice for 30 minutes. Heat shock 
was performed in a water bath at 42°C for exactly 10 seconds. The cell suspension 
was then equilibrated on ice for 5 minutes before the addition of 950 μL of SOC 
media. The cell suspension was incubated for 60 minutes in shaking incubator at 
200 rpm at 37°C. The resulting mixture was centrifuged at 1300 rpm for 5 minutes, 
and the supernatant was discarded. The cell pellet was resuspended in 50 μL of 
SOC medium and this cell suspension was used to inoculate freshly made LB agar 
plates in duplicate, and incubated overnight at 37°C. 
2.2.2 Protein expression 
The lac operon in the gene plasmid was used to control protein expression and 
ensure that only bacteria containing the gene scgfp-plgf2_123–144 was produced. 
The gene sequence scgfp-plgf2_123–144 was expressed using competent 
BL21(DE3) Escherichia coli cells, as established in section 2.2.1. A single colony 
was chosen to inoculate 10 mL of LB broth, containing carbenicillin (5 μg×mL-1) 
and incubated overnight at 37°C rotating at 200 rpm. The next day, the cell 
suspension was added to 1 L of autoclaved LB medium with 5 μg·mL-1 carbenicillin 
and stirred at 200 rpm at 37°C for approximately 4 hours, until the optical density 
reached 0.6–0.8 at a wavelength of 600 nm. Protein expression was induced using 
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10 mM of IPTG (Apollo Scientific, Japan). The cell suspension was incubated and 
agitated overnight at 200 rpm at 37°C. The bacteria culture was centrifuged at 
4000 g for 35 minutes at 4°C using Sorval RC6 centrifuge (Thermo Fisher 
Scientific, UK). Then, the supernatant was discarded, and the sediment was 
resuspended in 40 mL of lysis buffer (20mM Tris HCl, 1 M NaCl and 20 mM 
imidazole at pH 7.5). Cells were transferred to a 50 mL falcon tube before being 
lysed using sonication alternating 1 second on and 1 second off using a Vibra Cell 
VCX 1500 (Sonics & Materials, USA) at a 63% amplitude for 5 minutes in an ice 
bath. An aliquot of 50μL of phylmethylsulfonyl fluoride (PMSF) solution (100 mM 
PMSF in dimethyl sulfoxide DMSO) was added before and after sonication, along 
with a sufficient amount of lyophilised DNase I from bovine pancreas.  
The lysed sample was centrifuged at 20,000 g for 30 minutes, the supernatant was 
collected and filtered through a 0.22 µm cellulose membrane syringe filter and 
purified by immobilised metal affinity chromatography using nickel nitrilotriacetic 
acid (Ni-NTA) as the immobile phase. 
2.3 Purification of scGFP_PlGF2 
2.3.1 Immobilised Metal Affinity Chromatography 
The idea of immobilised-metal affinity chromatography (IMAC) was first introduced 
in 1975 by Porath et al., based on the observed affinity of positively charged 
transition metals such as nickel, copper, cobalt and zinc to cysteine and histidine 
in solutions4. The purification of proteins using this technique was accelerated by 
Hochuli et al. with the invention of an enhanced chelating agent, nitrilitriaceticacid, 




The Ni-NTA ligand strongly coordinates the nickel ions with four valences to form 
a complex. Then the resin is washed with low imidazole to remove unbound 
proteins. The elution is done via competitive elution by increasing the ionic 
strength of the imidazole buffer to chelate with the nickel6. 
2.3.1.1 Method 
An XK 16 column (GE healthcare life sciences, UK) containing 25 mL of Ni-NTA 
(Qiagen, UK) was washed with at least 5 column volumes of dH2O and equilibrated 
with the same amount of lysis buffer before the lysate was loaded into the column. 
The column was washed with lysis buffer and different gradients of imidazole using 
ÄKTA purifier (GE Healthcare, UK) until eluted with high imidazole buffer (500 mM 
Tris HCl, 1 M NaCl and 20 mM Imidazole adjusted to pH 7.5 with concentrated 
HCl). All eluted fractions were collected in 2 mL Eppendorf tubes. 
The resulting purified protein was buffer exchanged into working buffer (400 mM 
NaCl, 20 mM Tris HCl, pH 7.5) using a 14000 MWCO cellulose dialysis tubing, 
(Fisher scientific, US) at 4°C. The purified protein, named [scGFP_PlGF2], was 
analysed using SDS-PAGE and UV-vis spectroscopy to determine purity, yield and 
concentration. The same method was used to purify [scGFP]. 
2.4 Characterisation Techniques 
2.4.1 Polyacrylamide gel electrophoresis (SDS-PAGE) 
To assess the purity of the protein, [scGFP_PlGF2] was summited to SDS-PAGE. 
Electrophoresis is a technique widely used to separate macromolecules based on 
their molecular weight making use of an electric field. This requires a gel support 
as well as sodium dodecyl sulphate (SDS) to induce protein denaturation. Native 
proteins are able to keep their tertiary structure due to non-covalent forces i.e. 
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hydrogen bonds, ionic and hydrophobic forces. SDS disrupts the non-covalent 
interactions, whilst β-mercaptoethanol is also added to disturb the disulphide 
bonds in the molecule giving them a linear structure and a homogeneous 
distribution of a net negative charge7, making the charge of the protein relative to 
the molecular mass.  
When applying electric current, proteins move through the gel depending on their 
mass, leaving heavier proteins on the top of the gel and smaller molecules moving 
faster through the gel pores. 
2.4.1.1 Method 
For this analysis,10 µL aliquot of the sample was denatured at 95°C for 5 minutes 
with 10 µL of sample application buffer (SAB) containing 100 mL stock made of 
400 mM glycerol, 5% SDS, 50 mM ethylendiaminetetraacetic acid (EDTA), 0.5 mM 
Tris, 7 mM β-mercaptoethanol, and bromophenol was added until dark blue, to 
make them visible. A 4-20% bis-tris gel (Invitrogen, USA) was submerged into an 
X-Cell Surelock electrophoresis chamber (Thermo Fisher, UK) containing running 
buffer (50 mM Tris base, 38.5 mM glycine and 7 mM SDS). 10 µL of the denatured 
sample was added to each well, using a PageRuler Plus Prestained ladder 
(Thermo Fisher, UK) as reference. A power source of high voltage was used to 
apply 200 V to the system for 60 minutes. The gel was removed from the cast and 
distained using dH2O overnight in a shaking motion at 120 rpm at room 
temperature, or with distaining solution (20% ethanol and 5% acetic acid) for up to 
two hours. 
2.4.2 Bicinchoninic acid (BCA) 
BCA is an assay used to determine total protein concentration in a sample. The 
concentration is dependent on the colour change of the sample solution from 
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blue/green to purple caused by the reduction of Cu2+ to Cu1+ ions. The reduction 
is produced by the peptide bonds present in the protein. The amount of Cu1+ is 
proportional to the amount of protein in the sample. First, the copper in copper 
sulphate CuSO4 forms a complex with the protein in the sample solution. Then two 
bicinchoninic acid molecules coordinate with each copper ion to form a purple 
complex that absorbs light at 562 nm8. The spectrum is compared with protein 
solutions of known concentration. 
The reaction that leads to BCA colour formation is strongly influenced by four 
amino acid residues (cysteine or cystine, tyrosine, and tryptophan) in the amino 
acid sequence of the protein. 
2.4.2.1 Method 
A Pierce BCA Protein Assay kit (Thermo Fisher scientific, UK) was used for this 
process. Enough solution for working reagent (WR) was prepared according to the 
number of samples (200 μL of WR in a 96 well plate). This was prepared by mixing 
reagent A ([2,2'-Biquinoline]-4,4'-dicarboxylic acid, sodium salt) and B (Copper II 
sulphate pentahydrate) in a 50 to 1 ratio. 
An aliquot of 25 μL of [scGFP_PlGF2] in solution was added to a 96 well plate 
(Costar, UK), followed by the addition of 200 μL of WR to the same well. The plate 
was incubated at 37°C for 30 minutes and the absorption was measured at 562 
nm with a multi-mode plate reader Synergy neo2 (BioTek, USA). This was also 
performed with known concentrations of bovine serum albumin (BSA) as a control. 
The slope of the linear regression equation line from the plotted graph from 




2.4.3 Matrix-assisted laser desorption/ionization mass spectrometry 
time of flight (MALDI-TOF) 
MALDI-TOF is a technique generally employed to analyse the mass of a 
biomolecule. The mass to charge ratio is calculated by the time of flight, which is 
dependent on the size of the molecule, shorter TOF is characteristic for small 
molecules and longer time of flight for larger molecules9. 
First, the sample is embedded in a crystalline structure (matrix) and it is then 
deposited on a conductive plate. Then, the sample is irradiated with a pulsed laser 
beam, causing structural fragmentation. The resulting particles form a cloud and 
the ions are attracted by an electric field, finally, they reach a detector to produce 
a signal plot10. 
2.4.3.1 Method 
The average molecular weight of the expressed protein, or surfactant were 
obtained using a Bruker MALDI mass spectrometer (Applied Biosystems, UK) 
running FLEX control software (Bruker, USA). The sample was prepared using 1:1 
ratio of cinnamic acid matrix (50:50 solution of acetonitrile and 0.1% TFA and 
saturate with α-Cyano-4-hydroxycinnamic acid), spotted 1 µL sample on rough 
steel plate and let dry at room temperature for 10 minutes before loading into the 
machine. Spectra were taken between 10 and 55 kDa for proteins and 0 to 5 kDa 
for surfactants. 
2.4.4 Synchrotron Radiation Circular Dichroism 
Circular dichroism (CD) is used to analyse the secondary structure and folding 
properties of biomolecules11. A beam of light is circularly polarised and can rotate 
in a clockwise or counter clockwise direction. The enantiomeric properties of the 
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sample determine the absorbance or diffraction of the circularly polarised light in 
different amounts12. After reaching the detector, a single graph is formed 
specifically for that protein. 
2.4.4.1 Method 
Protein samples were used at a concentration between 3 and 3.6 mg×mL-1 in 20 
mM sodium phosphate buffer (100 mM 3.1 g of Na2HPO4, 10.9 g of NaH2PO4 in 
dH2O, pH adjusted with phosphoric acid). Synchrotron radiation circular dichroism 
(SRCD) was performed in Diamond Light Source (Oxford, UK) at the B23 beamline. 
Spectra were measured from 180 to 260 nm, using a cylindrical cell with a 200 μm 
pathlength in a Linkam System. The beam current was 300 mAmps, the slit width 
was 1 mm, and the integration time was two seconds. The CD spectra was 
obtained in a temperature ramp from 24 to 90°C with a measurement every 3 
degrees, equilibrating the sample for one minute every time. The collected data 
was analysed using BestSel Software13. 
2.4.5 Ultraviolet-visible UV-vis spectroscopy 
The most popular technique to quantitative determine the concentration of an 
aqueous substance is UV-visible spectroscopy. This method makes use of the 
electronic transitions of molecules when irradiated with ultraviolet and visible light. 
The wavelength would be absorbed if it emits the exact amount of energy to make 
a transition. Electrons are excited from the ground state into the excited state. A 
spectrum is acquired when the absorption is measured as a function of the 




UV-vis spectroscopy was used to calculate the concentration in aqueous buffer of 
the protein. The absorbance was measured using a Cary 60 UV-Vis spectrometer 
(Agilent Technologies, USA) over the wavelength range 200–600 nm. 
Concentration (C) was worked out using the Beer-Lambert law (Equation 2.1) 
where L is the cuvette path length, A is the absorbance at a wavelength of 280 nm 
and ε is the extinction coefficient, 17330 M-1cm-1 at 280 nm (Protein Calculator, 
RCSB Protein Data Bank). 
A = ε ´ C ´ L               Equation 2.1 
2.4.6 Fluorescence Spectroscopy 
Fluorescence spectroscopy is a kind of electromagnetic spectroscopy which 
analyses the fluorescence emitted from a given sample. The electrons in the 
molecule are excited with an incident photon source, usually UV or visible light. 
When vibrational relaxation occurs, the photons are released with lower energy 
and higher wavelength in the form of emission light. 
Usually, two types of spectrum can be achieved with this technique. An emission 
spectrum can be obtained when the sample is irradiated with a fixed excitation 
wavelength and the emission intensity is recorded as a function of the emission 
wavelength. An excitation spectrum is produced when the emission light is held at 
a constant wavelength and excitation changes are detected16. 
2.4.6.1 Method 
This method was predominantly used to measure fluorescence emission. Samples 
were analysed using a fluorescence spectrometer in Cary Eclipse fluorometer 
(Agilent Technologies, USA) using Cary Scan (Agilent Technologies, USA) 
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software. Excitation and emission scans were performed at room temperature. 
Emission spectra were taken at a different range of temperatures from 350 to 600 
nm, with a high emission peak at 511 nm. 
2.4.7 Dynamic Light Scattering 
Dynamic light scattering (DLS) is a technique used to determine the size 
distribution of particles at micro and sub-micro molecular level. A light 
monochromator is shot into the sample through a polariser, as a result, the incident 
wavelength is scattered in different directions. The scattering can cause 
constructive or destructive interference, leading to a time-dependent fluctuation in 
the scattered light, this pattern is then analysed by the detector17. 
2.4.7.1 Method 
DLS was performed using a UV-micro disposable plastic cuvette with ZetaSizer 
Nano ZS (Malvern Instruments, UK) and ZetaSizer software (Malvern Instruments, 
UK). Samples were filtered with a syringe filter (0.22 µm pore size) before 
measurement, the parameters selected were 3 runs with 10 measurements each 
with 120 seconds of equilibration time at 25 and 37°C. 
2.4.8 Zeta Potential 
Zeta potential is the electric potential in an interfacial double layer in a colloidal 
system. It allows to measure the charge present in molecule surfaces.  
2.4.8.1 Method 
These measurements were taken with ZetaSizer Nano ZS (Malvern Instruments, 
UK) and ZetaSizer software (Malvern Instruments, UK) using a plastic cuvette, the 
parameters selected were from 10 to 100 runs with 120 seconds of equilibration 
time at 25 and 37°C. 
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2.4.9 Small angle X-ray scattering 
SAXS can provide structural information about biomolecules in an aqueous 
solution. A collimated monochromatic beam is irradiated on a sample, generating 
a pattern from the scattered waves, which is the average of the scatter produced 
in all possible orientations. This means that the 2D collector will interpret the 
scattering as a magnitude and not as scattering intensity18. The Diamond beamline 
B21 is dedicated to measure SAXS for samples in aqueous solution. 
2.4.9.1 Method 
Sample measurements were carried out by the mail-in service provided by 
Diamond Light Source (Oxford, UK) in beamline B21. This beamline uses a 
bending magnet source and delivers approximately 3⨉1012 photons per second 
directly to the sample. These photons are then dispersed over a cross-section of 
0.8 mm by 2 mm to enhance the particle signal while minimising radiation damage. 
The detector (Eiger 4M) measures with a scattering vector (q) range from 0.0032 
to 0.38 Å-1 The beam size was <75 µm, operating with a fixed camera length at 
4.014 metres at 12.4 keV. SAXS measurements were coupled with size exclusion 
chromatography (SEC-SAXS) using a superdex 200 column (GE Healthcare). The 
data was collected in 30 successive frames, each with a one second exposure 
time. 
The 60 μL samples were prepared by concentrating the purified construct 
[scGFP_PlGF2], [scGFP] and [scGFP_PlGF2][S] with a 10 MWCO spin 
concentrator (Merck, USA) until the desired concentration was achieved, and 
verified with NanoDrop ND-1000 (Thermo Scientific, USA). The buffer was 
subtracted from the sample before the data was analysed using ScÅtter software 
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with ATSAS plugins19 following the instructions from www.bioisis.net tutorial 
website. 
2.4.9.2 Data representation and interpretation 
The three main plots that can be obtained to give an idea of the studied protein 
are: the raw scattering data, the Kratky plot, and the P(r) distribution plot. 
The obtained scattering data can be presented as a log I(q) vs log q(Å-1). The log 
I(q) axis emphasises the high q data, and the log q (Å-1) highlights the data at the 
low angle which carries the strongest signal. A monodisperse sample (i.e. no 
aggregates, or interparticle repulsion) would show a flat line at small angles20 
(Figure 2.1 a). 
 
Figure 2.1 Representative curves from data obtained with Scåtter. a) scattering data plotted 
as from log q(I) versus q(Å-1). The raw data (blue dots) and fitted data (magenta) display a 
flat line on the low q region, suggesting no aggregations or interparticle repulsion. Note the 
black line was a bead model fit. Adapted from20. b) representation of different Kratky plots 
of scattering data. Folded globular protein (black), a partially folded protein with a random 
coil, or flexible protein (grey), and a fully unfolded protein (red). Adapted from19. c) 
Representation of P(r) distribution plots. A globular protein (blue) displaying uniform 
distribution. Proteins with an elongated feature (red) display a longer tail at larger r. The 
different features in a multi-domain protein produce multiple peaks (black). Adapted from21. 
The Kratky plot (q2×I(q) vs q Å-1) of the scattering data is indicative of globularity 
of the studied protein. The curve for a globular protein would appear as a bell 
shape, whereas a partially folded flexible protein would have a bell shape with a 
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tail that does not return to 0 at high q, and an unfolded structure would display a 
plateau at higher q values (Figure 2.1 b) 
The P(r) distribution function plot is a representation of the distribution of the 
distances between the atoms in the protein in real space. For instance, a protein 
with a high aspect ratio would display a longer tail approaching to zero at larger r, 
while a globular protein would show a single uniform peak21. A protein with multiple 
domains would exhibit multiple peaks (Figure 2.1 c). 
The produced file from ScÅtter was submitted to EMBL DAMMIF online service22 
in order to obtain a dummy atom bead model. Subsequently, the available 
structure for superfolder green fluorescent protein (sfGFP) (PDB ID 2b3p) was 
modified by adding a hexa-histidine tag, and the sequence for PlGF2_123−144 on 
the N and C terminal, respectively. This was done utilising the build and fusion 
functions in PyMOL. Finally, these two models were superimposed on the obtained 
DAMMIF .pdb file. 
2.5 Oxidation of IGEPAL co-890 
Following previous methods23, the oxidised IGEPAL co-890 surfactant [S] was 
synthesised by the oxidation of the hydroxyl groups of polyoxyethylene (n=40) 
nonylphenyl ether to yield a carboxylic acid terminus. First, 2 g of IGEPAL co-890 
were dissolved in 50 mL of dH2O. The solution was then mixed with 30 mg of 
2,2,6,6–Tetramethylpiperidine 1-oxyl (TEMPO), 50 mg of sodium bromide (NaBr), 
and 5 mL of sodium hypochlorite (NaClO) containing 10-15% available chlorine. 
The solution was continually adjusted with sodium hydroxide (NaOH) until pH 11 
was reached and stirred for 24 h inside a safety fume hood. 10 mL of ethanol were 




To purify the oxidised surfactant, solvent extraction was performed by washing 
with three aliquots of 80 mL of chloroform and with the same amount of dH2O at 
pH 1. The chloroform was evaporated from the organic phase under reduced 
pressure at 40°C. The resulting solid was dissolved in 40 mL of ethanol at 65°C 
and recrystallized overnight at -20°C. The ethanol was decanted, and the solid 
product re-dissolved in 20 mL of ethanol at 65°C and dried under reduced pressure 
at 40°C. The resulting product was a waxy white/yellow solid. 
2.5.1 Fourier Transformed Infrared Spectroscopy (FTIR) 
FTIR is used to obtain the vibrational spectrum of a molecule and is a unique to a 
defined molecule. When a sample absorbs infrared radiation, a vibrational 
excitation is induced in the covalent bonds in the molecule. The vibrational modes, 
such as rocking, twisting, wagging, scissoring symmetric or asymmetric stretching, 
depend on the strength and mass of the bonds. The raw data is then analysed by 
the system using the mathematical process Fourier transform to obtain the 
spectrum24. 
2.5.1.1 Method 
The native IGEPAL co-890 and the oxidised resultant polymer were analysed 
using Fourier Transform Infra-Red spectrometer (Perkin Elmer, USA). A small 
amount was carefully deposited onto the sample compartment before spectrum 
acquisition. The data was obtained as the result of 15 accumulations scanning 
from wavenumber 550 to 4000 cm-1. 
2.5.2 Purity of oxidised IGEPAL co-890 
A solution of 2.5 mM oxidised surfactant was needed to perform an acid-base 
titration. 4.5 mL of the solution were titrated with 2.5 mM NaOH and the pH was 
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recorded after every addition and plotted as a function of the added volume. The 
resulting graph was used to determine the concentration of carboxylic acid in the 
oxidised surfactant. The ratio NaOH mol / COOH mol was used to know how many 
molecules of carboxylic acid had been neutralised by sodium hydroxide. 
2.5.3 Extinction coefficient of oxidised IGEPAL co-890 
A solution of 2.5 mg·mL-1 was used to measure absorbance at 280 nm with UV-
vis spectroscopy. A linear equation was used to fit absorbance as a function of 
concentration. The extinction coefficient (ε) was calculated using the gradient (m) 
and the path length of the cuvette (L = 1 cm). 
#
$
= 𝑚 = 𝜀	 × 	𝐿                 Equation 2.2 
2.6 Synthesis of scGFP_PlGF2 conjugate 
To form the nanobiohybrid conjugate [scGFP_PlGF2][S], the concentration of 
protein expressed [scGFP_PlGF2] was known by measuring UV-vis light 
absorbance at 280 and 487 nm. The number of positive sites was counted as 39 
lysine and 27 arginine molecules, giving a total of 66 positive residues (Appendix 
B). The surfactant amount to be added was calculated with Equation 2.3. 
𝑆 = 𝑃- × 𝐶/ × 𝑆0 × 1.4           Equation 2.3 
Where S is the surfactant to be added in mg, Pm is the number of moles calculated 
for [scGFP_PlGF2] Cn is the number of cationic residues present in 
[scGFP_PlGF2], 66, Sw surfactant molecular weight, and since the surfactant is 
added in excess, it is multiplied by 1.4. The solution was stirred overnight at 200 
rpm and it was then dialysed in a 14000 MWCO cellulose bag into 400 mM NaCl 
and 20 mM Tris at pH 7.5. 
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2.6.1 Calculating the amount of bound surfactant 
A UV-vis spectrum from [scGFP_PlGF2][S] before and after conjugation was taken 
from 200 to 600 nm. The difference in absorbance between the two peaks at 280 
nm was used to determine the surfactant to protein ratio after conjugation (Sr) 
using Equation 2.4. 
𝑆𝑟 = 56×77
$6856
    Equation 2.4 
Cn is the number of molecules calculated for [scGFP_PlGF2][S] whilst Pn is the 
number of molecules calculated for [scGFP_PlGF2], multiplied by the number of 
positive residues in the protein (66). 
2.7 General cell culture techniques 
2.7.1 Human mesenchymal stem cell culture 
For optimal cell growth and viability, there are several conditions that must be 
fulfilled by the culture medium. A buffering, such as sodium bicarbonate (NaHCO3), 
is necessary to maintain the cell surroundings at a constant and optimal pH. 
Phenol red is also used as a pH indicator for the system, which turns yellow under 
acidic environments and pink in alkaline environments. Furthermore, sodium 
pyruvate is in the medium as a carbon source for the cells to metabolise. Foetal 
bovine serum (FBS) is added to the media in order to constantly feed the cells with 
growth factors, sugars and lipids. To prevent and control bacterial growth, penicillin 
and streptomycin are supplemented into the medium. L-glutamine is 
supplemented into the media to provide essential nucleotides and energy to 
improve cell metabolism25. 
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In this case, Dulbecco’s Modified Eagle Medium (DMEM) low-glucose medium, 
containing sodium pyruvate and NaHCO3, with or without phenol red, was chosen 
for all cell culture. 
Human mesenchymal stem cells (hMSCs) were isolated from the proximal femur 
bone marrow of patients undergoing total hip replacement surgery, according  with 
the Bristol Southmead Hospital Research Ethics Committee guidelines (reference 
#078/01). All cell culture work was executed in SAFE 2020 laminar flow hoods 
(Thermo Fisher Scientific, UK), and incubated in Hera cell 150 (Thermo Fisher 
Scientific, UK) at 37°C under a 5% carbon dioxide atmosphere. hMSCs were 
expanded in monolayer using T25, T75 or T175 flasks (Fisher Scientific, UK) using 
5, 12, or 25 mL of culture medium respectively. The media was changed every 2 
days. 
The culture medium to expand the collected hMSCs: DMEM containing NaHCO3, 
supplemented with 100 units mL-1 penicillin, 100 µg mL streptomycin, 2 mM 
GlutaMAX supplement (Invitrogen, USA), 10% v/v foetal bovine serum (FBS), and 
5 ng×mL-1 of freshly added basic human fibroblast growth factors (FGF) (Peprotech, 
USA). 
2.7.2 Cell trypsinisation 
After cells reached 90% confluency, they were passaged. Culture medium was 
aspirated, and the cell monolayer was washed twice with 10 mL of Dulbecco’s 
phosphate buffered saline (PBS) without calcium and magnesium, then an aliquot 
of 5–6 mL of trypsin/EDTA solution (Sigma, UK) was added. The flask was placed 
inside the incubator for 5 minutes at 37°C. The flask was gently tapped to ensure 
cell detachment. To inactivate the trypsin, 10 to 12 mL of culture medium were 
added into the flask, and the resuspended cells were transferred into a 50 mL 
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falcon tube (Fisher Scientific, UK) for centrifugation at 1500 rpm for 5 minutes, 
Sorvall Legend RT centrifuge (Thermo Scientific, UK). The supernatant was 
discarded, and the cell pellet was resuspended in culture medium by gently 
pipetting up and down. The cells were counted by adding 10 μL of the cell 
suspension into an AC1000 improved Neubauer haemocytometer (Hawksley, UK). 
The resuspended hMSCs were either passaged to another flask to continue 
culture or treated for experiments. 
2.8 Stem cell modification with nanobiohybrids 
Human mesenchymal stem cells were seeded in well plates at desired density, 
and after adhesion to the plate, they were incubated for 15 and 30 minutes with 2 
mL of [scGFP_PlGF2] or [scGFP_PlGF2][S], and observed with a widefield 
fluorescent microscope (Leica LASX). There was no observable difference in the 
fluorescence intensity between the cells treated for 15 or 30 minutes, therefore an 
incubation time for 15 minutes was chosen.  
hMSCs were also treated in suspension. After trypsinisation and resuspension in 
phenol-free DMEM (without supplements), cells were treated for 15 minutes at 
37°C with 2 mL of 4 µM of either [scGFP], [scGFP_PlGF2] or [scGFP_PlGF2][S] 
in shaking motion at 50 rpm. The hMSCs suspension was centrifuged at 1500 rpm 
for 5 minutes to remove unbound proteins and resuspended in phenol-free DMEM 
without supplements at desired density. 
2.8.1 Cytotoxicity 
MTS is a colorimetric assay used to measure the metabolic rate of the cells to give 




tetrazolium (MTS) into formazan. This reduction is performed by NAD(P)H-
dependent dehydrogenase enzymes presents in the metabolic functioning cells. 
2.8.1.1 Method 
Mesenchymal stem cells from different patients were seeded in a 48 well plate 
(20,000 cells per well). In order to build a standard curve, 0, 500, 1000, 2000, 5000, 
10,000, 14,000 and 20,000 cells per well were seeded in duplicate. The wells 
containing 20,000 hMSCs were exposed to a range of different concentrations of 
[scGFP_PlGF2] and [scGFP_PlGF2][S] (2, 4, 6, 12 and 18 µM) in triplicate for 15 
minutes at 37°C. Cells were rinsed twice with 0.5 mL of PBS and 300 µL of DMEM 
phenol-free culture media (low glucose 1 mg×mL-1) DMEM containing pyridoxine-
HCL and NaHCO3, supplemented with 100 units×mL-1 penicillin, 100 µg×mL-1 
streptomycin, 2 mM GlutaMAX supplement (Invitrogen, USA), 10% v/v FBS and 5 
ng×mL-1 freshly added basic human fibroblast growth factors, FGF (Peprotech, 
USA) and placed in incubator overnight at 37°C in 5% CO2. 
The next day, the media was replaced with 300 µL of phenol-free culture media 
containing 60 µL of CellTiter 96 solution (Promega, USA), containing 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) and placed in incubator at 37°C in 5% CO2 atmosphere. After 
two hours, 100 µL of each well were transferred to a 96 well plate (Corning, UK) 
in triplicate and the absorbance was measured at 490 nm using microplate Mithras 
LB 140 (Berthold technologies, Germany). 
2.8.2 Cell proliferation 
After resuspending hMSCs in phenol-free DMEM (without supplements), they 
were treated for 15 minutes at 37°C with 2 mL of 4 µM of [scGFP_PlGF2] and 
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[scGFP_PlGF2][S] in shaking motion at 50 rpm. Cells were spun at 1500 rpm for 
5 minutes to remove unbound proteins and resuspended in phenol-free DMEM 
without supplements and counted. 100,000 cells were seeded in a T25 flask with 
5 mL of culture medium containing FGF. The medium was changed every two 
days. After seven days, cells were harvested as previously described, counted and 
seeded at the initial density. Population doubling rate (PD) was calculated from 
the number of cells seeded (ns) and harvested (nh), these numbers where then 




         Equation 2.5 
2.8.3 Flow cytometry 
Flow cytometry is used to analyse and/or sort cells in a population according to its 
internal and external characteristics. First, cells are arranged to individually pass 
through an interrogation point containing a laser beam. The light scattered from 
the irradiated cells is collected by detectors located parallel to the beam, forward 
scattering, or in a perpendicularly, side scattering. Additional detectors are placed 
to collect fluorescent emission. 
2.8.3.1 Method 
hMscs were expanded in a T175 flask (Fisher Scientific, UK) until 95% confluency. 
The cells were trypsinised (section 2.7.2) and resuspended in DMEM phenol-free 
medium before they were exposed to 2 mL of 4 µM [scGFP_PlGF2] or 
[scGFP_PlGF2][S] for 15 minutes inside cell culture incubator at 37°C in shaking 
motion 50 rpm. The cell suspension was centrifuged at 1500 rpm for 5 minutes 
and the pellet was resuspended in suitable buffer for flow cytometry, containing 2% 
v/v FBS, 2.5 mM EDTA in PBS, at 1´106 cells per mL with 0.004 mg×mL-1 
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propidium iodide (PI). The cell suspension was transferred to flow cytometry tubes 
(VWR, UK). Samples were analysed with NovoCyte flow cytometer (ACEA 
Biosciences, USA) and analysed using NovoExpress software (ACEA Biosciences, 
USA). Parameters were set to 100-300 events per second with 20,000 events 
accumulated for gate analysis. Untreated cells were used to define the four gates 
as follows: whole cells by forward scatter height (FSC-H) vs side scatter height 
(SSC-H), single cells by forward scatter area (FSC-A) vs (FSC-H), PI negative 
living cells by FSC-A vs Qdot605A and positively labelled cells with GFP were 
defined by FITC-A vs FSC-A. 
2.8.4 Calculating constructs per cell 
hMSCs were seeded at a density of 20,000 cell per well and treated with 0.25, 0.5, 
2, 4 and 6 µM solutions of [scGFP_PlGF2] or [scGFP_PlGF2][S] for 15 minutes at 
37°C under CO2 atmosphere. The supernatant was aspirated and collected for 
UV-vis analysis, taking a full spectrum from 200 to 600 nm. The absorption 
intensity at 487 nm was compared to the known initial absorption and the number 




𝑁#   Equation 2.6 
C0 refers to the initial concentration in moles, Cs is the concentration of the 




2.9 Fluorescent microscopy 
2.9.1 Confocal fluorescent microscopy 
Confocal microscopy is largely use for the detailed resolution images that can be 
obtained. It makes use of a focused laser beam able to focus on a specific spot 
and depth in a sample to emit light at precisely this area. A pinhole within the 
microscope prevents light that is out of focus to reach the detector to avoid 
background. This creates images of a particular optical plane. In order to make 3D 
representations, different optical planes in the sample are scanned. These images 
are then stacked on the z-axis with a suitable software26. 
2.9.1.1 Method 
hMSCs were seeded in glass bottom micro well dishes 35 mm (40,000 hMSCs per 
dish) (MatTek, USA) with culture media and let to adhere overnight. The nucleus 
was stained with 1 µL of Hoechst 33342 (Fisher scientific H3570) and the 
cytoplasm with 1 µL of cell tracker red CMTPX dye (Life technologies C34552) for 
30 minutes at 37°C under 5% CO2 atmosphere. This media was then aspirated 
and replaced with 2 mL of 4 µM of sample [scGFP_PlGF2] or [scGFP_PlGF2][S]. 
Cells were incubated for 15 minutes, then washed twice with 1 mL of PBS. Finally, 
2 mL of complete phenol-free medium (low glucose 1 mg×mL-1 DMEM containing 
pyridoxine-HCL and NaHCO3 with 100 units×mL-1 penicillin, 100 µg×mL-1 
streptomycin, 2 mM GlutaMAX supplement, 10% v/v foetal bovine serum FBS and 
5 ng×mL-1 FGF) was added. The cells were analysed using confocal fluorescent 
microscopy in a Leica DM I6000 inverted epifluorescent microscope in a chamber 
at 37°C under CO2 atmosphere. 
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2.10 Widefield fluorescence microscopy 
Wide field microscopy is a type of light microscopy used to image a fluorescent 
specimen within a sample. The light emitted illuminates at the excitation 
wavelength specific for the fluorophore and it is collected and interpreted by the 
detector as an image. In this case, the complete sample is illuminated and signals 
from all the optical and focal planes are detected27. 
2.10.1 Time lapse microscopy 
hMSCs were seeded at a density of 20,000 cells per well, in tissue cultured treated 
6 well plate 34.8 mm (Corning, UK) with supplemented culture media 24 hours 
previous to the experiment. The nucleus was stained with 1 µL Hoechst 33342 
(Fisher scientific H3570) for 20 minutes at 37°C under 5% CO2 atmosphere. This 
media was then aspirated and replaced with 2 mL of 4 µM of sample 
[scGFP_PlGF2] and [scGFP_PlGF2][S]. Cells were incubated for 15 minutes, then 
washed twice with 1 mL of PBS. Finally, 2 mL of supplemented phenol-free 
medium DMEM (low glucose 1 mg×mL-1) was added. The cells were analysed 
using inverted microscope (Leica LASX) with a 20´ lens at 37°C under CO2 
atmosphere for 12 hours taking one image every 15 minutes. 
2.11 Differentiation assays 
2.11.1 Osteogenesis 
Mesenchymal stem cells from two patients were harvested and 20,000 hMSCs 
were seeded in a 12 well plate. The cells were exposed to 300 μL of 
[scGFP_PlGF2] or [scGFP_PlGF2][S], and cultured in StemPro Osteogenesis 
differentiation medium (Thermo Fisher Scientific, UK), or complete hMSC culture 
medium, with media changes every two days. Antifungal water (100 units of 
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penicillin, 100 μg streptomycin and 2.5 μg of amphotericin in autoclaved dH2O) 
was added to fill the remaining wells of the plate. 
For osteocyte detection, sample wells were gently washed with 500 μL pf PBS 
twice, then cells were fixed with 4% paraformaldehyde (PFA) (BioLegend, USA) 
for 30 minutes at room temperature. The cell monolayer was washed with 500 μL 
of autoclaved dH2O before adding 500 μL of filtered solution of Alizarin Red S (2% 
w/v Alizarin Red S, pH adjusted to 4.1 with HCl). The plate was covered with tin 
foil to protect it from the light and incubated for 30 minutes at room temperature. 
The sample wells were washed four times with 1 mL of autoclaved dH2O, and PBS 
was added. The samples were immediately imaged with a widefield inverted 
microscope and analysed with Fiji software (NIH, USA). All images were converted 
into a 16-bit image and a mean threshold was applied. Then, each image was 
submitted to particle analysis, using 0 to infinity size and 0 to 1 circularity for the 
total area covered by the stained monolayer. 
2.11.2 Adipogenesis 
Cells from one patient were harvested and 20,000 hMSCs were seeded in a 12 
well plate. The cells were exposed to 300 μL of [scGFP_PlGF2] or 
[scGFP_PlGF2][S] for 15 minutes and rinsed twice with PBS. The cells were 
cultured in StemPro Adipogenesis cell medium (Thermo Fisher Scientific, UK), or 
complete hMSC culture medium, with media changes every two days. Antifungal 
water (100 units of penicillin, 100 μg streptomycin and 2.5 μg of amphotericin in 
autoclaved dH2O) was added to fill the remaining wells of the plate. 
After 21 days, the medium was removed by pipetting and the sample wells were 
washed twice with 500 μL of PBS. 500 μL of neutral buffered formalin 10% (10% 
of 37-40 formaldehyde, 90% dH2O, 33.5 mM sodium phosphate monobasic 
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NaH2PO4, and 45.5 mM sodium phosphate dibasic Na2HPO4) to cover the cell 
monolayer, this was incubated at room temperature. After 45 minutes, fixation 
buffer was aspirated, and the wells were washed with 500 μL of autoclaved dH2O 
followed by the addition of 500 μL of 60% isopropanol solution and incubated at 
room temperature for 5 minutes. To stain the cell monolayer, the isopropanol was 
aspirated and Oil Red O staining solution (stock 0.3% Oil Red O in isopropanol, 3 
parts diluted in 2 parts of autoclaved dH2O) was added to fill the wells, filtering the 
solution right before staining. Cells were incubated for 30 minutes and the wells 
were washed several times with dH2O. Images were taking using wide field 
inverted microscope. 
2.11.3 Chondrogenesis 
Cells from three different patients were plated in a 24 well plate at a density of 
50,000 cells per cm2. Cells were exposed to 1 mL of 4 μM of [scGFP_PlGF2] or 
[scGFP_PlGF2][S] for 15 minutes in incubator at 37 degrees. The wells were 
gently rinsed twice with 1 mL of PBS and then 1 mL of chondrogenesis media 
(4500 mg×mL-1 glucose) phenol-free DMEM (pyridoxine-HCl and NaHCO3, 
supplemented with 100 units×mL penicillin and 100 μg×mL streptomycin, 2 mM 
GlutaMAX, 1 mM sodium pyruvate and 1% v/v insulin transferrin selenium ITS 
solution), freshly supplemented 0.01 % v/v dexamethasone, 80 nM L-ascorbic acid 
2-phosphate, and 10 ng×mL-1 of TGF-β3 (R&D Systems, USA). This was done in 
triplicate, with unmodified cells as a control kept in hMSC culture medium, 
changing media every two days. After three weeks, the cells were lysed to extract 
RNA for qPCR analysis. 
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2.11.3.1 RNA extraction 
A Qiagen micro RNasy kit was used to extract RNA from the differentiated cells 
according to manufacturer’s instructions. Briefly, the cells were harvested with 
provided lysis buffer and processed immediately or stored at -80°C for later 
analysis.  
The cells were summited to homogenisation with a 21 G 1½ inch needle. Ethanol 
was added and then loaded into a column to bind RNA and washed to remove 
DNA. The purified RNA was then eluted with DNase free water. The samples were 
kept at -80°C or immediately processed for complementary DNA (cDNA). 
For cDNA preparation, a Takara PrimeScript RT reagent kit (Takara, Japan) was 
used according to the instructions provided by the manufacturer. This was 
performed in 200 μL RNase free PCR tubes, and the resulting mix was summited 
to PCR at 37°C for 15 minutes, 85°C 5 seconds and 4°C for cooling. The resulting 
DNA was immediately used or stored at -80°C for future analysis. 
2.11.3.2 qPCR 
For this technique, a MicroAmp Fast Optical 96-well reaction plate (Applied 
biosystems, UK) was used. On each well, 5.5 μL of a mixture containing 5 μL of 
Τaqman master mix and 0.5 μL of the gene set were deposited on the left wall of 
the well. Followed by the addition of 1 μL cDNA of the sample (section 2.11.3.1) 
with 3.5 μL of DNase-free water. The 96 well plate was covered with adhesive 
PCR plate film (Thermo Fisher Scientific, UK). qPCR was carried out using a 
QuantStudio™ 3D Digital PCR System (Life Technologies). The data obtained 
was analysed using the double delta Ct analysis method. 
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2.12 Measuring stem cell affinity 
2.12.1 Static affinity assay 
A non-tissue culture treated 96 well plate (Fisher, UK) was used to assess 
adhesion of treated cells to different proteins (fibronectin 10 μg×mL-1, collagen I 0.2 
mg×mL-1, collagen II 0.2 mg×mL-1 and BSA 10 mg×mL-1 was used as a control).100 
µL was added to each well in triplicate and left at 4°C overnight. The next day, 
wells were rinsed twice with 100 µL of PBS and unspecific binding sites were 
blocked with BSA solution for a minimum of one hour. 
hMSCs were counted and treated as mentioned in previous method (2.8) with 
either [scGFP], [scGFP_PlGF2] or [scGFP_PlGF2][S]. 10,000 cells per well were 
seeded in each well with 100 μL of DMEM phenol-free medium with no additives 
and incubated at 37°C in a 5% CO2 atmosphere. A standard curve was also made 
with different cell densities (250, 500, 1,000, 2500, 5,000, 7,500 and 10,000 cells 
per well in duplicate), adding DMEM medium with all supplements in a tissue-
culture treatet plate. After four hours, the media was aspirated, and the wells were 
rinsed with 100 μL of PBS twice to remove non-attached cells and debris. DNA 
quantification assay (CyQUANT NF cell proliferation assay kit, Invitrogen) was 
performed to assess cell adhesion to proteins. Τhe solution was prepared diluting 
HBSS buffer 5 times with DNase free water and adding the corresponding dye. 
100 μL of solution was added to each well and the plate was incubated for 60 
minutes. The fluorescence was measured with microplate reader with excitation at 
485 nm and emission at 530 nm. 
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2.12.2 Dynamic affinity assay 
Dynamic cell adhesion experiments were carried out with a Microfluidic pump 
ExiGo (Cellix Ltd, UK), with a shear stress precision of ±0.5%. Vena8 Fluoro+ 
biochips were used to perform this experiment. It contains a total of 8 channels 
(400 µm in width, 100 µm in depth, and 20 mm long), and a reservoir on each end 
(Figure 2.2). The biochip is marked with five equally distributed points, which are 
marked on the top pf each channel. The measurements were performed at each 
of these five positions. 
 
 
Figure 2.2 Schematic representation of a Vena8 Fluoro+ biochip. Each biochip contains 
eight channels 400 µm × 100 µm × 20 mm. Each channel is marked with five equally 
distribuited points, which were used for measurements. Image taken from wearecellix.com. 
All channels of the Vena8 Fluoro+ biochip (Cellix Ltd, UK) were coated with 0.1 
mg·mL-1 collagen II from bovine trachea and left overnight at 4°C in a humidified 
chamber. Unspecific sites were blocked with 10 μg·mL-1 BSA. The channel was 
washed with DMEM phenol-free medium with no additives for 30 seconds at 40 
μL·min-1. Cells were modified and resuspended at a density of 1´106 cells per mL 
in DMEM phenol-free medium without additives. A 50 μL aliquot of cells modified 
with [scGFP_PlGF2] and [scGFP_PlGF2][S] or unmodified, was added into the 
channel reservoir every time, and the suspension was withdrawn with a flow rate 
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of 6, 4 and 3 mL·min-1. This was performed with hMSCs from three different 
patients. In the same way, Vena8 Fluoro+ biochip (Cellix Ltd, UK) was coated with 
10 μg·mL-1 BSA to be used as a negative control. 
2.13 Bovine ex vivo explants harvest 
Cartilage explants were harvested form the lateral and patellar groove of 6–8-
week-old calves, obtained 6–8 hours after death from abattoir F Drury and Sons 
Ltd in Swindon, UK. The legs were carefully washed and disinfected with Rely+On 
Virkon (Dupont, UK) and warm dH2O. The skin from the legs was cautiously 
removed with 22-size surgical blades (Swann-Morton, UK) until the coronet to 
reveal the joint area. The hoofs and the top side of the leg were covered in 
aluminium foil and the exposed surface of the leg was sprayed with 70% ethanol 
in dH2O and placed inside a laminar hood (Figure 2.3 a-c). 
The outer layer was carefully cut to expose the articular cartilage, lateral and 
medial meniscus and to cut the anterior cruciate ligament. The cartilage was taken 
from the lateral and patellar grove. The explant disks were delimited with an 8 mm 
biopsy punch (Stiefel, Germany) and carefully detached with a 22-size surgical 
scalpel (Swann-Morton, UK) and collected with tweezers (Figure 2.3 d-h). The 
discs were added into a falcon tube in PBS containing 1% penicillin/streptomycin 
solution. After dissection, the pieces were placed in individual wells in a 48 well 





Figure 2.3 Cow leg dissection methodology. The legs were washed before removing the 
skin (a-b). Then, the sides were covered with aluminium foil and sprayed with 70% ethanol 
before being placed inside the laminar sterile hood (c). The layer was dissected to expose 
the articular cartilage (d-e). Finally, the cartilage discs were delimited with an 8 mm biopsy 
punch and detached with a scalpel and tweezers (f-h). 
2.13.1 Stem cell affinity assays in ex vivo explants 
Cartilage discs were washed twice in PBS before being cut to 6 mm diameter with 
a biopsy punch (Stiefel, Germany) and placed in a non-tissue culture treated 96 
well plate (Fisher, UK) with 200 μL of DMEM phenol-free medium without 
supplements. Tissue discs were then stained with Hoechst nuclei stain for five 
minutes. hMSCs were treated with [scGFP_PlGF2][S], and resuspended in DMEM 
phenol-free medium, using untreated cells as a control. hMSCs were counted and 
added onto the cartilage surface (20,000 cells) and placed in incubator at 37°C 
with 5% CO2 for four hours. The samples were then used for confocal analysis, 
fixed for scanning electron microscopy SEM imaging or histology analysis. 
2.13.2 Scanning Electron Microscopy 
All tissue samples were fixed with 2.5% glutaraldehyde for one hour. To remove 
excess of fixing agent, the samples were rinsed three times for 10 minutes with 
100 mM sodium phosphate buffer pH 7.4. Cartilage samples were then placed in 
1% osmium tetroxide for one hour and washed three times for 10 minutes with 100 
mM sodium phosphate buffer and washed with dH2O for 10 minutes. Dehydrations 
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steps were made with 25, 50, 70, 80, 90, 96, 100% ethanol before being processed 
with critical point dryer (CPD) Leica EM CPD300, set for 15 cycles of 15°C for 
cooling and slow heating at 35°C, with slow CO2 exchange. The samples were 
carefully removed from the CPD machine and mounted on a SEM specimen stub 
(Ted Pella, USA) with a conductive carbon mount grip on top. The dry samples 
were placed in a high-resolution sputter coater (Agar Scientific, UK) and coated 
with 15 nm from palladium or chromium filament. All samples imaged on Quanta 
200 FEI field emission scanning electron microscopy (Thermo Fisher Scientific, 
UK). 
2.13.3 Histology 
After hMSCs were seeded on ex vivo explants, the samples were fixed in 10% 
neutral buffered formalin overnight at room temperature. The tissue pieces were 
then bathed in 30% sucrose for cryo-sectioning or 70% ethanol. 
2.13.4 Stem cell affinity quantification in ex vivo explants 
Three-dimensional Z-stack images from cartilage with seeded hMSCs were 
flattened to 2D using the Z-project function from the Fiji software package (NIH, 
USA). Then, a median intensity threshold was applied to the images and the 
resulting image was changed into binary with a watershed segmentation. Finally, 
the number of cells were counted excluding sizes smaller than 10 µm. 
2.13.5 Differentiation on ex vivo explants 
Mesenchymal stem cells from three different patients were resuspended and 
treated in suspension with 2 mL of 4 µM [scGFP_PlGF2][S], and seeded in a 6 
mm bovine cartilage explant at a density of 20,000 cells per well in a 96 well plate. 
A control was made with untreated cells. After four hours, the cartilage was 
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transferred into a 24 well plate. The wells were gently rinsed twice with 1 mL of 
PBS and then 1 mL of chondrogenesis media (4500 mg×mL-1 glucose) phenol-free 
DMEM (pyridoxine-HCl and NaHCO3, supplemented with 100 units×mL penicillin 
and 100 μg×mL streptomycin, 2 mM GlutaMAX, 1 mM sodium pyruvate and 1% v/v 
insulin transferrin selenium ITS solution), freshly supplemented 0.01 % v/v 
dexamethasone, 80 nM L-ascorbic acid 2-phosphate, and 10 ng×mL-1 of TGF-β3 
(R&D Systems, USA), changing media every two days. A control was made where 
no TGF-β3 was added, for a total of 12 samples. After three weeks, the samples 
were fixed and sent to the Histology Unit at University of Bristol for sectioning. 
2.13.5.1 Immunohistochemistry 
After fixation in 10% neutral buffered formalin, cartilage samples were submitted 
to the Histology Services Unit (University of Bristol), where samples were 
embedded in paraffin wax to prepare for cutting with a diamond knife. Sections 
were 10 µM thick with 10 μM space between them. Sections were dried in a 
microscope slide (VWR, UK) and stored for analysis. 
Slices were baked for 1 hour at 56 degrees to prevent detachment and dewaxed 
by submerging for 30 minutes in Histoclear solution (National Diagnostics, USA). 
All slices were then rehydrated in three gradients of IMS, starting with 5 minutes 
in 100%, 90% and 70%, before they were put in a Coplin slide jar filled with tap 
water. Slices were rinsed with PBS and a wax pen ImmEdge PAP (Vector 
Laboratories, UK) was used to draw a hydrophobic barrier around each section. 
Proteinase K Ready-to-use (Dako, USA) was used for enzymatic retrieval. 
Sufficient amount of Proteinase K was used to cover the sample, and it was 
incubated at room temperature. After 10 minutes, slices were washed twice with 
PBS for 2 minutes to remove enzyme excess.  To inhibit endogenous peroxidase 
Chapter 2 
 96 
activity was quenched with the addition of 3% H2O2 for 10 minutes, and excess 
was removed with two PBS washes for 2 minutes.  
For the next steps, a Novolink polymer detection kit (Leica, UK) was used. To block 
non-specific proteins, a drop from Novolink Protein Block (0.4% Casein in 
phosphate-buffered saline, with stabilizers, surfactant, and 0.2% Bronidox L as a 
preservative) was placed on each sample for 5 minutes at room temperature, and 
the excess was washed by quickly submerging the slides in PBS. 
For collagen I detection, a Collagen I ab234466 primary antibody (Abcam, UK) 
was used. This was prepared in tris buffer saline TBS (15.2 mM Tris HCl, 4.6 mM 
tris and 150 mM NaCl) containing 1% goat serum, plus concentration matched 
isotope IgG as control Abcam isotype ab170190 Mouse IgG1 kappa monoclonal 
(Abcam, UK). Incubated overnight at 4°C in humidified chamber to avoid 
dehydration of samples. Unbounded antibody was removed by washing with TBS 
3 times for at least 3 minutes. One drop of Novolink post primary (Rabbit anti 
mouse IgG (<10 μg/mL) in 10% (v/v) animal serum in tris-buffered saline/0.09% 
ProClinTM 950) was placed on each sample and incubated for 30 minutes, 
followed by three washes with TBS to prepare for the addition of Novolink polymer 
(Anti-rabbit Poly-HRP-IgG (<25μg.mL-1) containing 10% (v/v) animal serum in tris-
buffered saline/0.09% ProClinTM). Finally, 200 µL of DAB substrate was added to 
all sections and incubated for 3 minutes. Incubation with DAB (1.74% w/v 3,3’ - 
diaminobenzidine, in a stabilizer solution) was necessary to make antigens visible. 
For background, a drop of <0.1% Hematoxylin was used and incubated for 3 
minutes and rinsed with tap water to remove excess solution. 
All slides were dehydrated by 2 minutes immersions in graded IMS 70%, 90% and 
100%, followed by three 5-minute immersions in xylene. Slides were left to air dry 
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for 10 minutes and mounted by adding DPX (mixture of distyrene, a plasticizer, 
and xylene) and sealed with a coverslip on top. Slices were imaged using widefield 
fluorescence microscopy. 
2.14 Surface functionalisation of bovine cartilage 
explants 
The 6 mm cartilage bovine ex vivo explants were first stained with Hoechst to 
identify the chondrocyte population. Then, cartilage discs were submerged in a 1 
µM solution of either [scGFP]. [scGFP_PlGF2] or [scGFP_PlGF2][S] with 1% BSA 
in 1.5 mL Nalgene tubes for 24 hours in a CO2 atmosphere at 37°C. The next day, 
the supernatant was collected and submitted to UV-vis analysis taking a spectrum 
of each solution from 200 to 600 nm. The analysis of the 487 nm absorbance peak 
was used to quantify the protein deposited on the cartilage. This method was taken 
from Krishnan et al.28. 
All discs were then fixed in 4% paraformaldehyde (PFA) overnight. A vertical cross 
section of the discs was cut and analysed using confocal microscopy. 
2.15 Statistical analysis 
All the data obtained was statistically analysed using a student T-test with two-
tailed unpaired samples in Microsoft Excel. Differences between the experimental 
and control groups were compared. The data was expressed as a mean of three 
biological repeats ± standard deviation. A value of p < 0.05 was considered 
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Polymer surfactants have been successfully conjugated with proteins to confer 
beneficial properties such as improved solubility in organic solvents1,2, and 
increased proteolytic resistance3, allowing for the activity of the biological molecule 
to be retained. The formation of these protein-surfactant conjugates can be via 
electrostatic and hydrophobic forces4, where anionic surfactants bind to positive 
residues such as lysine, arginine and histidine, whilst cationic surfactants bind to 
negatively charged residues, such as aspartic acid and glutamic acid; and alkyl 
chains are likely to interact with hydrophobic sites5. 
The formation of these surfactant-conjugates are facilitated by homogenizing the 
surface charge through chemical cationization, as described by Armstrong et al., 
who chemically cationized myoglobin and enhanced green fluorescent protein 
(eGFP) to make it suitable for electrostatic conjugation with anionic polymer 
surfactants6. Here, the team were able to show that the resulting polymer 
surfactant corona reconfigured at the plasma membrane of human mesenchymal 
stem cells, promoting spontaneous and persistent adhesion of the complex6. This 
itself was built upon the pioneering work done by Perriman et al., who cationized 
proteins in order to electrostatically conjugate them with polymer surfactants, 
allowing the conjugates to be dehydrated to create solvent-free liquid proteins7–10. 
Significantly, these protein-polymer surfactant conjugates were folded, exhibited 
high levels of thermal stability and maintained their biological functions, under 
almost completely anhydrous conditions7–10. 
The two-step synthesis described above has shown that it can be used to create 
artificial membrane binding proteins, nevertheless, the cationization step is non-
discriminative, i.e. it might potentially modify all acid sidechains. Although this did 
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not prove to be a problem for oxygen delivery (myoglobin) and fluorescence (eGFP) 
at the cell membrane, amino acid sequences associated with hitting specific 
binding targets on the cell surface or extracellular matrix (ECM) need to be highly 
conserved and not chemically modified. Accordingly, to impart artificial ECM 
binding properties to cells, a supercationic mutant of green fluorescent protein, 
supercharged GFP (scGFP), with a fused peptide from placenta growth factor 2 
(PlGF2_123–144) was expressed and purified, termed [scGFP_PlGF2]. This 
protein was characterised to ensure the peptide-fusion protein did not affect the 
properties of the native scGFP. This was followed by the synthesis and 
characterisation of an anionic surfactant derived from IGEPAL co-890. Finally, as 
some ionic surfactants are known to be protein denaturants when added at 
concentrations near or above their critical micellar concentration (CMC)5,11, the 
properties of the protein-surfactant conjugate were explored to ensure that the 




3.2 Results and discussion 
3.2.1 Characterisation of scGFP_PlGF2  
3.2.1.1 Analysis of the primary structure of scGFP_PlGF2 
The transformed E. coli containing scgfp-plgf2_123-144 gene or scgfp, was 
cultured until the optical density reached 0.8 at 600 nm before protein expression 
was induced using IPTG (see Materials and Methods 2.2.1 and 2.2.2). The 
resulting cell suspension was lysed and purified using immobilised metal affinity 
chromatography, whereby the histidine tag in the protein formed a complex with 
the Ni-NTA, and it was then eluted by competitive elution with high imidazole 
gradients. The protein solution obtained yielded approximately 3–5 mg·L-1 of 
culture. 
The collected fractions of scGFP fused PlGF2_123–144-peptide protein, 
[scGFP_PlGF2], were analysed for purity and molecular weight using 
polyacrylamide gel electrophoresis (SDS-PAGE). Analysis of the SDS-PAGE gel 
with the image analysis software FIJI (NIH, USA) showed a single band at 
approximately 32 kDa, which is close to the theoretical molecular weight, 32.118 
kDa obtained with online tool Protein Calculator v3.4 (Appendix B) (Figure 3.1). 
MALDI-TOF mass spectrometry determined the average molecular weight to be 




Figure 3.1 Polyacrylamide gel (SDS-PAGE) analysis in Fiji software. a) Polyacrylamide gel 
(SDS-PAGE) of purified protein with ladder (right), b) image analysis with Fiji software 
calculated mass to be approximately 32 kDa. 
The extinction coefficients for [scGFP_PlGF2] were determined using the BCA 
assay (see section 2.4.2) with ε=30900 M-1 cm-1 at 487 nm and ε=17391 M-1 cm-1 
for 280 nm. These values were used to calculate subsequent protein 
concentrations and are approximate to the values obtained with the protein 
calculator tool (Appendix B). The ratio of absorbance at 280 and 487 nm was used 
to analyse the protein purity, as contaminant proteins would contribute to 
absorbance at 280 nm but not at 487 nm. 
Similar expression and purification methods were used to obtain scGFP alone, 
[scGFP], to use as a control to determine any changes in the properties caused 
by the fused peptide PlGF2_123–144. Both samples were analysed using MALDI-
TOF mass spectrometry and the peaks were found using mMass software. A 
summary of the mass:charge ratios is found on Table 3.1. The molecular weight 
of [scGFP] was 29275 Da (Figure 3.2), whereas the molecular weight of 
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[scGFP_PlGF2] was 32110 Da (Figure 3.3). The difference in molecular weight 
between [scGFP] and [scGFP_PlGF2] was 2835 Da, which was close to the 
predicted molecular weight of the peptide sequence for PlGF2_123–144, 
calculated to be 2988 Da. This difference could have been be due to the calibration 
of the instrument at the time the molecular weight was determined or potential 
fragmentation of amino acids (Appendix C). 
 
Figure 3.2 Mass spectrometry spectrum from [scGFP]. The mass of the construct was 29275 
Da. The protein sample [scGFP] was mixed with sinapinic acid matrix in a 1:1 ratio. 
 
Figure 3.3 Mass spectrometry spectrum from [scGFP_PlGF2]. The mass of the construct 
was 32110 Da. The protein sample [scGFP_PlGF2] was mixed with sinapinic acid matrix in 
a 1:1 ratio. 
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Table 3.1 The three peaks of MALDI-TOF mass spectrum with corresponding mass divided 
by charge. 
 m/z 
Charge [scGFP] [scGFP_PlGF2] 
1 29275 32110 
2 14637 16046 
3 9759 10703 
 
3.2.1.2 Analysis of the secondary structure of scGFP_PlGF2 
Synchrotron radiation circular dichroism (SRCD) was used to determine the 
secondary structure and thermal stability of [scGFP] and [scGFP_PlGF2]. All 
obtained data was deconvoluted and converted from millidegrees to delta epsilon 
values using the beta-structure selection algorithm (BeStSel)12. In particular, this 
software considers the existing twist in beta-structures and can differentiate 
between parallel and antiparallel beta sheets reliably to accurately predict the 
secondary structure over a wide range of proteins and is optimised for spectra 
obtained from SRCD. Definitions of the analysed parameters can be found in 
Table 3.2. 
Table 3.2 Secondary structure elements identified by BeStSel. 
BeStSel Protein structure 
Helix 1 – regular α-helix The middle part of α-helices 
Helix 2 – distorted α-helix 2-2 residues at the ends of α-helices 
Anti 1 – left-twisted β-strand Left-hand twisted antiparallel β-sheet 
Anti 2 – relaxed β-strand Relaxed (slightly right-handed twisted) antiparallel β-sheet 
Anti 3 – right-twisted β-strand Right-hand twisted antiparallel β-sheet 
Parallel β-strand Parallel β-sheet 
Turn Turns 




The resulting spectra for [scGFP] and [scGFP_PlGF2] have negative peaks at 218 
nm and positive peaks at 195 nm13 (Figure 3.4 a,b). These features are typical for 
the antiparallel β-sheets present in the β-barrel structure of scGFP14, and other 
GFP variants15. In contrast, disordered proteins yield negative peaks near 195 
nm16, which are not present in the spectra obtained. Furthermore, the negative 
features at 222 and 208 nm, and the positive value for 194 nm correspond to the 
literature values for α-helical structures in proteins17. These peaks are more 
pronounced in the experimental data than the beta features as alpha-helices 
absorb more intensely, since the number of residue-residue contacts is higher than 
strands, making it a more robust structure18. The fitting with BeStSel was able to 
clearly define the beta peaks, where protein concentration and the amino acid 
count were considered. 
The right-twisted β-sheets comprise 10–20 % of folding and left-hand twisted β-
sheets are maintained in lower proportions, 1–6%, in both [scGFP] and 
[scGFP_PlGF2] (Figure 3.4 c,d). This was not surprising, given that right-hand 
twisted β-sheet have been found to be more stable than left-hand twisted β-sheet, 
since the right-twist has a lower free-energy19. The greater helical structure in 




Figure 3.4 Synchrotron radiation circular dichroism spectra. All data was fitted and 
deconvoluted with BeStSel software. a) Fitted spectrum from [scGFP] (green) and 
experimental data (black crosses) and residuals (red bars). b) Fitted spectrum and 
experimental data from [scGFP_PlGF2] (orange) with experimental data (black crosses) and 
residuals (red bars). c) Secondary structure composition of the [scGFP] CD spectrum 
deconvoluted. d) Secondary structure composition of the [scGFP_PIGF2] CD spectrum. 
Measurements were taken at 36°C, at a concentration of 0.35 mg·mL-1. 
Lui et al. created +36 scGFP by mutating 29 solvent exposed amino acids on 
superfolder green fluorescent protein (sfGFP) to cationic lysines and arginines20. 
For this reason, sfGFP was used as a standard to compare with the obtained 
SRCD spectra of [scGFP] and [scGFP_PlGF2]. The structural composition for 
sfGFP was calculated from the protein data bank (PDB), accession number 
2B3P21 with BeStSel online tool. However, it should be noted that the data from 
PDB has been analysed using a defined crystal structure at room temperature, 
whereas the data obtained was using a liquid protein [scGFP] and [scGFP_PlGF2] 










































0.10%  Helix1 α-helix
3.38%  Helix2 distorted α-helix
1.37%  Anti1 β-(left-twisted)
16.69%  Anti2 β-(relaxed)




3.84%  Helix1 α-helix
4.51%  Helix2 distorted α-helix
6.69%  Anti1 β-(left-twisted)
16.57%  Anti2 β-(relaxed)






Table 3.3 Summary of secondary structure for modified green fluorescent proteins. The 
composition of [scGFP] and [scGFP_PlGF2] are compared to a standard superfolder GFP. 
 Predicted % Measured % 
 sfGFP scGFP scGFP_PlGF2 
Helix 1 – regular α-helix 0.0 0.1 3.8 
Helix 2 – distorted α-helix 1.7 3.4 4.5 
Anti 1 – left-twisted β-strand 2.0 1.4 6.7 
Anti 2 – relaxed β-strand 27.0 16.7 16.6 
Anti 3 – right-twisted β-strand 13.3 10 16.1 
Parallel β-strand 4.6 11.4 0.1 
Turn 12.3 11.9 13 
Others 39.1 45 39.2 
 
No crystal structure of [scGFP] exists, but by comparing the crystal structure of 
sfGFP with the predicted secondary structure from the PDB21 and primary 
sequence of [scGFP], it was found that 5 of the 29 cationic mutations fall into 310-
helix structures. The sfGFP has six of these helices. Thus, the observed increase 
in the ‘others’ category, where 310-helix content is placed, could derive from these 
mutations disrupting the 310-helix structures in [scGFP]. Although there are studies 
that show that the 310-helix structure can be observed in SCRD with data from 
173–260 nm22, there are also studies that dispute this claim, as truncated data 
from 185–240 is still able to elucidate the 310-helix structure23. This area of CD still 
needs to be explored. 
The supercharged proteins [scGFP] and [scGFP_PlGF2] were further examined 
at a range of temperatures to investigate their thermal stability. This was done by 
taking a measurement at 3-degree intervals from 24 to 90°C, which was the 




Figure 3.5 Temperature ramp synchrotron radiation circular dichroism spectra. a) Fitted 
spectra from [scGFP] and b) [scGFP_PlGF2] coloured with a gradient from blue for lower 
temperatures from 24 to red for temperatures approaching to 90°C. Total conformation 
percentages across the temperature range are shown for each protein, c) [scGFP] and d) 
[scGFP_PlGF2]. Data deconvoluted with the BeStSel web service. Measurements were 
taken at a concentration of 0.35 mg·mL-1. 
There was no observable protein denaturation at 90°C or a change in the overall 
protein structure of [scGFP] compared to [scGFP_PlGF2]. The right-twisted β-
sheets comprise 10–20% of folding and left-hand twisted β-sheets are maintained 
in lower proportions, 5–8%, in both [scGFP] and [scGFP_PlGF2] (Figure 3.5 c,d). 
3.2.1.3 Analysis of the tertiary structure of scGFP_PlGF2 
UV-vis spectrometry revealed two absorbance peaks in the proteins. The 
absorbance peak at 280 nm is due to the aromatic amino acids tryptophan and 
tyrosine in the sequence24, whereas the peak at 487 nm corresponds to the correct 
folding of the chromophore present in both [scGFP] and [scGFP_PlGF2], a 
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tripeptide consisting of the residues threonine (Thr65)25, tyrosine (Tyr66) and 
glycine(Gly67)15 (Figure 3.6).  
 
Figure 3.6 UV-vis spectrum of purified [scGFP] (green) and [scGFP_PlGF2] (orange). 
Measurements were taken in buffer 400 mM sodium chloride, 20 mM Tris.HCl at pH 7.5. 
There was no observable difference between the two different protein constructs 
at 487 nm, indicating that the folding and maturation of the fluorophore remained 
unchanged when the GFP is expressed with the fused PlGF2-123–144-peptide on 
the C terminus. A small increase in the 280 nm region is observed for 
[scGFP_PlGF2], this might be due to the presence of small traces of imidazole 
(which also absorbs at 280) in the buffer, small amounts of protein aggregates at 
the time of measurement, or the due to the presence of lysine or glutamic acid in 
the peptide PlGF2_123-14426. 
A key benefit of using GFP is that it fluoresces when it is correctly folded, and it is 
excited with blue light. Both [scGFP] and [scGFP_PlGF2] absorbed 487 nm light, 
and emit light at 511 nm, which is consistent with previous Stokes shift values 
reported in the literature for scGFP14 (Figure 3.7). This is evidence that when 
expressing the protein with the fused peptide, [scGFP_PlGF2], the fluorescent 
properties of [scGFP] remain unchanged. 




















Figure 3.7 Fluorescence emission and excitation peaks at 10 μM concentration. [scGFP] 
(green solid trace) and [scGFP_PlGF2] (orange solid trace) both peak at 487 nm for 
excitation and at 511 nm for emission (dashed lines). Measurements were taken in buffer 
400 mM NaCl and 20 mM Tris.HCl pH 7.5. 
Dynamic light scattering (DLS) measurements were carried out in triplicate to 
determine the hydrodynamic diameter of the purified proteins (Figure 3.8). The 
average hydrodynamic diameter of [scGFP] was 4.6±0.3 nm, whilst 
[scGFP_PlGF2] resulted in an average hydrodynamic diameter of 5.6±0.7 nm. 
Size and errors were calculated by fitting a non-linear gaussian function and 
combining the standard deviation of the fit and the measurements. The diameter 
of [scGFP] and [scGFP_PlGF2] are within error of the green fluorescent protein 
barrel structure, which is known to be 4.2 nm × 2.4 nm27, although values of 4 nm 
× 2.5 nm have also been reported15. The difference in size between 
[scGFP_PIGF2] and [scGFP] of approximately 1 nm is most likely due to the 
presence of the 21 amino acid peptide chain. DLS particle sizing for number 
distribution measurements assume that all particles are spherical and that the 
refractive index of the particles are known28. 












Figure 3.8 Hydrodynamic diameter size distribution obtained with dynamic light scattering. 
The number percentage measurement was averaged for [scGFP] (green trace) 
[scGFP_PlGF2] (orange trace). Three successive measurements were taken at a 37°C. 
Small angle x-ray scattering (SAXS) was used to understand the conformational 
tertiary structure in space of [scGFP] (Figure 3.9) and [scGFP_PlGF2] (Figure 
3.10). This was performed using in-line size exclusion chromatography at 
Diamond Light Source on the B21 beamline. For details about the SAXS 
experiment, please refer to section 2.4.9. The obtained structural parameters are 
summarised in Table 3.4. 
Table 3.4 Summarised parameters obtained from small angle x-ray scattering for [scGFP] 
and [scGFP_PlGF2]. 
Structural parameters [scGFP] [scGFP_PlGF2] 
Rg (Å) [from P(r)] 25.2 28.1 
Molecular mass Mr [from I(0)] 24 kDa 35 kDa 
 
The size data was consistent with the values obtained from DLS, with an increase 
of approximately 6 angstroms in diameter which might be the contribution from the 
PlGF2 peptide in [scGFP_PlGF2]. The calculated molecular mass for the proteins 
was also within 10% of the previously obtained value with MALDI-TOF. The 















difference in the mass could be due to the quality of the data obtained and the 
software analysis. 
 
Figure 3.9 Small angle scattering (SAXS) data obtained for [scGFP]. a) SAXS scattering 
curve after buffer subtraction. b) Kratky plot demonstrated flexibility in the construct. c) The 
radial probability distribution of the protein. d) PyMOL bead model obtained for [scGFP] 
compared to crystal structure from superfolder GFP 2b2p and manually added multi-
histidine tag in blue. 
The Kratky plot indicates a compact protein containing a flexible component29, 
which could be attributed to the multi-histidine tag fused to the protein for 
purification. The Porod exponent is used as an indication of the flexibility of 
structures: a Porod exponent of 2 corresponds to a highly flexible structure, 
whereas a value of 4 is indicative of inflexibility30. In this case, the resulting Porod 
exponent was calculated to be 2.4, indication of the presence of a flexible molecule. 
Additionally, a bead model obtained with EMBL DAMMIF online service31 showed 
an overlap with the sfGFP crystal structure (Figure 3.9 d) and added hexa-histidine 







































tag. This was done by manually editing the primary sequence in PyMOL to obtain 
the desired chain. 
 
Figure 3.10 Small angle scattering (SAXS) data obtained for [scGFP_PlGF2]. a) SAXS 
scattering curve after buffer subtraction. b) Kratky plot demonstrating flexibility in the 
construct. c) The radial probability distribution of the protein. d) PyMOL bead model 
obtained for [scGFP_PlGF2] compared to crystal structure from superfolder GFP 2b3p and 
manually added multi-histidine tag in blue. 
The results for [scGFP_PlGF2] did not differ considerably from [scGFP]. It did 
show a larger radius of gyration, which is likely due to the presence of the peptide. 
This construct was also shown to be flexible, according to the Kratky plot shape. 
However, the Porod exponent for [scGFP_PlGF2] was calculated to 2.6, which 
could be indicative of increased rigidity from the fused peptide. The resulting bead 
model correlated well with the adapted sfGFP structure with the manually added 
peptide chain and histidine tag (Figure 3.10 d). This was done by manually editing 







































3.2.2 Synthesis of the protein-polymer surfactant nanobiohybrid 
[scGFP_PlGF2][S] 
An oxidised form of IGEPAL co-890 ([S]) was synthesised in order to create an 
anionic surfactant that could electrostatically conjugate with the positive residues 
present on the surface of [scGFP_PlGF2] (Figure 3.11). The hydrophilic head 
group is followed by an amphiphilic polyethylene glycol (n=39) and a hydrophobic 
nonyl phenyl tail Figure 3.11). For detailed information about the surfactant 
synthesis and characterisation, please refer to Appendix D. 
                      
Figure 3.11 Representation of IGEPAL co-890 change after oxidation. The native surfactant 
IGEPAL co-890 (left) is oxidised to obtain the oxidised version presenting a carboxylic acid 
at the end (right). 
The [scGFP_PlGF2], was conjugated with oxidised IGEPAL co-890 to form 
[scGFP_PlGF2][S]. This was facilitated by electrostatic interactions between the 
anionic carboxylic acid of the oxidised IGEPAL co-890 and the 66 cationic residues 
in [scGFP_PlGF2] to form a stable conjugate. Spectroscopic characterisation was 
carried out to determine the nature of the secondary and tertiary structure of 
[scGFP_PlGF2][S]. 
To quantify the stoichiometry of the oxidised surfactant with [scGFP_PlGF2] to 
form [scGFP_PlGF2][S], a UV-vis spectrum was taken before and after 














Figure 3.12 UV-vis spectrum of [scGFP_PlGF2] before surfactant addition (orange) and 
[scGFP_PlGF2][S] (blue). The increased absorption at 280 nm is contribution of the 
surfactant IGEPAL co-890. Measurements were taken in buffer 400 mM sodium chloride, 20 
mM Tris.HCl in pH 7.5. 
The difference in absorbance between the two peaks was used to calculate the 
amount of surfactant bound to each positive residue present in the protein (Sr) 
using Equation 2.4 (section 2.6.1). 
𝑆𝑟 = 56×77
$6856
    Equation 2.4 
Where Cn is the number of molecules calculated for [scGFP_PlGF2[S] and Pn is 
the number of molecules calculated for [scGFP_PlGF2], multiplied by the number 
of positive residues present in [scGFP_PlGF2], 66. The ratio was determined to 
be 1.27 surfactant molecules per positive residue, which implied the presence of 
hydrophobically-driven interactions (in addition to electrostatic) at the surface of 
the protein, as the dynamic surfactant tail could be interacting with hydrophobic 
amino acids in the scGFP domain. 





















3.2.2.1 Analysis of the secondary structure of [scGFP_PlGF2][S] 
Some surfactants have the ability to disrupt tertiary and secondary structure of 
proteins32. Therefore, it was necessary to fully characterise the structure of this 
new hybrid structure to assess the maintenance of structural properties. 
To confirm that the secondary structure of [scGFP_PlGF2] was not affected by the 
addition of the synthetic polymer surfactant, SRCD analysis was performed at 
Diamond light source on the B23 beamline. The obtained data was deconvoluted 
and converted from millidegrees to delta epsilon values using the beta-structure 
selection algorithm (BeStSel)12 with the same parameters used for [scGFP] and 
[scGFP_PIGF2] as above section 3.2.1.2 (Table 3.2). From these data (Figure 
3.13) it can be observed that there was no significant protein denaturation, as the 
secondary structure parameters were maintained, as described in section 3.2.1.2. 
However, there was some evidence of beta to alpha structuration, which may 
result from changes in the local dielectric constant, which is brought about by the 
amphiphilic polymer surfactant corona. The deconvoluted values for 
[scGFP_PlGF2] and [scGFP_PlGF2][S] structures were compared to the DSSP 






Figure 3.13 Synchrotron radiation circular dichroism spectra. All data was fitted and 
deconvoluted with BeStSel software. a) Fitted spectrum from [scGFP_PlGF2] (orange) with 
experimental data (black crosses) and residuals (red bars). b) Fitted spectrum from 
[scGFP_PlGF2][S] (blue) with experimental data (black crosses) and residuals (red bars). c) 
Secondary structure composition of the [scGFP_PlGF2] CD spectrum deconvoluted, d) 
Secondary structure composition of the [scGFP_PIGF2][S] CD spectrum deconvoluted. 
Measurements were taken at 36°C at a concentration of 0.35 mg·mL-1. 
Table 3.5 Summary of secondary structure for modified green fluorescent proteins. The 
composition of [scGFP_PlGF2] and [scGFP_PlGF2][S] are compared to a standard 
superfolder GFP. 
 Predicted % Measured % 
 Superfolder GFP [scGFP_PlGF2] [scGFP_PlGF2][S] 
α-helix 10 8.3 10.1 
β-strand 47 39.4 34.6 
Turn 12 13 12.3 
Others 31 39.2 43 
 
The [scGFP_PlGF2] and [scGFP_PlGF2][S] proteins were examined at increasing 
temperatures from 24 to 90°C, to elucidate whether the addition of the polymer 






















3.84%  Helix1 α-helix
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Figure 3.14 Temperature ramp synchrotron radiation circular dichroism spectra. a) Fitted 
spectra from [scGFP_PlGF2] and b) [scGFP_PlGF2][S] coloured with a gradient from blue 
for lower temperatures from 24 to red for temperatures approaching to 90°C. Total 
conformation percentages across the temperature range are shown for each construct, c) 
[scGFP_PlGF2] and d) [scGFP_PlGF2][S]. Data deconvoluted with the BeStSel web service. 
Measurements were taken at a concentration of 0.35 mg·mL-1. 
There was no observable protein denaturation at 90°C or significant change in the 
overall protein structure between [scGFP_PlGF2] and [scGFP_PlGF2][S]. This 
confirms that the polymer surfactant does not affect the thermal stability of 
[scGFP_PlGF2]. 
The preservation of the secondary structure and function of [scGFP_PlGF2][S] 
could be explained with the 39 PEG chains present in the oxidised surfactant33, 
since surfactants containing alkyl chains alone tend to promote protein 
denaturation by disrupting non-covalent protein bonds and binding to the most 
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hydrophobic chain6, preventing denaturation making [scGFP_PlGF2][S] soluble in 
aqueous solvents. These findings also suggest that this anionic surfactant has the 
ability to form compact monolayers around proteins as predicted before by 
molecular dynamics36. 
3.2.2.2 Analysis of the tertiary structure of [scGFP_PlGF2][S] 
To assess the effect of the conjugation on the folding of the tertiary structure, 
[scGFP_PlGF2] and [scGFP_PlGF2][S] were submitted to fluorescence 
spectroscopy. The absorption of both constructs was observed at 487 nm and the 
emission peak was at 511 nm, which is consistent with previous stokes shift values 
related to scGFP14 and the experimentally derived values obtained above (section 
3.2.1.3). The only observable difference is an increase in the fluorescence 





Figure 3.15 Fluorescence emission and excitation spectra. The excitation of [scGFP_PlGF2] 
(orange solid trace) and [scGFP_PlGF2][S] (blue solid trace) both peak at 487 nm, and the 
emission peak at 511 nm respectively (dashed lines). Measurements were taken in buffer 
400 mM NaCl and 20 mM Tris.HCl pH 7.5. 
The average hydrodynamic diameter increased from 5.6±0.7 nm to 8.3±0.3 nm 
after addition of [S]. This corresponds to a polymer surfactant corona of 
approximately 1.35 nm encapsulating the protein, which is consistent with 
dimensions reported for cationized protein-polymer surfactant analogous33 (Figure 
3.16). All measurements were done in triplicate. Size and errors were calculated 
by fitting a non-linear gaussian function and combining the standard deviation of 
the fit and the measurements. 












Figure 3.16 Hydrodynamic diameter size distribution obtained with dynamic light scattering. 
The number percentage measurement was averaged for [scGFP_PlGF2] (orange trace) and 
[scGFP_PlGF2][S] (blue trace). Three successive measurements were taken at a 37°C. 
Zeta potentiometry was used to determine the electric potential for the native 
[scGFP_PlGF2] and conjugated [scGFP_PlGF2][S] at pH 7.5, which had an 
average surface charge of 21±0.8 mV and  -0.5±0.5 mV, respectively. The positive 
charge is expected due to the positive charge of the solvent exposed cationic 
residues in [scGFP_PlGF2] sequence, lysine and arginine14. It is also important to 
state that the protein is in a pH lower than the previously calculated isoelectric 
point, 10.63 with the online tool Protein Calculator v3.4 (Appendix B). The neutral 
charge in [scGFP_PlGF2][S] was indication that oxidised IGEPAL co-890 was 
electrostatically bound to the [scGFP_PlGF2] positive sites, making the overall 
charge close to zero.  















3.3 Chapter conclusions 
In this chapter, the synthesis and characterisation of a novel biohybrid was 
discussed. Crucially, CD, DLS and SAXS analysis showed that the recombinant 
attachment of the PIGF2 peptide sequence to supercharged GFP did not have a 
detrimental effect upon protein folding conformation or optical properties. 
Furthermore, fluorescence spectrophotometry and CD showed no observable 
change between [scGFP_PlGF2] and the surfactant conjugate [scGFP_PlGF2][S], 
while DLS analysis showed an increase in the radius consistent with the presence 
of a compact polymer surfactant corona. 
3.4 Further work 
Small angle neutron scattering (SANS) could be performed to [scGFP_PlGF2] and 
[scGFP_PlGF2][S], to gain an understanding of the distribution of the surfactant 
corona around the protein by contrast. Here contrast variation SANS experiments 
could be performed using deuterated surfactants to provide more detailed 
structural information of the polymer surfactant corona. 
Obtaining the crystal structure of supercharged proteins, although ambitious 
(supercharged proteins are difficult to crystallise due to their inherent resistance to 
aggregation), would give a better understanding of the effects of mutations carried 
out on superfolder GFP. This could determine if the helices that are mutated are 
still correctly folded in the structure. The sfGFP has also been mutated to change 
the most solvent exposed residues to negative amino acids. It could be interesting 
to explore if a negatively-supercharged protein is able to form conjugates with a 
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4.1.1 The cell membrane  
The cell membrane has long been an important focus of study. It is the barrier that 
separates the cell from its environment, allowing the transport of nutrients 
essential for cell survival, and at the same time preventing it from any damage that 
can be caused by exogenous materials. The cell membrane has been 
characterised as a lipid structure1. In 1972 Singer and Nicholson made the most 
iconic representation to interpret the cell membrane, the fluid mosaic model2, 
which has since served as a platform to interpret the lipid bilayer. This model takes 
into account the most predominant force that holds the membrane together: 
hydrophobic interactions3 (Figure 4.1). 
 
Figure 4.1 Adaptation from the lipid-globular mosaic fluid membrane model. In this cross-
sectional image, the lipids are shown in a variety of colours representing the hydrophobic 
heads towards the outside while the hydrophilic tails face the inside, with globular integral 




The study of the interactions between the cell membrane and its environment, 
such as cell-cell, cell substrate, and cell-environment are of high importance. 
These interactions can be exploited in order to further improve cell therapies. 
Presently, it has been estimated that there are 500–1000 different proteins on the 
cell surface5. These lipids and proteins have a direct effect on the function of the 
membrane, and also inside of the cell. Additionally, the cell membrane possesses 
a layer of glycoproteins (mainly sulphated) on the outer layer called the glycocalyx, 
which allows the cell to interact with the external environment changing cell 
permeability6. Importantly, the glycocalyx has a negative charge. 
The bilayer is a very dynamic interface containing a large amount of proteins, lipids, 
polysaccharides, and fatty acids, interacting with the environment in different 
manners, and modification of it may have an impact in cell behaviour, viscosity, 
stiffness, elasticity, and dynamics. 
4.1.2 Stem cell modification 
Mesenchymal stem cells have broad utility due to their multilineage potential, 
ability to proliferate in vitro, and their relative facile accessibility7. However, there 
are a number of issues that need to be addressed to enhance stem cell therapies 
and tissue engineering, such as adhesion, rapid proliferation and differentiation, 
which may require the modification of cells. 
One of the approaches carried out to enhance cell properties is gene modification, 
which consists on transfecting the cells with new genetic material using, for 
example, viral vectors8 or lipofection8. However, this requires extensive 
experimentation and handling. Furthermore, cultured stem cells tend to mutate if 
they are cultured for long periods of time9. 
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Another technique is functionalisation of the cell membrane which, in contrast, 
offers a less invasive approach which may lead to a faster translation for in vivo 
therapies. Different methods have been explored to functionalise cells with lipids10, 
amino acids11, cytokines12, antibodies13, and nanoparticles14, to mention a few. 
Cell wall turnover, which is the enzymatic process for removal of fragments from 
the lipidic bilayer structure15 should be taken into consideration when modifying 
membranes. 
In order to decorate the outside of the cell, covalent modifications have been made 
to the membrane to attach functional groups that can subsequently interact with 
other particles or antibodies13. Cationic species added in the surrounding media 
to electrostatically bind molecules to the negatively charged cell membrane have 
also been studied. Another strategy is to make use of the hydrophobic interactions 
to anchor lipid tails bound to exogenous particles into the phospholipid bilayer16. 
For instance, in 1991 Kim and Peacock17 used palmitate-conjugate protein A to 
anchor antibodies onto the membrane lipidic bilayer. This technique has been 
further use to anchor and target specific antibodies for chondrogenic cells in 
cartilage18 and to provoke anti-tumour responses19. 
Regardless of the technique used, there needs to be a compromise between 
modifying the surface enough to have a positive effect, but without having an 
impact on the natural properties of the cell. The main factors that need to be 
maintained in the design of surface modification of stem cells are viability, 
proliferation, and differentiation. 
In this chapter, the effects of modifying stem cell membranes with proteins and 
protein–surfactant conjugates are assessed, including cytotoxicity, proliferation 
and differentiation. Furthermore, the affinity of the constructs for cell membranes, 
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and their localisation over time is determined with light microscopy and flow 
cytometry. 
4.2 Results and discussion 
4.2.1 Measuring the viability of stem cells 
Modifying the membrane of human mesenchymal stem cells (hMSCs) with 
proteins and protein–surfactant conjugates could lead to cell damage or death due 
to disruption of membrane structure or function. Cell metabolism has been widely 
used as a marker for viable cells20. Accordingly, the viability of functionalised cells 
was assessed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) colorimetric assay, which measures the 
rate of metabolism of MTS into formazan by breaking a nitrogen-nitrogen bond. 
The cytotoxicity of [scGFP_PlGF2] and [scGFP_PlGF2][S] was shown to be 
dependent on the incubation concentration for either construct (Figure 4.2). In this 
experiment, the viability was normalised to the negative control as a 100% rate 
survival. 
The results showed that after 15-minute incubation, concentrations of 12 μM and 
above, for both native protein and the conjugate, were linked to a significant 
decrease on cell viability. Accordingly, all subsequent experiments were carried 
out using a 4 μM protein concentration for both [scGFP_PlGF2] and 
[scGFP_PlGF2][S]. Studies have revealed that cationic polyplexes might interfere 





Figure 4.2 Cytotoxicity effects of [scGFP_PlGF2] and [scGFP_PlGF2][S] on human 
mesenchymal stem cells (hMSCs). The viability of hMSCs was measured by assessing the 
cell metabolism of MTS into formazan. The data was normalised with respect to the survival 
of the untreated hMSCs used as control (green). hMSCs were exposed for 15 minutes to a 
different range of concentrations of a) [scGFP_PlGF2] (orange) and b) [scGFP_PlGF2][S] 
(blue); measurements were taken 24 hours after exposure. N=5 different patients hMSCs. 
Individual values, mean, and standard deviation are reported; *: p<0.05. 
Another reason for the observed decrease in metabolic rate in the modified cells 
could be due to the presence of unbound exogenous polymer surfactant. In fact, 
it has been reported that detergents can disrupt the cell membrane by forming 
mixed micelles with phospholipids on the surface membrane, which cause cell 
solubilisation23. In order to explore potential surfactant cytotoxicity, a viability assay 
was carried out on hMSCs with solutions containing the free oxidised IGEPAL co-
890 over a range of concentrations that were equivalent to the conjugated 
surfactant concentration in [scGFP_PlGF2][S] (Figure 4.3), e.g., for a protein 
concentration of 2.75 μM, 0.5 mg·mL-1 of surfactant was added in solution. 
Interestingly, the cell survival was not significantly affected by the oxidised IGEPAL 
co-890 until added at 2 mg·mL-1, equivalent to a concentration of 8 μM of 
[scGFP_PlGF2][S], indicating that the toxicity of [scGFP_PlGF2][S] was not 
caused by unbound polymer surfactant molecules. Instead, cell death could be 



















































linked to protein distributed on the cell membrane, preventing the cell from 
interacting with necessary nutrients and growth factors present in the cell medium. 
+36 scGFP has been used as a DNA delivery agent for mammalian cells, however, 
the concentrations used for such experiments were in the nanomolar range24. In 
contrast, the large amount of exogenous protein or conjugate could also have 
caused membrane disruption or bind to intracellular components, causing cell 
death. 
 
Figure 4.3 Cytotoxicity effects of oxidised IGEPAL co-890 on human mesenchymal stem 
cells (hMSCs). The metabolism of human mesenchymal stem cells (hMSCs) was measured 
by assessing the cell metabolism of MTS into formazan. hMSCs were exposed for 15 
minutes to a different range of concentrations of polymer surfactant, and measurements 
were taken 24 hours after exposure. The data was normalised with respect to the survival 
of the untreated hMSCs used as control. N=2 different patients hMSCs. Mean and standard 
deviation are reported; *: p<0.05. 
To evaluate the expansion rate of modified hMSCs, a proliferation assay was 
developed by counting the cells 7 and 14 days after exposure to [scGFP_PlGF2] 
or [scGFP_PlGF2][S] at a concentration of 4 μM (Figure 4.4 and Equation 2.5). 
After one week, the treated cells appeared to show a minor decrease in cell growth 
when compared to untreated cells, however, this change was not significant. The 
result could be due to short-term stress induced by the blocking of cell receptors 
by the modification25, which may prevent the exchange of nutrients and growth 
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factors between the cells and the medium. Importantly, the cells did not lose their 
ability to proliferate after a further 7 days, indicating that there were no long-term 
side effects on exposing cells to [scGFP_PlGF2] or the conjugate 
[scGFP_PlGF2][S] (Figure 4.4). One possibility for this resistance, could be 
clearance of the constructs from the membrane by excision or endocytosis. The 
persistence of the conjugate on the membrane will be discussed in section 4.2.3. 
 
Figure 4.4 Proliferation of human mesenchymal stem cells (hMSCs). hMSCs were exposed 
to 4 µM of [scGFP_PlGF2] (orange) and [scGFP_PlGF2][S] (blue), compared with untreated 
cells (green) as a control. Proliferation was evaluated by manual count of the cells every 
seven days for two weeks. N=3 different patients hMSCs. Mean and standard deviation are 
reported; *: p<0.05. 
The average population doubling time (PD) for each modification was evaluated 




         Equation 2.5 
Where nh is number of cells harvested, and ns corresponds to the initial seeded 
cells. The results from two passages were normalised to the untreated cells, 
summarised in Table 4.1. The difference between modified and unmodified 
populations were not significant. 


















Table 4.1 Normalised population doubling rate for cells treated with [scGFP_PlGF2] and 
[scGFP_PlGF2][S]. The data was normalised to the population doubling rate of the control 
over seven days. 
Time/Construct Control [scGFP_PlGF2] [scGFP_PlGF2][S] 
Day 7 1 0.82±0.08 0.94±0.02 




4.2.2 Measuring the cell membrane affinity for the new constructs 
Flow cytometry was used to evaluate the cell membrane-nanobiohybrid interaction. 
The cells were labelled by resuspension in a solution of 4 µM of either 
[scGFP_PlGF2] or [scGFP_PlGF2][S] (Figure 4.5). 
 
 
Figure 4.5 Two-dimensional flow cytometry with enclosed gates using a density map from 
red to blue. Non-labelled human mensenchynal stem cells (hMSCs) were used to define four 
gates based on granularity, size, viability, and fluorescence. a) Size and granularity 
parameters forward scattered-height vs side scattering-height (FSC-H vs SSC-H) were used 
to identify the population of hMSCs to exclude debris. b) This gate was next used to select 
the single cell population comparing it with forward scatter-area (FSC-A vs FSC-H). c) 
Selected cells were sorted for their viability as determined by a negative staining with a 
propidium iodide gate (FSC-A vs Qdot 605-A). The living cell population was measured with 
FITC-A channel to separate labelled and non-labelled cells within the given sample d) 
untreated cells, e) [scGFP_PlGF2] or f) [scGFP_PlGF2][S] conjugated with surfactant in 




Untreated hMSCs were used as a control to outline the gates for cell type, 
according to their size and granularity using forward scattered (FSC-H) and side 
scattered light (SSC-H) respectively. A red fluorescent Qdot 605-A gate was 
necessary to identify and exclude unviable cells stained with propidium iodide (PI). 
This was followed by a FITC channel to detect hMSCs labelled with 
[scGFP_PlGF2] or [scGFP_PlGF2][S] (Figure 4.5). This gating was designed to 
evaluate the extent of cell affinity for the protein [scGFP_PlGF2] and 
corresponding surfactant conjugate. A 100% of the treated cells with 
[scGFP_PlGF2] and [scGFP_PlGF2][S] were positively labelled with the 
nanobiohybrids, compared to 0.02% fluorescence in untreated cells, confirming 
the affinity of these constructs for the cell membrane. However, when comparing 
the fluorescent intensity of the cells labelled with [scGFP_PlGF2] or 
[scGFP_PlGF2][S], the intensity was higher for cells modified with [scGFP_PlGF2] 
(Figure 4.6). It was hypothesised that there was a difference in the number of 
constructs per cell, depending on whether or not surfactant is present. In order to 
test this, the amount of [scGFP_PlGF2] and [scGFP_PlGF2][S] distributed on the 






Figure 4.6 Mean fluorescence intensity of cells. Human mesenchymal stem cells (hMSCs) 
were treated with 4 µM of [scGFP_PlGF2] (orange) or [scGFP_PlGF2][S] (blue) for 15 
minutes, compared to untreated cells (green). Mean fluorescence intensity was obtained by 
comparing whole living cells with a green fluorescent channel. N=3 different patients 
hMSCs. Mean and standard deviation are reported; *: p<0.05, **: p<0.01. 
hMSCs were seeded at a density of 20,000 cell per well and treated with known 
concentrations of [scGFP_PlGF2] or [scGFP_PlGF2][S] for 15 minutes, the 
supernatant was collected and analysed by measuring the absorption peak at 487 
nm. The absorption intensity was compared to the known initial absorption. The 




𝑁#  Equation 2.6 
Where C0 is initial concentration in moles, Cs is the concentration of the 
supernatant in moles, N is the seeded cell number, and NA is Avogadro’s constant. 



























Figure 4.7 UV-vis spectroscopy was used to analyse the number of constructs deposited 
onto human mesenchymal stem cells (hMSCs). The absorption of the remnant supernatant 
after cell exposure for 15 minutes was measured to assess the number of [scGFP_PlGF2] 
(orange) and [scGFP_PlGF2][S] (blue) constructs per cell. Mean and standard deviation are 
reported. N=2 different patients hMSCs. 
The cell membrane appeared to be saturated after 2 μM for [scGFP_PlGF2][S] 
and 4 μM for [scGFP_PlGF2] as at this point the data suggests that there is no 
significant difference on the number of constructs per cell when treated at higher 
concentrations. The number of nanobiohybrids per cell was calculated according 
to the protein concentration added, giving on average 7.6×109 and 3.5×109 
constructs for [scGFP_PlGF2] and [scGFP_PlGF2][S] respectively, when treated 
at 4 μM working concentration. This result may explain the fluorescent data from 
the flow cytometry experiment in (Figure 4.6), whereby the increased mean 
fluorescence intensity of [scGFP_PlGF2] corresponds to a greater number of 
construct bound relative to the conjugate [scGFP_PlGF2][S]. 
The difference in the amount of protein binding to the cell membrane could be due 
to the high positive charge of [scGFP_PlGF2] protein, as previous studies have 
revealed that positively charged molecules, such as liposomes or polyplexes 
(formed by charged proteins and nucleic acids), have higher binding capacity for 























cells compared to neutral polyplexes due to the negative charge on the cell 
membrane26. There is also the possibility that [scGFP_PlGF2] is being internalised 
by the cells. Indeed, supercharged proteins have been used as transfection agents 
because of their ability to undergo rapid endocytosis in mammalian cells24. In the 
same manner, it has been demonstrated that surfactants can shield the positive 
charge on polyplexes to decrease internalisation rates27. 
The size of the nanobiohybrids could also be playing a role in this matter, since 
the protein with the surfactant corona increases the hydrodynamic diameter, as 
seen in section 3.2.2.2, limiting the number of constructs cells can accommodate 
compared to [scGFP_PlGF2]. Another possibility is that the deposited 
nanobiohybrids could be forming multiple layers on the surface of the cell for 
[scGFP_PlGF2][S]. Changes in absorption and fluorescence of the constructs due 
to denaturation of the fluorophore were considered to be negligible since 
supercharged GFP has exhibited significant protease resistance24. Due to the 
nature of the experiments it is difficult to tell where the protein has been localised 
after exposure, methods such as imaging flow cytometry which allows to take 
images of individual cells, could be used for further experiments. 
4.2.3 Live cell imaging 
To observe the interaction between the nanobiohybrid and hMSC membrane in 
greater detail, live cell confocal microscopy was performed. The images were 
taken after exposing the cells to 4 µM of [scGFP_PIGF2] or [scGFP_PIGF2][S] for 
15 minutes (Figure 4.8). In both cases, it is possible to observe the association of 
the constructs on the surface of the cell membrane. The images appear to show 
green dots in the background, which is due to the tendency of the protein to stick 
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to the surface of the substrate even after two wash steps with PBS, and software 
background subtraction. 
 
Figure 4.8 Confocal images from hMSCs exposed to the constructs for 15 minutes at 37°C. 
a) [scGFP_PlGF2] and b) corresponding conjugate [scGFP_PlGF2][S]. Blue: Hoechst nuclei 
stain, green: [scGFP_PlGF2] or [scGFP_PlGF2][S], red: cell tracker cytoplasm stain. Scale 
bar: 50 μm. 
Time-lapse microscopy was performed to observe the interaction between 
[scGFP_PlGF2] or [scGFP_PlGF2][S] with the hMSCs membranes over 12 hours 
( 
Figure 4.9). The images taken showed that [scGFP_PlGF2] was completely 
internalised by the cells within the first hour, whilst the conjugate was visibly 
retained on the cell surface for up to 12 hours. This suggests that the distinct 
intrinsic physicochemical properties of [scGFP_PlGF2] and [scGFP_PlGF2][S] 
have an impact on their interaction with the cell membrane. The [scGFP_PIGF2] 
likely associated via electrostatic interactions with sulphated proteoglycans, 
whereas [scGFP_PIGF2][S] may interact through a hydrophobic manner with 
lipids in the membrane bilayer. After 24 hours, however, both [scGFP_PlGF2] and 




Figure 4.9 Widefield microscopy time-lapse. Human mesenchymal stem cells (hMSCs) were 
treated for 15 minutes with [scGFP_PlGF2] or [scGFP_PlGF2][S]. a) hMSCs treated with 
[scGFP_PlGF2][S] T=0, and b) one hour after treatment. d) hMSCs treated with 
[scGFP_PlGF2] at T=0, and e) T=1. The same samples were analysed after 24h exposure to 
[scGFP_PlGF2] (c), or conjugate [scGFP_PlGF2][S] (f). Images were taken every 15 minutes 
with an inverted microscope using a 20× lens under a 5% CO2 atmosphere at 37°C. Blue: 




The observation that the [scGFP_PlGF2] was quickly internalised by hMSCs is 
consistent with a previous report, which shows that positively charged 
biomolecules have a higher rate of association and endocytosis28. This energy-
dependent endocytosis of the protein is due to the electrostatic binding that occurs 
between the positively charged protein and the negatively charged sulphated 
proteoglycans on the cell membrane29. Indeed, such positively charged molecules 
have been used as transfection agents due to their efficacy for delivery of 
biomolecules inside plasma membrane21. 
In contrast, [scGFP_PlGF2][S] was retained on the cell membrane for longer due 
to the presence of oxidised IGEPAL co-890, which alters the charge of the 
molecule making it neutral. Previously, it has been demonstrated that when cells 
are pre-treated with sodium chlorate, which inhibits the formation of the cell 
negatively charged proteoglycans, did not influence the affinity for surfactant 
conjugated protein with the cell membrane30. This suggests that the nonylphenyl 
tail of the surfactant inserts into the plasma membrane of hMSCs. 
Mechanistic studies where cells were treated with chlorpromazine, a known 
inhibitor of clathrin formation have demonstrated a decrease in the endocytosis of 
+36 scGFP31, cationized enhanced GFP, and cationized enhanced GFP 
conjugated with oxidised IGEPAL co-89030, although +36 scGFP cellular 
internalisation was still dependent on the presence of anionic sulphated 
proteoglycans31. This energy-dependent process is fully shown after 24 hours of 
exposure. 
Following endocytosis, it was considered important to understand when the 
constructs would be completely removed from the cells. To achieve this, the cells 
were treated as explained in section 4.2.2, and submitted for flow cytometry 
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analysis. The reduction in fluorescence intensity on day two may be a sign of 
denaturation or degradation of [scGFP_PlGF2] and [scGFP_PlGF2][S]. 
Alternatively, cell proliferation and membrane turnover could play a role in the 
dilution of nanoconstructs across the cell population. Additionally, after 12 days of 
treatment, modified hMSCs have lost all exogenous fluorescence (Figure 4.10). 
 
 
Figure 4.10 Cell fluorescence intensity over the course of 12 days. Human mesenchymal 
stem cells (hMSCs) were modified in suspension with 4 µM of [scGFP_PlGF2] (orange) or 
[scGFP_PlGF2][S] (blue). Untreated hMSCSs were used as a control (green). Fluorescence 
was measured every 2–3 days using flow cytometry, with a FITC gate. N=3 different patients 
hMSCs. Mean and standard deviation are reported. Standard deviation bars are smaller than 
the symbol. 
4.2.4 Differentiation 
Human mesenchymal stem cells (hMSCs) are known for their ability to differentiate 
into a variety of tissues, including bone, muscle, cartilage, ligament, and adipose32. 
Differentiation studies were performed on the modified cells to assess their 
capacity to maintain their multipotency. hMSCs cultivated in a monolayer were 
treated with 4 μM of [scGFP_PlGF2] or [scGFP_PlGF2][S], washed and then 
exposed to distinct differentiation environments by replacing the basal culture 



























medium with osteogenic, adipogenic or chondrogenic differentiation medium. 
There was no visible difference when comparing the modified cells with the control 
cells, indicating that the cell membrane modification does not impede the ability of 
the cells to undergo multilineage differentiation (Figure 4.11 and Figure 4.12). 
 
Figure 4.11 Representative images of mesenchymal stem cells (hMSCs) osteogenic 
differentiation. Untreated hMSCs were used as a control (a). Cells modified with 
[scGFP_PlGF2][S] (b) and [scGFP_PlGF2] (c) were cultured for 21 days in osteogenic 
differentiation medium, then assessed for calcium deposits with Alizarin red S stain. A mean 
threshold was applied to achieve discrete sections. Pixel count at the bottom of the image 
was used to identify calcium deposits by measuring the total count of the white area. Scale 
bar: 500 μm. 
 
Figure 4.12 Representative images of mesenchymal stem cells adipogenic differentiation. 
Untreated stem cells were used as a control (a).  Cells modified with [scGFP_PlGF2][S] (b) 
and [scGFP_PlGF2] (c) were cultured for 21 days in adipogenic differentiation medium, then 




Furthermore, chondrogenesis was examined by quantitative PCR (qPCR) 
experiments to measure the degree of mRNA production from col1a2 and col2a1, 
the genes responsible for collagen type I and type II production, respectively. Their 
expression levels were compared to the housekeeping gene GAPDH, which is 
involved in glycolysis and is expressed constitutively33. A significant increase in 
the transcription of the col2a1 gene was observed in the modified cells with 
[scGFP_PlGF2][S] (Figure 4.13). 
 
Figure 4.13 Quantitative PCR results for chondrogenesis differentiation. qPCR data 
comparing variations in mRNA expression relative to housekeeping gene GAPDH in 
undifferentiated human mesenchymal stem cells (hMSCs). Equal amounts of hMSCs were 
modified with [scGFP_PlGF2] (orange), [scGFP_PlGF2][S] (blue) and unmodified cells were 
used as a control (green). All samples were treated with chondrogenic medium for three 
weeks under a 5% CO2 atmosphere at 37°C. N=3 different patients hMSCs. Mean and 
standard deviation are reported; *: p<0.05. 
There are various parameters that can affect the differentiation pathway in stem 
cells, such as rearrangement of the cell cytoskeleton caused by mechanical 
forces34, physicochemical change on the cell surface or oxygen tension35. It has 
been demonstrated that genetic changes can be seen after 24 h of starting 
differentiation36, which is within the time frame that [scGFP_PlGF2][S] persists 
















rearrangement of the actin cytoskeleton is crucial during the first 48 h after 
differentiation has started because disruption in this period may decrease 
osteogenesis37. It has also been reported that a decrease in the actin cytoskeletal 
structure favours chondrogenic and adipogenic differentiation38. In the same 
manner, reduction in the stiffness of the hMSCs has been associated with an 
increase in chondrogenesis and adipogenesis while  osteogenesis is favoured by 
an increase in stiffness39. The above experiments revealed no visual difference in 
the level of osteogenic differentiation between modified and unmodified cells 
(Figure 4.11), suggesting that a change in the mechanical properties of the actin 
cytoskeleton is unlikely to result from cell modification with [scGFP_PlGF2] or 
[scGFP_PlGF2][S]. 
The oxidised IGEPAL-co890 used to build [scGFP_PlGF2][S] contains at least 39 
polyethylene glycol units (PEG). Studies of polyethylene glycol surfactant have 
elucidated its low toxicity40, biocompatibility, and, more recently its ability to 
interact with biomolecules to form conjugates with other proteins41. It has been 
demonstrated that this polymer facilitates the crossing of reagents through cell 
membranes by endocytosis42, as it has been hypothesised that it can lower the 
surface tension of the membrane to improve transport of metabolites in 
mammalian cells43. Another hypothesis is that the polyethylene glycol chains could 
be sequestering nutrients present in the cell medium, and then internalised them 
into the cell when endocytosis occurs within the first 24 hours. 
Finally, hypoxia has been suggested as a factor to drive chondrogenesis in stem 
cells30,35. In light of this, it is possible that the polymer surfactant impedes oxygen 
transfer during the first 12 hours whilst [scGFP_PlGF2][S] is retained on the cell 
membrane.   
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4.3 Chapter conclusions 
In this chapter the ability of the nanobiohybrid constructs to interact with the stem 
cell membrane was evaluated. Cytotoxicity assays demonstrated that the working 
concentration of 4 μM of [scGFP_PlGF2] and [scGFP_PlGF2][S] did not cause 
significant damage to cell metabolism or proliferation rates. Flow cytometry 
experiments revealed that hMSCs labelled with [scGFP_PlGF2] have a higher 
mean fluorescence than [scGFP_PlGF2][S]. This could be due to the rapid 
internalisation of the protein molecules into the cell, making the overall quantity of 
protein higher than [scGFP_PlGF2][S], since this only covers the outer cell 
membrane at the time when the fluorescence measurements were taken. 
The surface modification of the cell did not negatively affect multilineage 
differentiation into osteoblasts, adipocytes and chondrocytes. Conversely, it was 
shown that the construct can upregulate the transcription of co2la1 during 
chondrogenesis. The change in collagen II transcription is due to the surface 
modification of the cell with [scGFP_PlGF2][S] during the first 12 hours. This might 
be due to the polyethylene glycol chains in the polymer surfactant facilitating the 
transport of important nutrients across the cell membrane, and the saturation of 
the membrane with the nanobiohybrid leading to a hypoxic environment, therefore 
promoting differentiation.  
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4.4 Further work 
There are a great number of experiments that have not been explored thus far. It 
would be important to determine the exact mechanism that decrease cell viability 
on modified cells, as this could lead to the fate and interaction of [scGFP_PlGF2] 
and [scGFP_PlGF2][S] with cells. It could be useful to know the path of the cell 
death, since it can occur by apoptosis, autophagy or necrosis, which could be done 
by treating the cells with different markers for colorimetric or flow cytometry assays. 
It was shown that both [scGFP_PlGF2] and [scGFP_PlGF2][S] are fully 
internalised by the cells, however, it would be useful to know if [scGFP_PlGF2][S] 
is endocytosed as a whole entity or if the oxidised IGEPAL co-890 is left outside 
the cell membrane. In this case, a surfactant with a fused fluorescent probe to act 
as a marker could be useful to observe localisation through time. 
Corelated light electron microscopy is a technique that makes use of both 
transmitted electron and fluorescence microscopy to identify co-localisation and 
identify changes in cells. This method could be used to measure the thickness of 
the layer deposited on the cell membrane, as the fluorescent protein could be seen 
by light microscopy. 
Furthermore, exploring the change on the surface membrane after modification is 
of great importance, since changes in the stiffness and surface area of the cell 
have a major impact on cell differentiation and interaction with its environment. 
Atomic force microscopy has been used for these findings in the past to map the 
topographic surface at the cell membrane44. More experiments could be carried 
out to fully investigate the quality of the chondrocytes with qPCR technology to 
elucidate any pathways that are favoured as a result of cell modification, as this 
could have major implications in cell therapies. Finally, it is essential to evaluate 
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the extent of the effect of the polyethylene glycol chains in chondrogenic 
differentiation. This could be done by varying the polyethylene glycol chain length 
in IGEPAL co-890 or by conjugating [scGFP_PlGF2] with different surfactants that 
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5.1.1 The cartilage and the extracellular matrix 
Cartilage tissue can be found throughout the human body in the form of elastic, 
hyaline, and fibrocartilage1. Hyaline articular cartilage provides a smooth gliding 
surface for articulation and enables the transmission of loads to protect the ends 
of the bones in diarthroidal joints1. This type of tissue is avascular, aneural and 
alymphatic2. It contains one type of highly specialised cells, chondrocytes, which 
secrete the extracellular matrix (ECM). 
The cartilage ECM is mainly comprised of water, collagen II and proteoglycans, 
which confer to cartilage the shape and compressive strength3,4. The ECM is 
formed of fibres varying from 50 to 500 nm in diameter5. Particularly, the collagen 
fibres in the superficial zone of the cartilage are densely packed and are arranged 
in parallel to the articular surface1. 
Within the articular cartilage, there are three zones based on their distance to the 
chondrocytes: pericellular, territorial and interterritorial matrix6. The pericellular 
matrix contains glycoproteins, proteoglycans and other non-collagenous 
molecules. It is the closest in proximity to the chondrocytes, surrounding the cell 
membrane7. The territorial matrix encapsulates the pericellular matrix and contains 
fine collagen fibrils forming a network around the cells6. 
5.1.2 Cell-extracellular matrix interactions 
Cell-ECM interactions are not only responsible for the arrangement, 
morphogenesis, phenotype acquirement and maintenance of the cells, but also 
play an important role in wound healing8. These interactions allow cells to bind to 
the ECM through focal adhesions and promote direct communication between the 
Chapter 5 
 162 
cells and ECM8. These interactions also prompt a change in the cytoplasmic 
domain of the integrin receptor, which associates with the cytoskeleton at focal 
adhesion sites, and regulates the response of the cells as a consequence of ECM 
adhesion9. 
The cell surface possesses two kinds of receptors for the attachment to ECM: non-
integrin and integrin receptors10. Integrins are heterodimeric cell transmembrane 
proteins, that enable cell-ECM adhesion11. Once cells have approached the 
substrate surface and commenced the attachment process, the spreading phase 
of adhesion is induced by integrins (Figure 5.1). As the integrins on the cell surface 
bind to certain sequences on the ECM, they cluster on the surface of the cell 
membrane associating with the cytoskeleton and promote the production of actin 
filaments11.The association of integrin receptors with the actin cytoskeleton may 
also induce the rearrangement of the matrix9 and modify the ability of cells to 
proliferate and differentiate12. 
 
Figure 5.1 Schematic representation of cell-extracellular matrix interactions. Integrin 
receptors bind to extracellular matrix proteins. Reproduced from13. 
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The ECM is also able to interact with proteins including growth factors. In fact, they 
have been used as agents to improve wound healing14. Due to the innate ability of 
growth factors to bind to ECM, their binding moieties have been isolated such as 
those that interact with the heparan sulphate proteoglycans on the ECM15. For 
instance, the sequence from 123 to 144 in placenta growth factor 2 (PlGF2_123–
144) has high affinity for the main proteins on the ECM such as fibronectin, 
fibrinogen, and vitronectin14. 
Stem cells, due to their capacity for proliferation and differentiation, are a 
promising tool for minimally invasive tissue engineering approaches. Accordingly, 
there has been significant interest in the development of injectable cell therapy 
approaches to treat cartilage damage. For example, Murphy et al. showed the 
therapeutic benefit after injecting stem cells into an osteoarthritic caprine animal 
model, delaying the progression of OA. Saulnier et al. also reported on the 
inhibition of metalloproteinases after injecting mesenchymal stromal stem cells 
into the knee joints of rabbits16. However, one of the major challenges associated 
with these approaches is directing the cells to the desired locations in sufficient 
numbers without off-target effects. For example, Adachi et al. reported the 
generation of scar tissue free-bodies after the transplantation of stem cells in the 
knee due to the excess and free movement of the cells17. 
A possible solution would be the rational modification of hMSC membranes to 
enhance their adhesion, engraftment, and integration in place. Accordingly, in this 
chapter, the interaction of [scGFP], [scGFP_PlGF2] and [scGFP_PlGF2][S] 
modified hMSCs with ECM protein components and bovine articular cartilage 
explants is explored. First, the adhesion of the modified cells was investigated on 
a controlled surface with collagen I and collagen II. Then, the cell adhesion in a 
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dynamic environment was examined using microfluidics over a rage of shear 
stresses. Bovine ex vivo explants were also used as a substrate to evaluate the 
degree of mesenchymal stem cell association in a living ECM. Finally, the 




5.2 Results and discussion 
5.2.1 Static affinity assay 
The stability of the nanobiohybrids on the surface of human mesenchymal stem 
cells (hMSCs) was evaluated on Chapter 4. The viability, proliferation rate and 
multilineage differentiation were not inhibited after hMSC membrane modification 
with [scGFP_PlGF2] and [scGFP_PlGF2][S]. Additionally, it was found that 
[scGFP_PlGF2][S] could persist on the surface membrane for up to 12 hours after 
modification, and be completely removed from the cell after 12 days. Accordingly, 
in this chapter, the affinity of the modified hMSCs for extracellular matrix (ECM) 
proteins is explored. 
Collagen II is the predominant collagen secreted by chondrocytes, and it 
comprises 95% of articular cartilage18. Although collagen I is a minor constituent 
of normal articular cartilage19, it has also been found in osteoarthritic cartilage20 
and fibrocartilage21. Furthermore, collagen III, IV, V, VI, IX, and XI are all present 
in the cartilage ECM19 in low quantities. 
To quantify the affinity of modified hMSCs for ECM components, plate-wells 
coated with collagen I, collagen II, or bovine serum albumin (BSA) were exposed 
to suspensions of hMSCs modified with either [scGFP], [scGFP_PlGF2], or 
[scGFP_PlGF2][S], as described in section 2.8. The number of hMSCs was 




Figure 5.2 Static affinity assay. Human mesenchymal stem cells (hMSCs) were used 
untreated as a control (green), or treated for 15 minutes with [scGFP_PlGF2] (orange), 
[scGFP_PlGF2][S] (blue), or [scGFP] (grey). hMSCs were suspended in DMEM phenol free 
media without any supplements and plated into wells pre-coated with collagen type I (0.2 
mg×mL-1), collagen type II (0.2 mg×mL-1) or bovine serum albumin (BSA) (10 mg×mL-1). The 
hMSCs were incubated on the wells for four hours at 37°C in a 5% CO2 atmosphere. Cell 
attachment was measured by DNA quantification. N=4 different patient’s hMSCs. Mean and 
standard deviation are reported; *: p<0.05. 
Figure 5.2 shows that there is a significant difference in the cell affinity between 
surfaces coated with collagens and BSA, since hMSCs are naturally adherent to 
surfaces coated in collagen type I22 or II23. For the substrate coated with collagen 
I, hMSCs modified with [scGFP_PlGF2] did not show a significant difference when 
compared with the unmodified hMSC control. The treatment with 
[scGFP_PlGF2][S] appeared to show an increased in the number of cells attached 
onto the substrate, however, this change was not significant. The number of cells 
attached when modified with [scGFP] was not different between collagen I and 
collagen type II. 
Importantly, the presence of both PlGF2_123–144 peptide and surfactant IGEPAL 
co-890 ([scGFP_PlGF2][S]) had a significant impact on the cell affinity for collagen 
type II when compared to [scGFP], [scGFP_PlGF2], and the unmodified hMSCs. 
This could be attributed to the longer persistence of the conjugates on the cell 

















membrane surface (Chapter 4, section 4.2.3). Alternatively, the increased affinity 
for collagen type II may have resulted from the orientation and display of the 
peptide in the fusion when membrane binding was via hydrophobic tail insertion. 
With respect the difference in the adhesion between the collagens, it has 
previously been determined that the fibrils of collagen I and collagen II pack 
differently, with collagen I exhibiting less space between the fibres24, which might 
reduce cell binding due to a lower surface area for interaction. 
Martino and colleagues demonstrated that the PlGF2_123–144 domain, present 
in placenta growth factor 2, has affinity for heparan sulphate, vitronectin, and 
fibrinogen, poor binding to collagen I, but did not do assays against collagen type 
II14. This was not unexpected given that a binding site for collagen I to growth 
factors has not yet been found14. 
5.2.2 Dynamic affinity assays 
Due to the inherent adhesion of hMSCs to collagen I and collagen II, adhesion 
experiments were performed under flow. This not only provides a more effective 
method for separating highly adhesive cells, but also valuable information on how 
the modified cells would perform when shear stress is present (Figure 5.3). Shear 
stress is the result of the friction caused by the fluid flow against a capillary surface, 
in this case, the human body25. For instance, 2 dyne×cm-2 is approximately the 
shear stress in human arteries in vivo26, and in large arteries this range can be as 
high as 10 to 40 dyne×cm-2 27,28. Since there was no significant difference between 
the groups in the collagen I substrate assays, the dynamic affinity assays were 
only carried out using a collagen II substrate. 
For this experiment, a biochip was coated with collagen type II and hMSCs were 
modified with either [scGFP_PlGF2] or [scGFP_PlGF2][S]. Unmodified cells were 
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used as a control. Flow rates of 0.75, 1.0 and 1.5 dyne×cm-2 were utilised, which 
are in the vicinity of the a physiologically relevant flow in the synovium (0.5 
dyne×cm-2) 29–31, and cell adhesion quantified in five different positions of the 
channel (Figure 5.3). Importantly, the hMSCs modified with [scGFP_PlGF2][S] 
exhibited a significantly increased affinity for collagen II, even at the fastest flow 
rate tested of 1.5 dyne×cm-2. A negative control was also performed whereby the 
biochip was coated with only BSA, which resulted in negligible cell adhesion 
(Figure 5.3 a). 
 
Figure 5.3 Dynamic affinity assays. Human mesenchymal stem cells (hMSCs) were treated 
for 15 minutes with [scGFP_PlGF2] (orange) and [scGFP_PlGF2][S] (blue) compared to 
untreated cells as a control (green) at a density of 1´106 cells per mL in a serum-free medium. 
The cells were added to a reservoir in a VenaFluoro8 biochip coated with a) collagen type II 
(0.2 mg×mL-1), and b) bovine serum albumin (BSA) (0.1 mg×mL-1). N=3 different patients 
































This result is an indication of the greater binding affinity that is provided to the cells 
after modification with [scGFP_PlGF2][S], which supports the hypothesis that the 
surfactant-modified construct effectively presented the collagen II binding motif in 
a conformation that was not sterically hindered and for long enough periods for 
binding. 
5.2.3 Adhesion assays on bovine cartilage ex vivo explants 
After having verified that the engineered hMSCs with [scGFP_PlGF2] and 
[scGFP_PlGF2][S] were able to bind to and be retained on ECM proteins in a 
coated substrate, it was necessary to determine whether delivering these cells 
could express the same strong association for bovine ex vivo explants. 
Accordingly, bovine articular cartilage discs were taken from the lateral and 
patellar groove from 6 to 8-week-old calves, 8 hours after slaughter (section 2.13). 
Bovine calves’ joints are rich in collagen II, and similar to the human knee joint. 
hMSCs were resuspended, modified with [scGFP_PlGF2] or [scGFP_PlGF2][S], 
and then added to ex vivo explants. After four hours, the unbound cells were 
washed with phosphate buffer saline (PBS) and the cartilage was imaged with 
fluorescent widefield microscope to observe the remaining adhered cells (Figure 
5.4). 
It was observed that hMSCs were able to attach to the surface of the bovine 
explant discs. The images suggest that [scGFP_PlGF2][S] was retained on the 




Figure 5.4 Widefield images from modified human mesenchymal stem cells (hMSCs) on 
cartilage ex vivo explants. hMSCs were treated for 15 minutes with 4 μM of [scGFP_PlGF2] 
(upper row) and [scGFP_PlGF2][S] (middle row). Untreated cells were used as a control 
(bottom row). The cells were then added to bovine cartilage discs of 6 mm diameter and 
were allowed to attach for four hours at 37°C in a 5% CO2 atmosphere in a serum-free 
medium. a) transmitted light image of bovine cartilage, b) green fluorescent channel 
showing modified cells with [scGFP_PlGF2] on surface and c) overlay of the two channels. 
d) transmitted light image, e) fluorescent channel showing modified cells with 
[scGFP_PlGF2][S], f) overlay of channels, g) transmitted light image, h) fluorescent red 
channel showing control cells, i) overlay of channels. Green: [scGFP_PlGF2] and 
[scGFP_PlGF2][S], red: cell tracker cytoplasm stain. Scale bar: 100 μm. 
In order to quantitatively measure the adhesion of hMSCs, confocal fluorescent 
microscopy was performed on ex vivo explants after the addition of hMSCs 
modified with [scGFP_PlGF2][S], using unlabelled cells as a control. Calculations 
were done by image analysis with Fiji (NIH, USA). The modification of 
mesenchymal stem cells with [scGFP_PlGF2][S] led to a marked increase in 
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adhesion to the ECM of ex vivo explants when compared to unmodified hMSCs. 
The numbers correspond to cells per acquired image (Figure 5.5). 
 
Figure 5.5 Adhesion assay in bovine ex vivo explants. Human mesenchymal stem cells 
(hMSCs) were treated for 15 minutes with [scGFP_PlGF2][S] (blue), using untreated cells as 
a control (green). hMSCs were suspended in DMEM phenol-free media without any 
supplements and added to 96 well plate containing a 6 mm diameter bovine ex vivo explant 
disc. Cells were allowed to attach for four hours at 37°C in a 5% CO2 atmosphere. N=6 
cartilage discs. Mean and standard deviation are reported; *: p<0.05. 
In addition to water and collagens, bovine and human cartilage ECM is also rich 
in heparan sulphate proteoglycans, which are important for cartilage 
development32. Growth factors, such as fibroblast growth factor, are known to be 
heparin-binding proteins that also have a high affinity for heparan sulphate 
proteoglycans33. Heparin and heparan sulphate in articular cartilage are 
structurally related34. In light of this, it could be inferred that the heparin-binding 
peptide (PlGF2_123–144) of placenta growth factor 2 may also bind the heparan 
sulphate present in the bovine cartilage. 
Martino et al. also found that the sticky peptide PlGF2_123–144 could be retained 
by the ECM in vivo when, in a mouse model, the addition of growth factors with 















of the growth factors on the damaged bone, which could then recruit stem cells to 
the site. 
In light of this, hMSCs were allowed to adhere for further 24 hours and they were 
subjected to histological analysis (Figure 5.6). It was observed that when hMSCs 
were submitted to treatment with [scGFP_PlGF2][S], they displayed adhesion and 
retention in bovine cartilage explants (Figure 5.6 d-f). 
 
Figure 5.6 Histological fluorescent slices of bovine ex vivo cartilage discs. Human 
mesenchymal stem cells (hMSCs) were treated for 15 minutes with 4 μM of [scGFP_PlGF2][S] 
(middle row). Uncoated hMSCs were used as a control (bottom row). The cells were then 
seeded on bovine cartilage discs of 6 mm diameter and were allowed to attach for 24 hours 
at 37°C in a 5% CO2 atmosphere in a serum-free medium. Samples were fixed and stained 
before being submitted to cryo-sectioning at 10 μm thickness. a, b, c) cartilage without 
seeded hMSCs. d, e, f) cartilage with seeded hMSCs modified with [scGFP_PlGF2][S]. g, h, 
i) control hMSCs seeded on ex vivo explants. Blue: DAPI cell nuclei, green: 
[scGFP_PlGF2][S], red: cell tracker cytoplasm stain. Scale bar: 100 μm. 
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The untreated hMSCs did not seem to be retained, as it was difficult to locate them 
on the surface of the cartilage, even at higher magnification. While these three 
sets of images were not used to calculate adhesion, they gave a strong visual 
indication of the affinity of the modified hMSCs for bovine cartilage. 
Likewise, it was considered appropriate to image the ex vivo explants using 
scanning electron microscopy to observe the surface of the cartilage (Figure 5.7). 
There was a large contrast in the observed number of hMSCs after they were 
modified with [scGFP_PlGF2][S]. Furthermore, it can be observed that the cells 
are spreading out as a sign of the development of focal adhesion sites. 
 
Figure 5.7 Scanning electron microscopy images of modified human mesenchymal stem 
cells (hMSCs) on bovine explant surface. hMSCs were treated for 15 minutes with 4 μM of 
[scGFP_PlGF2][S], then seeded on bovine explant discs of 6 mm diameter and allowed to 
attach for four hours at 37°C in a 5% CO2 atmosphere in a serum-free medium. Samples 
were fixed, treated with osmium to improve contrast, dehydrated with ethanol and coated 
with platinum. a) untreated control hMSCs on bovine cartilage and b) hMSCs treated with 
[scGFP_PlGF2][S] on bovine cartilage.  
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5.2.4 Modifying ex vivo explants with acellular nanobiohybrids 
Drugs injected into the intraarticular cartilage need to infiltrate the full depth in 
order to have an influence in the ECM and the residing chondrocytes. Therefore, 
new delivery procedures have been developed, such as the use of polymeric 
nanoparticles35, and polypeptides36. These micro-sized carriers might be able to 
release drugs in a more efficient manner. However, the penetration and retention 
on the cartilage is still a challenge, especially in the middle and deep cartilage 
zones, which could be owed to the negative charge present in the ECM37. 
Accordingly, an investigation lead by Grodzinsky et al., has recently given an 
insight of the interactions between cartilage and charged or neutral small 
molecules, as this might be used as a platform for drug delivery. The experiments 
were carried out using variants of supercharged GFP. They coated bovine 
explants, similar to those used in this project, with neutral GFP, +9 GFP, +15 GFP, 
+25 and +36 GFP and concluded that the protein-cartilage interaction was 
dependent on the surface charge of the protein38. 
In order to assess the interaction of the novel nanobiohybrids with cartilage, 
analogous experiments were carried out. Using the methods from the Grodzinsky 
group, [scGFP], [scGFP_PlGF2] and the charge neutral [scGFP_PlGF2][S] 
(described in Chapter 2) were used to coat bovine ex vivo explants38. Briefly, 
bovine cartilage discs were submerged in equal 1 μM solutions of [scGFP], 
[scGFP_PlGF2] and [scGFP_PlGF2][S]. The solution also contained 1% of BSA 
to avoid loss of protein due to unspecific binding to the plastic container. After a 
24-hour period, the absorbance of the supernatant bath solution was measured at 
487 nm, and the number of constructs was normalised to cartilage volume (Figure 




Figure 5.8 24-hour uptake of [scGFP_PlGF2], [scGFP_PlGF2][S] and [scGFP] by bovine 
cartilage explants. After one day, the supernatant was collected and compared to the initial 
concentration by measuring the UV absorption at 487 nm. N=3 cartilage discs assuming a 
uniform volume of 56.6 mm3. Mean and standard deviation are reported; *: p<0.05. 
A comparable result to Grodzinsky was obtained, since after quantification, the 
uptake of the neutral [scGFP_PlGF2][S] by the cartilage was almost half of the 
positively charged species [scGFP] and [scGFP_PlGF2]. This could be explained 
by the numerous amount of negatively charged sulphated glycosaminocans 
present in the surface of the articular cartilage, which produced a coulombic 
attraction38. 
In order to identify the location of the nanobiohybrids and [scGFP] after 24 hours 
incubated in the same bath, confocal microscopy was performed on the cross 
section of the cartilage discs (Figure 5.9 and Figure 5.10). 
 
Figure 5.9 Schematic representation of ex vivo explants modification with proteins. a) 
bovine discs explants were harvested from articular cartilage. b) a 6 mm disc was 
submerged in a protein bath containing 1% bovine albumin serum and 1 µM of either 
[scGFP], [scGFP_PlGF2] or [scGFP_PlGF2][S]. c) after 24 hours, the cartilage was removed, 




















Figure 5.10 Bovine cartilage ex vivo explants exposed to nanobiohybrids. Discs were 
incubated in 1 μM solutions of [scGFP] (upper rows), [scGFP_PlGF2] (d to f) and 
[scGFP_PlGF2][S] (g to i) with 1% bovine serum albumin. The cross section was imaged 
after 24 hours. Green: supercharged proteins, blue: Hoechst nuclei stain. Scale bar: 100 μm. 
In bovine cartilage discs exposed to [scGFP] (Figure 5.10 a-c), the protein appears 
to be localised inside the chondrocytes as the green areas are homogenous and 
appear to be elliptical in shape, correlating with the cell nuclei (blue channel). 
Therefore, the [scGFP] may not interacting with the ECM but is instead being 
captured by the chondrocytes, which agrees with the results obtained by 
Grodzinsky et al. and the results obtained in Chapter 4. 
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The bottom right corner of the images shows chondrocytes that are in the process 
of internalisation and may have interacted with the protein not long before being 
imaged. 
The [scGFP_PIGF2] did not tend to always localise where the cells were. The 
green patches are not homogenous and appeared to be far more numerous than 
the nuclei locations. There is a strong possibility that the PIGF2 component was 
interacting with ECM components, aggregating, and thus preventing the 
[scGFP_PIGF2] from interacting and entering the chondrocytes. 
Finally, [scGFP_PIGF2][S] correlated with the location of the chondrocytes, but in 
contrast to [scGFP], the protein clearly outlined the cells. This could be an 
indication of interaction with the ECM at the pericellular matrix or the territorial 
matrix and thus retained there. The background ‘haziness’ may suggest the 
[scGFP_PIGF2] is binding to the ECM throughout the cartilage in the interterritorial 
region. This could be due to the neutrality of the particle not being able to interact 
electrostatically, and the presence of the PlGF2_123–144 peptide which strongly 
binds to the ECM. 
Additionally, this could serve as an alternative instead of modifying hMSCs, 
whereby the cartilage is first modified with nanobiohybrids and hMSCs are 
subsequently added; or the supercharged proteins could be loaded with drugs to 
enhance delivery deep in to the cartilage.  
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5.3 Chapter conclusions 
Static adhesion assays revealed that human mesenchymal stem cells (hMSCs) 
are naturally adherent to collagens, as there was not significant difference 
between treated and untreated cells for collagen I. Importantly, there was a 
considerable increase in hMSCs affinity for collagen type II in artificially coated 
wells, when the surface membrane was modified with [scGFP_PlGF2][S], 
compared to untreated control hMSCs and [scGFP_PlGF2] and [scGFP]. In a 
similar manner, when hMSCs were modified with the nanobiohybrid 
[scGFP_PlGF2][S], their ability to adhere to collagen II in a dynamic environment 
of 0.75 to 1.0 dyne×cm-2 shear stress was significantly enhanced. This was 
attributed to the presence of the peptide PlGF2_123–144 that has a strong affinity 
for extra cellular matrix proteins (ECM). These data suggest that the peptide is 
exposed on the outer membrane available to bind collagen II, and that the 
surfactant IGEPAL co-890 in the nanobiohybrid, served as an anchor to the cell. 
Importantly, the proficiency of hMSCs to interact with bovine ex vivo explants was 
amplified for surface engineered hMSCs with 4 μM [scGFP_PlGF2][S]. Moreover, 
experiments also demonstrated that [scGFP_PlGF2][S] alone has affinity for 
bovine cartilage in vitro, and were retained on the ECM. These data suggest that 
modifying the lipidic membrane of hMSCs may be a suitable platform to deliver 
cells into cartilage ECM.  
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5.4 Further work 
The modification of hMSCs with [scGFP_PlGF2][S] enhanced affinity for ECM 
proteins, such as collagen II. However, their ability to improve would healing in 
bovine ex vivo explants needs further investigation. This could be done by 
measuring the amount of aggrecan and collagen II secreted by the explants before 
and after the addition of hMSCs at different time points. Importantly, the 
immunogenicity of the proteins used for these experiments should be measured 
in order to avoid rejection of the nanobiohybrids. 
An attempt to evaluate stem cell differentiation into chondrocytes after adhesion 
was made (section 2.13.5), nevertheless, the results from such experiments were 
not conclusive and the data was not shown. It would be interesting to perform 
adhesion assays whereby the cartilage is first treated with [scGFP_PlGF2] and 
[scGFP_PlGF2][S] (as in the last figure) and plain hMSCs are then added to see 
if the adhere to the nanobiohybrid, having an untreated cartilage disc as a control. 
In order to better understand this technology, it could be necessary to develop in 
vivo assays in small mammals such as mouse or rabbit. These experiments could 
be performed by stem cell injection into the defective site and use histology 
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The global aim of this project was to develop an approach to improve OA-based 
stem cell therapies. In practice, this involved re-engineering the plasma membrane 
of human mesenchymal stem cells (hMSCs) with a novel nanobiohybrid construct. 
This modification was designed to enhance adhesion to the natural extracellular 
matrix (ECM) in articular cartilage. 
The designer nanobiohybrid [scGFP_PlGF2][S] consists of a polymer surfactant 
(S) conjugated supercharged green fluorescent protein (scGFP)1 fused to a 
heparin binding domain found in placenta growth factor 2 (PlGF2_123-144)2. Here, 
the solvent-exposed positive residues in scGFP would be electrostatically 
conjugated with anionic polymer surfactant comprised of a polyethylene glycol 
(PEG) containing a nonylphenyl tail. Significantly, it was hypothesised that the 
hydrophobic tail would penetrate into hydrophobic bilayer of the cell membrane, 
anchoring the nanohybrid construct to the cell surface. 
6.2 Outcomes from the study 
Overall, study yielded a host of exciting new results which are summarised below. 
The scgfp-plgf2_123-144 gene was designed by adding the plgf2_123-144 peptide 
sequence to the C-terminal of the scgfp gene, then incorporating an N-terminal 
hexahistidine tag. Then, the plasmid carrying the scgfp-plgf2_123-144 was 
successfully transfected into Escherichia coli (E. coli) for protein expression. The 
hexa-histidine tag in the expressed protein [scGFP_PlGF2] facilitated protein 
isolation with immobilised metal affinity chromatography. The purification of 
[scGFP_PlGF2] was evaluated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and matrix assisted laser desorption ionisation mass 
spectrometry, indicating a highly pure isolate. UV spectroscopy was also used to 
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establish the purity of the protein by utilising the ratio between its two extinction 
coefficients values at 280 and 487 nm. 
The isolation of the pure [scGFP_PlGF2] protein was followed by conjugation with 
the anionic oxidised IGEPAL co-890, by continuous stirring at 4°C to form 
[scGFP_PlGF2][S]. The presence of the surfactant corona was confirmed by 
dynamic light scattering (DLS) and zeta potential measurements by an increase in 
hydrodynamic diameter attributed to the surfactant corona around the protein. 
Circular dichroism showed that the secondary structure of the native protein was 
not compromised after surfactant conjugation.  
Further characterisation included other spectroscopic techniques, such as UV-vis 
and fluorimetry, from which it was determined that [scGFP_PlGF2] and 
[scGFP_PlGF2][S] shared similar optical characteristics. UV spectroscopy was 
used to ascertain the extent of the electrostatic conjugation with the surfactant. 
The emission and excitation maxima were found in the same wavelength 
regardless the addition of the surfactant, further suggesting that the folding of the 
β-barrel structure of scGFP and chromophore were not perturbed, and that the 
protein was not denatured. DLS confirmed the protein did not aggregate in solution, 
and that conjugation lead to an increase in the hydrodynamic diameter. 
Small-angle X-ray scattering (SAXS) validated the β-barrel tertiary structure of the 
protein [scGFP] and the flexibility of the fused peptide [scGFP_PlGF2]. SAXS also 
supported data obtained from DLS and mass spectrometry with respect to the size 
and molecular mass, respectively. 
After the biophysical characterisation of [scGFP_PlGF2] and [scGFP_PlGF2][S], 
experiments were carried out to explore the affinity of the constructs for the cell 
membrane of human mesenchymal stem cells (hMSCs). First, the viability of stem 
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cells was correlated to the ability of the cells to maintain their metabolic rate after 
being treated with various concentrations of the nanobiohybrid. hMSCS were 
exposed to increasing concentrations of [scGFP_PlGF2] and [scGFP_PlGF2][S]. 
Significant toxicity was observed when hMSCs were exposed to 12 μM of native 
protein or surfactant conjugate. All subsequent experiments were carried out at a 
concentration of 4 μM where no cytotoxicity was observed. Secondly, the 
proliferation of the modified hMSCs was assessed by manually counting the cell 
population every seven days for 14 days. The population doubling time remained 
stable after modification. 
The affinity of the nanoconstructs for the hMSC membrane was evaluated with 
flow cytometry. All hMSCs were successfully labelled with the constructs 
[scGFP_PlGF2] and [scGFP_PlGF2][S], as they showed an increase in 
fluorescence in the GFP region, though it was observed that the fluorescent 
intensity was greater in cells labelled with [scGFP_PlGF2]. It was hypothesised 
that this was due to the number of constructs deposited on the cell surface. In the 
future, the use of correlated light electron microscopy and atomic force microscopy 
could assist in the measuring of the thickness of the layer of nanoconstructs on 
the cell membrane and the roughness of the engineered membrane, respectively. 
Subsequent experiments were carried out to determine the number of constructs 
on the hMSC surface. As a result, it was quantified that hMSCs carried 
approximately twice the amount of [scGFP_PlGF2] than [scGFP_PlGF2][S]. It was 
hypothesised to be the result of rapid internalisation of [scGFP_PlGF2] by the cells, 
as it has been demonstrated before that scGFP can be internalised by mammalian 
cells3,4 via clatherin derived endocytosis. 
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Live cell imaging confirmed that [scGFP_PlGF2][S] was associated with the hMSC 
membrane, as it appears to surround the entire cell, and it was not found within 
the cell cytoplasm or the nucleus, when cells were imaged immediately after 
exposure. Similarly, time-lapse microscopy was performed to trace the fate of the 
nanobiohybrids once it was added onto the cell membrane. It was observed that 
[scGFP_PlGF2] was rapidly internalised by the cells. This event has been 
observed before for positively charged molecules5, as they are electrostatically 
attracted to the negatively charged proteoglycans in the cell surface and induce 
internalisation6. In contrast, the conjugate was retained on the surface of the 
hMSCs membrane. This is likely due to the nonylphenyl tail of the surfactant 
serving as a hydrophobic anchor to cell membrane. Both constructs were fully 
internalised after 24h, however, future experiments should be performed to 
determine if the surfactant is internalised together with the protein as one entity, 
or if the surfactant stays anchored on the cell membrane. 
Further assessment with flow cytometry was used to evaluate the persistence of 
[scGFP_PlGF2] and [scGFP_PlGF2][S] would be completely removed from the 
hMSCs. After 12 days all exogenous fluorescence was removed. 
Significantly, the multipotency of the mesenchymal stem cells was not inhibited by 
the modification of the cell membrane. Osteogenesis and adipogenesis did not 
show an observable difference versus the untreated control. Nevertheless, 
chondrogenesis differentiation seemed to be improved for hMSCs modified with 
[scGFP_PlGF2][S]. It might possible that the anchored polymer surfactant reduced 
the oxygen transport into the cells, by saturating the membrane surface, i.e., 
hypoxic environments are often associated with the induction of chondrogenesis. 
The change in chondrogenesis could also be owed to the presence of the PEG 
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chains in the surfactant, as it has been suggested that PEG facilitates the transport 
of nutrients to inside of the cell7. However, this has yet to be elucidated for the 
surfactant used in this project (oxidised IGEPAL co-890). 
After the stability of [scGFP_PlGF2][S] on the cell membrane was evaluated, the 
adhesion properties of the modified hMSCs was tested in wells coated with 
collagen type I and II, and bovine cartilage ex vivo explants. The cells modified 
with [scGFP_PlGF2][S] demonstrated superior affinity to collagen II in a static and 
a physiologically relevant dynamic environment. Importantly, when the modified 
cells with [scGFP_PlGF2][S] and control cells were seeded in bovine ex vivo 
explants, the number of modified cells found in the cartilage was greater than that 
of unlabelled control cells. 
Using a different approach, bovine cartilage explants were exposed to 
[scGFP_PlGF2][S], [scGFP_PlGF2] or [scGFP]. The nanobiohybrid 
[scGFP_PlGF2][S] was found distributed on the cartilage ECM unlike 
[scGFP_PlGF2] or [scGFP], which appeared to be internalised by the residing 
chondrocytes. Further hMSC adhesion studies on the modified cartilage would be 
needed in order to explore the idea that this could be used as a platform to attract 
hMSCs. Moreover, in vivo studies need to be performed in order to assess 
adhesion and cell engraftment, and the immune response after in vivo injection of 
supercharged GFP, as well as differentiation capacity in a damaged cartilage 
model. Taken together, all these findings suggest that mesenchymal stem cell 
membrane modification with [scGFP_PlGF2][S] is able to improve cell adhesion to 
cartilage, which is of crucial importance for regenerative therapies to treat 
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scGFP Nucleotide Sequence (714) 
GCT TCG AAA GGT GAA CGC CTG TTT CGC GGT AAA GTT CCG ATT CTT 
GTG GAA CTG AAA GGC GAT GTG AAC GGA CAC AAA TTT TCG GTA CGT 
GGG AAA GGT AAA GGC GAT GCA ACC CGC GGA AAA CTG ACC CTC AAA 
TTC ATT TGC ACC ACT GGC AAG CTG CCC GTT CCA TGG CCA ACC TTA 
GTG ACA ACC TTG ACC TAT GGC GTT CAG TGC TTC TCT CGT TAT CCG 
AAA CAC ATG AAA CGT CAT GAC TTC TTT AAA TCC GCG ATG CCG AAA 
GGC TAT GTG CAG GAA CGC ACG ATC AGC TTT AAG AAA GAC GGC AAA 
TAC AAG ACT CGC GCG GAA GTC AAG TTT GAA GGA CGT ACG CTT GTG 
AAT CGC ATC AAA CTG AAA GGG CGC GAT TTC AAA GAG AAA GGC AAC 
ATT CTG GGC CAC AAA TTA CGG TAC AAC TTT AAC AGT CAC AAG GTC 
TAC ATT ACG GCC GAT AAA CGG AAG AAT GGC ATC AAA GCG AAA TTC 
AAA ATT CGT CAC AAT GTG AAG GAT GGT AGC GTT CAA CTG GCC GAT 
CAT TAC CAG CAG AAT ACG CCC ATT GGT CGT GGT CCG GTA TTG TTA 
CCG CGG AAC CAT TAT CTG AGT ACA CGC TCA AAA CTG AGC AAA GAC 
CCG AAA GAA AAG CGC GAT CAT ATG GTA CTG CTG GAA TTT GTC ACT 
GCA GCT GGG ATC AAG CAT GGT CGC GAT GAG CGC TAT AAA 
 
PIGF-2123-144 Amino Acid Sequence (21) 
RRPKGRGKRRREKQRPTDCHL 
 
PIGF-2123-144 Nucleotide Sequence (63) 
CGC CGC CCT AAA GGC CGT GGT AAA CGT CGT CGT GAG AAA CAA CGC 
CCT ACC GAC TGT CAT CTC 
  









Synthetic Gene Nucleotide Sequence (777) 
GCT TCG AAA GGT GAA CGC CTG TTT CGC GGT AAA GTT CCG ATT CTT 
GTG GAA CTG AAA GGC GAT GTG AAC GGA CAC AAA TTT TCG GTA CGT 
GGG AAA GGT AAA GGC GAT GCA ACC CGC GGA AAA CTG ACC CTC AAA 
TTC ATT TGC ACC ACT GGC AAG CTG CCC GTT CCA TGG CCA ACC TTA 
GTG ACA ACC TTG ACC TAT GGC GTT CAG TGC TTC TCT CGT TAT CCG 
AAA CAC ATG AAA CGT CAT GAC TTC TTT AAA TCC GCG ATG CCG AAA 
GGC TAT GTG CAG GAA CGC ACG ATC AGC TTT AAG AAA GAC GGC AAA 
TAC AAG ACT CGC GCG GAA GTC AAG TTT GAA GGA CGT ACG CTT GTG 
AAT CGC ATC AAA CTG AAA GGG CGC GAT TTC AAA GAG AAA GGC AAC 
ATT CTG GGC CAC AAA TTA CGG TAC AAC TTT AAC AGT CAC AAG GTC 
TAC ATT ACG GCC GAT AAA CGG AAG AAT GGC ATC AAA GCG AAA TTC 
AAA ATT CGT CAC AAT GTG AAG GAT GGT AGC GTT CAA CTG GCC GAT 
CAT TAC CAG CAG AAT ACG CCC ATT GGT CGT GGT CCG GTA TTG TTA 
CCG CGG AAC CAT TAT CTG AGT ACA CGC TCA AAA CTG AGC AAA GAC 
CCG AAA GAA AAG CGC GAT CAT ATG GTA CTG CTG GAA TTT GTC ACT 
GCA GCT GGG ATC AAG CAT GGT CGC GAT GAG CGC TAT AAA CGC CGC 
CCT AAA GGC CGT GGT AAA CGT CGT CGT GAG AAA CAA CGC CCT ACC 





Fusion Tag; MAHHHHHHSSGLEVLFQÞGP…tag 
 
Forward Primer Sequence 
AAG TTC TGT TTC AGG GCC CG 
 
Reverse Primer Sequence 
ATG GTC TAG AAA GCT TTA GAG ATG ACA GTC GGT AGG (reverse 









Protein calculator results: 
Accepted Sequence 
MAHHHHHHSS GLEVLFQGPA SKGERLFRGK VPILVELKGD VNGHKFSVRG KGKGDATRGK  60   
LTLKFICTTG KLPVPWPTLV TTLTYGVQCF SRYPKHMKRH DFFKSAMPKG YVQERTISFK  120  
KDGKYKTRAE VKFEGRTLVN RIKLKGRDFK EKGNILGHKL RYNFNSHKVY ITADKRKNGI  180  
KAKFKIRHNV KDGSVQLADH YQQNTPIGRG PVLLPRNHYL STRSKLSKDP KEKRDHMVLL  240  
EFVTAAGIKH GRDERYKRRP KGRGKRRREK QRPTDCHL                          278  
 
 
Amino Acid Count 
Residue Number Found 
A Ala Alanine  10 
R Arg Arginine  27 
N Asn Asparagine  9 
D Asp Aspartate  12 
Q Gln Glutamine  7 
E Glu Glutamate  11 
G Gly Glycine  26 
H His Histidine  17 
I Ile Isoleucine  10 
L Leu Leucine  22 
K Lys Lysine  39 
M Met Methionine  4 
F Phe Phenylalanine  13 
P Pro Proline  13 
S Ser Serine  12 
T Thr Threonine  16 
Y Tyr Tyrosine  9 
V Val Valine  17 
W Trp Tryptophan  1 
C Cys Cysteine  3 













Isotopically Averaged Molecular Weight = 32118.2656 
 
Estimated pI = 10.58 
 
WARNING: pI estimate assumes all residues have pKa values that are equivalent 
to the isolated residues. For a folded protein this is	not	valid. However, this rough 
value can be useful for planning protein purfications. pKa values for the individual 
amino acids from Stryer Biochemistry, 3rd edition. 
 
 
Estimated charge at pH 7.00 = 46.9 
WARNING: pI estimate assumes all residues have pKa values that are equivalent 
to the isolated residues. For a folded protein this is not valid. However, this rough 
value can be useful for planning protein purfications. pKa values for the individual 


















Extinction coefficient estimated by the method of Gill and von Hippel (Analytical 
Biochemistry, 182:319-326,1989) where lyophilized proteins were used to 
establish an absorbance curve based on the number of tyrptophans, tyrosines, 
and disulfide bonds. Units are in M-1 cm-1. 
 
Wavelength Molar Extinction w/o Disulfides Molar Extinction w/ All Disulfides 
278 18200 18327 
279 17765 17885 
280 17210 17330 





Extinction coefficient estimated by the method of Gill and von Hippel (Analytical 
Biochemistry, 182:319-326,1989) where lyophilized proteins were used to 
establish an absorbance curve based on the number of tyrptophans, tyrosines, 
and disulfide bonds. Units are in (mg/mL)-1 cm-1. 
 
Wavelength Molar Extinction w/o Disulfides Molar Extinction w/ All Disulfides 
278 0.5667 0.5706 
279 0.5531 0.5568 
280 0.5358 0.5396 
282 0.5106 0.5137 
 




















The oxidation reaction of IGEPAL co-890 was carried out as previously reported1 
and section 2.4. An oxidation was carried out on the alcohol group into a carboxylic 
acid in order to make it an anionic surfactant. In the surfactant structure, 
hydrophilic head group is followed by an amphiphilic polyethylene glycol (n=39) 
and a hydrophobic nonyl phenyl tail group (Figure 1). 
 
                      
Figure 1 IGEPAL co-890 oxidation. The native surfactant IGEPAL co-890 (left) is oxidised to 
obtain the oxidised version presenting a carboxylic acid at the end (right). The reaction is 
carried out on the presence of TEMPO, NaClO and NaBr in a basic pH of 11. 
Fourier transformed infrared spectroscopy was performed in order to ensure the 
addition of the carboxylic group (Figure 2). It was possible to see the appearance 
of the carboxylic group stretch band at 1760 cm-1, which is expected for a carbonyl 
stretch between2 , This value corresponded to the C=O bond stretch in a saturated 
carboxylic acid, which is not present when the spectrum is taken from the neat 
polymer. Other relevant peaks on the spectrum are O-C-O asymmetrical stretch 














Figure 2 FTIR spectrum from native and oxidised surfactant. IGEPAL co-890 (red line) and 
IGEPAL co-890 (black line) after oxidation showing the carbonyl stretch C=O between 1600 
and 1800 cm-1, O-C-O asymmetrical stretch between 1180 and 1290 cm-1, and C-OH at 
approximately 3000 cm-1. 
An acid-base titration was carried out with sodium hydroxide (NaOH) in order to 
quantify the oxidation of IGEPAL co-890 (Figure 3). 
 
Figure 3 Titration curve of oxidised IGEPAL co-890 against sodium hydroxide added. The 
neutralisation point was determined to calculate surfactant purity. Aliquots of 200 μL were 































The neutral pH 7 was reached when 5.8 mL of 2.5 mM NaOH are added to the 
solution. The ratio between carboxylic acid and sodium hydroxide (NaOH mol / 
COOH mol) was determined to be 1.03, meaning that a 100% of the surfactant 
was oxidised to have a carboxylic acid ending. 
MALDI-TOF mass spectrometry was performed in both samples IGEPAL co-890 
and the oxidised version. A shift in the molecular weight of 14 Da is observed due 
to the addition of the oxygen at the end of the chain, along with the periodicity of 
44 Da from the polyethylene glycol chain (Figure 4). 
 
Figure 4 MALDI-TOF mass spectrometry of polymers. a) spectrum from IGEPAL co-890 from 
sigma (black) and b) oxidised IGEPAL co-890 (blue). c) Reduced range demonstrated the 
peak shift on the mass of the oxidised polymer (blue) as well as 44 Da periodicity of 
polyethylene glycol chain. 
In order to determine the extinction coefficient of the surfactant, a UV-vis 
absorbance measurement was made with a known surfactant concentration 
(Figure 5). 

































Figure 5 UV-vis spectrum from oxidised IGEPAL co-890. This was performed at room 
temperature in buffer 20 mM Tris.HCl with 400 mM NaCl at pH 7.5. 
Using Beer-Lambert equation it was possible to calculate the extinction coefficient 
to be 1563.4 when the surfactant was dissolved in buffer 20 mM Tris.HCl with 400 
mM NaCl at pH 7.5. 
The critical micellar concentration (CMC) of oxidised IGEPAL co-890 was obtained 
in the buffer to be used for protein conjugation, as this could vary depending on 
the solvent used. This experiment was carried out by mixing a known surfactant 
concentration and 1,6-diphenyl-1,3,5-hexatriene (DPH). The CMC was found to 
be in between 0.5 and 1 mg·mL-1, when the fluorescence was positive, which is 


















Figure 6 Critical micellar concentration of oxidised IGEPAL co-890. Data was obtained in 
buffer 20 mM Tris.HCl and 400 mM NaCl at pH 7.5. 
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